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ABSTRACT 	
BACKGROUND: Evidence Reversal (ER) is the phenomenon whereby new and stronger 
evidence contradicts previously established evidence. 
OBJECTIVES: To quantify evidence reversals and to determine characteristics associated 
with reversibility. 
METHODS: Original articles from the New England Journal of Medicine (2000 to 2016) 
were screened for three inclusion criteria: tested a clinical practice; Randomized 
Controlled Trial design; and tested an established clinical practice. The proportion of 
RCTs that represented ER was determined. Association of trial characteristics with 
reversal was explored using logistic regression in order to inform a potential framework 
of reversibility. 
RESULTS: In total, 611 RCTs met the inclusion criteria, of which 54% were evidence 
reversals. Based on variables associated with ER, a reversibility framework was 
proposed, comprised of eight trial characteristics.  
CONCLUSION: More than 50% of RCTs published in the NEJM that test established 
practices are evidence reversals. The characteristics of RCTs that are associated with 
reversal will inform future research to further understand reversibility. 
 
 
KEYWORDS: Evidence Reversal, Medical Reversal, Evidence-Based Medicine, 
Evidence Synthesis, Randomized Controlled Trials, Adoption, De-Adoption, 
Implementation, De-Implementation, Decision-Making 		 	
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CHAPTER 1 
 
 
 
 
 
Introduction to Evidence Reversal 
 
 
 
 
 
Riaz Qureshi 
 
 
 
 
 
 
 
Note:  After this chapter of this thesis was drafted, a manuscript to introduce concepts, 
contained within this chapter was drafted for publication. As such, there are 
many similarities in the sections of the paper and this chapter. However, I was 
able to expand this chapter and go into more detail than the paper due to space 
and formatting restrictions within the publication.  
 
Citation:  Qureshi R, Sutton D, & Martin J. (2016). Approaching Evidence Reversal and 
Medical Reversal – When to say, “Enough is enough.” Ready for submission 
for publication to Mayo Clinic Proceedings, Apr 2017.  
 
Chapter summary: This chapter presents an introduction to the phenomenon of reversal 
and describes some of the issues that surround research in this field, as well as 
the current tools in the field of reversal research and the proposed rationale and 
impact that this research will have on future research. 
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CHAPTER 1 
1.0  WHAT ARE MEDICAL REVERSAL AND EVIDENCE 
REVERSAL? 
 A medical reversal is the phenomenon whereby a medical practice, procedure, or 
technology that has been embraced by the medical community loses its standing when 
better conducted studies show that it is not as effective as was thought, or even harmful to 
the population.1–3 As medicine has advanced, so too has study methodology, and new 
trials are often superior – through better design, greater power, or more appropriate 
control groups – to the original studies of a medical practice.1,2 When such superior 
studies are conducted to test the effectiveness of current clinical practices, they may 
contradict the original studies – with results that are incongruent with the beliefs and 
practices of the general medical community – and find that the current practice, 
procedure, or technology, is inferior to a prior standard of care, does not produce the 
promised results, or is even more harmful than beneficial to a patient’s health.2  
Evidence reversal occurs when new evidence comes to light and shows that the 
established evidence, often based on a combination of low quality research or limited 
availability, is incorrect.1 While similar to the phenomenon of ‘medical reversal,’ the 
phenomenon of ‘evidence reversal’ differs in two regards. Firstly, the term ‘medical 
reversal’ limits the phenomenon to clinical practices, whereas ‘evidence reversal’ 
expands this definition beyond medicine alone to also include other fields relevant to 
health and healthcare, such as public and population health. Secondly, ‘medical reversals’ 
refers only to practices that are already adopted and implies de-adoption after reversal, 
whereas ‘evidence reversal’ refers only to the evidence for the practices as being reversed 
and the practices, if already adopted, may continue. It is for this reason that we propose 
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‘evidence reversal’ as being a more appropriate term to describe contradictory findings of 
new studies, and consequently, more appropriate than ‘medical reversal.’  
 While evidence reversal may arise from the findings when a trial investigates an 
already established intervention, there are several other possible outcomes when studying 
interventions in general. When an established intervention is tested and found to be 
inferior to what was originally believed, this is a reversal, as has previously been 
established.4 As the counterpart to reversal: when an established intervention is tested by 
newer studies and found to be as good as, or better than, was originally believed, this is 
termed “evidence reaffirmation.”1,4 When a new practice, device, or intervention is being 
tested and is found to be superior to an old standard of care, this constitutes an “evidence 
replacement.”1,4 The counterpart to evidence replacement is sometimes referred to as 
“back to the drawing board” – which occurs when a trial that tests a new practice, device, 
or intervention finds it equal to or no better than an old standard of care.1,4 
 The term ‘medical reversal’– as applied to describing the phenomenon of new 
trials contradicting clinical practice – was first used in 2011 by Prasad and colleagues.1 
While the designation is still in its infancy and the term is not well known, physicians are 
familiar with the phenomenon of evidence reversal and subsequent de-implementation of 
established clinical practices.5 Awareness of the phenomenon is increasing, even within 
the general public, as examples of reversals have been highlighted in the medical news of 
the popular media.6,7 
 
1.1  FREQUENCY OF MEDICAL REVERSAL 
Given the frequency with which guidelines and practices change in the medical 
literature, several researchers have tried to quantify the rate of reversal. Ioannidis and 
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colleagues found that among highly influential studies published in the New England 
Journal of Medicine (NEJM), Journal of the American Medical Association (JAMA), and 
Lancet between 1990 and 2003 that have been cited more than 1000 times, 16% were 
found to be contradicted by subsequent studies and an additional 16% were found to have 
smaller effects than initially found.8 In further assessments of all original research articles 
published in the NEJM, Prasad and colleagues suggest that reversal could be even more 
prevalent. The proportion of trials published in 2009 that tested an established medical 
practice and found contradictory evidence constituting a reversal was 46%.1 A similar 
assessment over a 10-year period, from 2001 to 2010, found that 40.2% of trials found 
contradictory evidence for their tested practice.4  	
1.2  EXAMPLES OF EVIDENCE AND MEDICAL REVERSAL 
 Three debated reversals include: stenting for stable coronary artery disease, 
vertebroplasty for osteoporotic fracture, and hormone replacement therapy for prevention 
of coronary heart disease.  
1.2.1 Percutaneous coronary intervention for stable coronary artery disease 
Ever since their invention, coronary artery stents – a small wire mesh tube 
designed to expand and open an artery with stenosis – have been used to treat people with 
myocardial infarction (MI). Placing a stent in an occluded artery at the site of blockage – 
percutaneous coronary intervention (PCI) – opens the vessel and restores blood flow, 
improving the chances of surviving the event. Due to their effectiveness in restoring flow 
to a damaged artery, PCI was also used in the treatment of typical angina – recurring 
chest pain with exertion that is experienced as a direct result of coronary artery disease 
(CAD). The physiology and mechanism for action was logical, and patients reported 
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feeling better after undergoing the procedure. However, a 2007 randomized, blinded trial 
of PCI plus medical therapy versus medical therapy alone in patients with stable CAD 
found that it did not reduce the risk of death (both cardiac and all-cause mortality), 
recurrent MI, stroke, hospitalisation for acute coronary stenosis, or revascularization.9 
This trial showed that while PCI for stable CAD relieved some symptoms, such as typical 
angina, for a brief time, placing a stent did nothing to improve patient survival or risk of 
future cardiovascular events and was therefore not as effective as was believed while 
subjecting patients to the risks associated with surgical intervention, such as: anaesthesia, 
infection of site wound, and hospital stay.9 Despite the findings of this trial, the practice 
persists and is consequently more appropriately described as an evidence reversal than a 
medical reversal.   
1.2.2 Vertebroplasty for osteoporotic fracture 
In the early 1990s, a simple outpatient procedure for the management of 
osteoporotic spinal fractures became popular and gained widespread use. Vertebroplasty 
involves the injection of medical cement into fractured spinal bone with the intention of 
restoring original shape, stabilizing the fragments, and reducing pain from the fracture.10 
The procedure appeared to work: patients who underwent the procedure experienced 
drastically reduced pain and disability.10 Based on these reports and several early trials 
that did not include controls, vertebroplasty was added to the list of Medicare-funded 
procedures in 2001.11 Vertebroplasty quickly became a multi-million dollar industry and 
the number of procedures performed each year increased from 14,142 in 2001, to 29,090 
in 2005.11 However, the evidence for this procedure was reversed in 2009 when two 
randomized and double-blinded trials of vertebroplasty versus a sham procedure (simple 
salt water injection) found no difference between groups in response to treatment: 
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saltwater injection caused just as much reduction in pain and disability as medical 
cement.12,13 Although the two trials provided convincing evidence to discredit the 
practice, its use has persisted and is consequently representative of evidence reversal.  
1.2.3 Hormone replacement therapy for prevention of coronary heart 
disease 
Prescription of hormone replacement therapy (HRT) – a combination of estrogen 
and/or progestin – to reduce the symptoms of menopause and as primary prevention for 
coronary heart disease (CHD) has been routine since the mid-1960s.14–17 These 
endogenous hormones are critical for a number of physiologic processes including the 
reduction of osteoporotic bone loss, cardiovascular health, reproductive function, and 
temperature regulation dependent on hormonal homeostasis.18 Following endogenous 
estrogen reduction after menopause, women experience increased risk of osteoporosis 
and bone fracture, MI, stroke, uterine and vaginal wall changes, and hot flushes.18,19 
Treatment with exogenous estrogen and progestin was a physiologically sound solution 
to improve bone mineral density and reduce the risk of MI, stroke, and other 
perimenopausal symptoms. The therapy seemed to work for select symptoms such as hot 
flushes and bone mineral density. However, two randomized controlled trials conducted 
between in 1993 and 1998 reported that women receiving HRT were at significantly 
higher risks for CHD, stroke, breast cancer, pulmonary embolism, and venous 
thromboembolic events than women not receiving HRT.15,20 The risk-to-benefit ratio of 
HRT was too great for a primary prevention of CHD and osteoporosis, and the therapy 
quickly fell out of favour among post-menopausal women, although its use in other 
population subgroups remains contested.14 While HRT use continues for some women, 
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the contraindication and cessation of routine use in most post-menopausal women is what 
designates it as an example of a medical reversal. 
 
1.3  WHY SHOULD WE CARE ABOUT REVERSALS? 
 Reversals of evidence, whether in medicine or other health-related disciplines are 
an important phenomenon to the scientific community and the population as a whole. 
Society should care about this phenomenon because reversals pose several real dangers to 
clinical practice if left unchecked. Minimizing the impact and occurrence of reversals 
caused by the premature adoption of practices would benefit society in several ways.  
1.3.1 The dangers of unnecessary reversal 
 Although the phenomenon of evidence reversal is a natural consequence of the 
scientific method – contradicting prior beliefs when new information and better methods 
to test those beliefs are available – the premature implementation of practices (whether 
they be medical, public health, or population based) that may have little to no benefit, or 
are potentially harmful can lead to serious consequences for society. These risks of 
premature adoption are often discussed in the literature as being the harms associated 
with reversal. 
One of the primary dangers of reversal is unnecessary cost (i.e. wasted resources). 
Any technology or practice that does not work as intended, especially medical, has no 
place in the market. However, new technologies are often promoted by industry without a 
complete understanding of their effectiveness – often for uses for which they have not 
been tested nor approved. Furthermore, it is not only industry that does this as 
governments will support technologies or interventions that have a demonstrated need in 
their population, based on whatever evidence is available at the time.21 The presence of 
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reversed practices in medicine places an unnecessary burden on the healthcare system as 
the government utilizes limited resources to provide services that are no better, or worse 
than, previously implemented standards of care, placebo, or even no intervention.2,3,22  
Another danger of reversals is the potential risk at which those who receive 
reversed interventions have been placed for no benefit. Medical practice revolves around 
the principles of beneficence and non-maleficence: doing what is best for one’s patient 
and not causing undue harm. These must always be kept in balance when determining the 
most suitable intervention: what level of risk is acceptable, given the expected benefit 
that the patient should receive? When patients receive reversed medical practices, they 
have undergone unnecessary risk for less benefit than they believed they were receiving, 
and this is ethically and morally wrong.  
Another danger of reversal in medicine is the undermining of trust in the medical 
system. It is generally accepted that the public trusts that physicians know what treatment 
is best for their health problems and will administer a suitable therapy that has their 
interests in mind.23,24 The core tenet of evidence-based medicine (EBM) is the integration 
of clinical expertise, best available evidence, and patient preferences in choosing the most 
suitable intervention.25 However, all clinicians know that there are times when no clear 
path is available and sometimes the best that can be done is an educated guess. When 
patients receive multiple misdiagnoses or mistreatments they may lose faith in the 
medical system. In addition, the media portrayal of medical uncertainty, changing 
guidelines, and exaggerated claims of the benefits or risks of practices compound this 
mistrust. This damage that is done to a patient’s or clinician’s faith in the medical system 
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may be irreparable and undermine the ability of the system to help these people in the 
future.26 
A further danger of medical and evidence reversals lies in the difficulty associated 
with removing an already established standard from the scientific community: de-
adoption.27 It is an established fact of knowledge translation that it takes many years for 
practices to be implemented in clinical care or for a scientific technique to be adopted. 
However, it is more difficult to remove an engrained intervention, technology, or 
paradigm from practice because the scientific community is not unbiased.28,29 
Practitioners will often justify the continued use of a popular standard or practice, despite 
evidence that it does not work as was originally believed. Once something has been 
reversed, there is no guarantee that it will cease to be used. 
1.3.2 The benefits of eliminating unnecessary reversal 
 Premature uptake of practices, before sufficient evidence exists (leading to 
subsequent unnecessary evidence reversals when better evidence accrues), is common in 
medicine and poses a real risk to the health of the population. If the incidence of reversed 
practices could be reduced, or the impact of the phenomenon minimized, all members of 
society would benefit. The benefits of reducing the amount of medically reversed 
practices and technologies are all complementary to the dangers that accompany reversal, 
as discussed above. 
Eliminating or reducing unnecessary evidence reversals due to premature 
knowledge translation would improve the overall health of the population because 
potentially harmful or ineffective practices may be stopped earlier or prevented from 
implementation. Many medical practices that are reversed place the recipients at risk for 
little to no benefit. It logically follows that reducing the number of practices that do not 
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work as planned or are more harmful than originally believed would subsequently reduce 
the burden of harm that is placed on the population.  
If the number of reversals due to premature adoption were reduced, there would 
be increased trust in the medical community. Fewer practices would be implemented that 
later need to be de-adopted. This may lead patients to put more trust into their physicians 
and to be more open to seeking medical care when it is necessary. 
With a reduction in reversals due to premature adoption, government 
administrators and policy makers may see an increase in available funding. This increase 
may be possible if premature conclusions based on insufficient evidence could be 
minimized, to prevent the premature uptake of practices. This prevention would lead to a 
reduction in unnecessary expenditure as money that was previously wasted on 
technologies and interventions that are no better or worse than placebo would be 
available for use in areas based on adequate evidence and proven efficacy. 
 
1.4  APPROACHING EVIDENCE REVERSAL 
The phenomenon of evidence reversal is difficult to approach because of its 
inherent ethical and logistic challenges. The primary dangers of reversal revolve around 
the fact that practices and paradigms that need to be reversed are often already engrained 
in the scientific community and/or widely believed. In approaching the phenomenon of 
evidence reversal – and in consideration of these dangers – it is vital to consider where 
the burden of proof may lie for identifying reversals.  
Given the difficulties surrounding de-adoption of established practices, the most 
effective approach to minimizing their impact is to stop them before they gain a strong 
presence in clinical practice and population health. However, one of the difficulties in 
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identifying reversals before they have been adopted is establishing where the 
responsibility for identification lies.22,26 Using the arguments presented by Prasad and 
Cifu for the identification of medical reversals, we believe that the burden of proof lies 
primarily with manufacturers, researchers, and regulatory bodies who develop and 
approve interventions and practices to ensure effectiveness before implementation.26 
In asking this question, it is easiest to rule out where the burden of proof does not 
lie, and this is with the patients. Undoubtedly, the general population that is served by the 
medical community suffers when technologies that will be later reversed see widespread 
dissemination and use. As has been outlined in previous sections, reversals have many 
dangers and the public has the right to interventions that have proven efficacy.22  
The burden of proof for identifying reversals must lie partly with physicians as the 
administrators of therapies. However, beyond their physiological knowledge and personal 
clinical experience and expertise, they can only know as much about the interventions 
that they prescribe as is given to them by the researchers and industry. The burden of 
proof lies in part with physicians, as they must be cognizant of the evidence for a 
treatment’s efficacy before prescribing it to their patients. It is a physician’s ethical duty 
to act in the best interests of the patient and when technologies are put into practice 
before their effects are fully understood, physicians take a risk in their prescription as 
they may be unknowingly putting the patient at increased risk of unnecessary harm.22 
Following the description of the dangers of medical reversal, the rationale for why 
the burden of proof lies primarily with the governmental institutions that support the 
research and grant regulatory approval, the industry that creates the interventions, and the 
researchers who study their effectiveness and efficacy in clinical practice is clear: 1) it is 
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very difficult and costly to remove an already established practice from the field and it is 
safer and more efficient to confidently determine an intervention’s efficacy and 
effectiveness before it is implemented than after it has been implemented – which is the 
responsibility of governmental institutions that support research and grant regulatory 
approval; 2) the actual proportion of interventions that have clinically relevant and 
significant impacts on patient important and meaningful outcomes is very low – which is 
the responsibility of the industry that creates interventions; and 3) the implementation of 
practices that may later be reversed is a waste of valuable health-care resources that could 
be avoided by adequately studying their effects before promoting their use – which is the 
responsibility of the researchers who study effectiveness and efficacy in practice and the 
agencies that fund research.22  
 
1.5  TOOLS FOR APPROACHING EVIDENCE REVERSAL 
In knowing where the burden of proof lies, consideration must be given to the 
methods and tools that are currently employed for identifying and reducing the impact of 
evidence reversals. While standards of practice exist in all scientific disciplines, new 
findings will always require knowledge dissemination before they can be implemented. 
As such, there currently exist several tools that attempt to mitigate the effects of 
unnecessary reversals by providing evidence-based recommendations: clinical guidelines, 
knowledge translation, and various tools for de-implementation.  
An ideal clinical guideline should serve to inform practitioners and patients of the 
most appropriate treatment or course of action in any given circumstance. While there are 
many faults with the current processes employed in creating clinical guidelines – faults 
which themselves may sometimes lead to premature adoption and unnecessary reversal – 
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an ideal clinical guideline that is rigorous, unbiased, and uses the best available evidence 
should provide a recommendation for the most appropriate care within the context of the 
quality and quantity of available evidence.  
Similarly, an ideal translation of research findings into practice could lead to a 
reduction in premature uptake of practices because clinicians and policy makers would 
consequently know which practices have a proven efficacy and which do not. Despite 
this, however, there remain a plethora of potential reasons as to why a practice may be 
prematurely adopted or remain in use after it has been reversed.  
In attempting to reduce the impacts of unnecessary reversals and premature 
adoption, many different campaigns and programs have been developed to aid in the de-
adoption of reversed practices and increase awareness of the value of different practices. 
These programs attempt to summarize the totality of evidence and provide 
recommendations to practitioners and even the general public to inform better health care.  
In providing these recommendations for the implementation of new practices or 
de-adoption of established practices, an important consideration is the maturity of the 
evidence base to support the practice. Sufficiency and stability are characteristics to 
describe accumulated evidence and provide a measure of evidence maturity: the point at 
which an intervention has been studied enough that conducting another test no longer 
provides any information of value. There are several different methods of assessing the 
sufficiency and stability of evidence to aid decision-making including: cumulative meta-
analysis, trial sequential analysis / monitoring, Bayesian analysis, value of information 
analysis, GRADE (Grades of Recommendation Assessment, Development, and 
Education), and the fragility index. Chapter 7 provides a detailed discussion of the 
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strengths and weaknesses of these tools and how the results of this thesis may be applied 
to inform their development and use in the context of medical and evidence reversal.  
 
1.6  CAUSES OF EVIDENCE REVERSAL  
 Evidence reversal is a complex phenomenon that occurs when new research 
contradicts the established evidence for a claim or belief, suggesting it is not what was 
originally believed. Evidence reversal has many causes. The causes of evidence reversal 
are related to the characteristics of the original research itself – including characteristics 
of the innovation being studied – that played a role in the misguided investment, 
dissemination, and utilization of the practice, procedure, or technology that must 
consequently be reversed. 
One of the common causes of reversal has already been shown in previous 
examples is a strong belief in the pathophysiological model that leads to the assumption 
that intervening on parts of the pathophysiologic causal pathway will translate to 
effectiveness, despite never demonstrating either effectiveness or efficacy with respect to 
clinically meaningful outcomes in a trial setting. Placing a stent in an artery with severe 
stenosis when someone is experiencing chest pain should prevent cardiac-related 
mortality or MI, but it does not. Neither does injecting medical cement into fractured 
bone to stabilize the fracture have an effect beyond a simple saline solution, even though 
it theoretically should. These seemingly logical pathways that are common to many 
evidence reversals are important to keep in mind because they demonstrate that unless 
there is direct evidence of an effect on an important outcome of interest – particularly 
clinically relevant outcomes – it is difficult to know the net effect a proposed intervention 
will have on a population in practice.22  
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There are many clinical practices that are established based on tradition and have 
never truly been tested in a randomized trial.30 Such practices, sometimes called “sacred 
cows,” are often based on positive observed effects within a pathophysiological model 
that do not translate to meaningful clinical outcomes.31,32 Examples of practices that were 
used without proven efficacy, until they were reversed by trials, include: non-invasive 
measurement of blood pressure in children, oxygen administration for patients with 
chronic obstructive pulmonary disorder, and supplemental oxygen administration for 
acute MI.33 A further complexity that these “sacred cows” impose on health care is that 
such practices are not easily tested to find their true value. Practices that have been used 
for a long time and are engrained cannot easily have their efficacy assessed because they 
are overwhelmingly believed to be effective, thus failing to satisfy the principle of 
clinical equipoise that is necessary to ethically justify randomization to not receive the 
therapy, and therefore would be seen as unethical by many practitioners.34  
Trusting a physiological model may also lead to a related cause of evidence 
reversal, which is overgeneralization to non-study populations.35 The expanded 
application of interventions to populations for which they have never been tested is a 
common cause of reversal.1 Some practices may only be reversed for a particular 
indication (e.g. PCI is effective at saving the lives of those with MI, but has been reversed 
for preventing future heart-related incidents among those with stable CAD).1,9 
Over reliance on physiological models is also directly related to another cause of 
medical reversals: the use of surrogate outcomes in trials that do not appropriately 
represent important clinical outcomes.22,36 Surrogate outcomes (e.g. blood pressure, bone 
mineral density, tumour growth) are often used as endpoints in studies of new 
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interventions because they are cheaper and require less time to get results than using 
clinically meaningful outcomes (e.g. all-cause mortality or health-related quality of life). 
However, improvement in a surrogate outcome does not always correspond with an 
improvement in outcomes that are clinically meaningful and important to patients. Some 
examples of treatments that were implemented on positive effects on surrogate outcomes, 
but were later reversed when their effectiveness was examined with regard to clinically 
relevant outcomes, include: PCI for stable CAD, high-dose steroids for spinal cord injury, 
administration of calcium during cardiac arrest, cyclo-oxegenase-2 (COX-2) inhibitors 
for inflammation, a glycated haemoglobin (HbA1C) level of less than 7% for the 
management of diabetes, and bevacizumab for metastatic breast cancer survival.22,36  
It is commonly assumed that the most expensive option is the best: that a higher 
price will result in better outcomes than a cheaper alternative, without considering the 
known value of the intervention.37 This assumption can lead to unnecessary reversal 
because newer and more expensive practices are adopted to replace older and cheaper 
practices before the evidence has matured to support their use, leading to reversal when 
they are not found to be any better than the older or cheaper standard.38 
There are also several characteristics of research that can lead to poor quality 
findings and an increased likelihood that the results are false or exaggerated, which in 
turn may lead to future reversal.39 Increased financial interests or prejudices and the non-
declaration of conflicts of interest are both established reasons for questioning the 
validity of research findings, as is novelty of a research field.23,39 Novelty of a field in 
particular can create public pressure for early adoption of technologies that have not yet 
been fully tested. This public pressure often comes in the wake of sensationalized media 
Riaz	Qureshi	 	 	
Chapter	I		 	 Introduction	to	Evidence	Reversal	 	 	
17	
coverage of scientific breakthroughs which suggests that poor science reporting may also 
play a role in the premature adoption of practice, leading to higher risk for future 
reversal.40,41  
  The causes of reversal are not limited to suboptimal original research practices, 
as is the case in many of the examples above. Reversal should be a respected 
phenomenon and an expected element of scientific enquiry as new evidence emerges to 
contradict prior beliefs and standards. Medical and evidence reversal can occur because 
of newly discovered long-term side effects that could not have been known early in the 
course of a new treatment, even with well conducted trials: the kinds of side effects that 
require population-wide use over the longer term, as in Phase IV trials, to be 
discovered.42 Reversals may occur over time because a practice that was a standard of 
care is no longer worth the cost because cheaper alternatives with similar effectiveness 
have since become available.42 There is also a logistic issue surrounding the study of 
practices to the point of maturity before implementation, as the resources required to 
conduct multiple, large, clinical trials that follow patients for a sufficient length of time to 
determine the “true” effects of an intervention on patient-important outcomes make such 
a goal infeasible for some interventions. It is for these reasons that eliminating reversal 
entirely is impossible. However, reducing the impact of unnecessary reversals through 
preventing premature adoption of practices before a reasonable level of evidence has 
accrued would positively influence the harmful effects of reversal. 
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1.7  EXPLORING THE CHARACTERISTICS OF EVIDENCE 
REVERSAL  
There are many factors that can contribute to the reversal of an established 
practice and many characteristics of research that can lead to the immature 
implementation of a practice before its true efficacy and effectiveness is understood. 
However, despite the knowledge that these causes of reversal exist, there are no 
frameworks that describe the characteristics of research that are associated with the 
contradiction of already established practices.4,43,44  
‘A decade of reversal: An analysis of 146 contradicted medical practices’ by 
Prasad et al. was a major review of original research articles published in the New 
England Journal of Medicine (NEJM) between 2001 and 2010 that explored the 
prevalence of medical reversal in the medical literature.4 They estimated the rate of 
contradiction over a 10-year period and found it to be approximately 40% of studies 
testing an existing practice.4 They also provided descriptive statistics about the studies 
collected in their search – including the prevalence of various study designs, authors’ 
conclusions, and the proportion of studies that tested medical practices that were new 
versus existing – and detailed qualitative descriptions of the 146 studies that they 
identified as reversals.4  
While ‘A decade of reversal’ fulfilled a necessary and important step in moving 
towards a better understanding of this new field, the data provided was insufficient to 
accommodate an analytic assessment of the characteristics of research that may be 
associated with reversal. Prasad et al. conducted no quality assessments of the included 
studies, provided no details of study-level results (e.g. number of events and subjects in 
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study groups), and provided insufficient description of methodology with regards to their 
decision-making processes to facilitate reproducibility.4  
However, these limitations provided a rationale for reproducing, updating, and 
expanding this review: using the results to create a database upon which to conduct a 
more quantitative analysis of the characteristics of reversal. The exploration of relevant 
characteristics in a database of trials with a logistic regression model – the outcome being 
the contradiction or reaffirmation of prior beliefs – will be one of the final steps in the 
development of a framework for identifying when established practices have been 
reversed: informing the framework with the strengths of associations that study 
characteristics may have with reversal.  
In her thesis – the body of which laid much of the groundwork for this current 
thesis – Desirée Sutton proposed a framework of reversibility.45 This framework included 
several summary measures of study quality covering question design and methodology, 
reporting (i.e. PICOTS, ROB, and modified GRADE), and several other measures 
including: modified optimal information size, fragility index, study abstract conclusions, 
and the lengths of time from a trial’s start to its registration and from completion to 
publication.45 These elements will be informed by our analyses and the framework will 
be developed and adapted accordingly. 
 
1.8  CONCLUSIONS, IMPACT, AND THESIS OUTLINE  
Despite its complexity, there is a paucity of research concerning the 
characteristics of reversal. Reversal imposes several dangers to the wellbeing of the 
population and minimizing the impact of unnecessary reversal would have tangible 
benefits. Overall health could be improved as potentially harmful practices may be 
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stopped earlier or prevented from implementation, trust in the medical and scientific 
communities would improve as fewer practices are redacted and undergo de-investment 
and de-adoption, and unnecessary resource expenditure would be reduced.  
The meta-research community has only recently begun to explore reversals in a 
clinical context, hence the use of the term “medical reversal.” In this thesis we propose 
the term “evidence reversal” as a more appropriate general term for the phenomenon of 
contradictory findings, as well as proposing a framework to identify when a reversal of 
evidence has occurred and several key areas of future research in the field of reversal. 
This thesis provides an in-depth exploration of evidence reversal and the process of 
developing a framework of reversibility. This exploration will contribute to the field of 
evidence reversals by bringing together multiple themes – both philosophical and 
practical – into a cohesive whole. This framework will promote consistent use of 
terminology related to reversal and serve to provide guidance for researchers in designing 
robust trials, potentially decreasing the risk of reversal in the future.  
This first chapter has provided an overview of the concepts and theories that will 
be explored in the following chapters. The second chapter provides an updated systematic 
review on the concept of reversal and how it has been explored in the literature. The third 
chapter presents the methodology for our update of ‘A decade of reversal’ and how data 
extraction was conducted to create a database of trials and their characteristics. The 
fourth chapter provides an in-depth discussion of the process that we used to build our 
regression model and develop a framework of reversibility – from conceptualization and 
the analysis plan, to building the framework. The fifth chapter will present all results of 
our analysis of the characteristics of reversal including reproducing the descriptive 
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statistics originally published by Prasad et al., as well as our expanded analyses (logistic 
regression) and framework. The sixth chapter contains the discussion of our findings, as 
well as the strengths and remaining limitations. The seventh chapter presents the impact 
and possible future applications of our proposed framework of reversibility, as well as 
introducing an initial toolbox for future reversal research and presenting the conclusions 
of the overall thesis, wherein we review our findings and what we have learned from our 
various reviews. 
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Chapter Summary: This chapter is a systematic review of the literature to explore how the 
phenomenon of evidence reversal has been talked about in the past. Terms and 
definitions related to the phenomenon are compiled and organized into four 
major areas of research in the field of reversal.   
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CHAPTER 2 
2.0  INTRODUCTION 
 In 2011, Prasad and Cifu coined the term “medical reversal” for the phenomenon 
of new evidence for an established practice that is methodologically stronger than 
previously conducted research, finding that the clinical practice is less effective or more 
harmful than was originally believed.1 When such evidence arises for an established 
practice, it is “reversed” and steps should be taken to initiate its de-adoption, or removal, 
from practice. A medical reversal does not mean that the practice must be removed in its 
entirety; it is much more common that a reversal will provide a contraindication for a 
particular use in a particular population. Hormone replacement therapy (HRT) and 
percutaneous coronary intervention (PCI) still have clinical validity in an appropriate 
population, but it is now widely recognized that HRT does not reduce the risk of 
cardiovascular disease among post-menopausal women, and evidence shows that PCI for 
stable CAD does not reduce the risk of future adverse cardiac events, even though these 
practices were once though to provide net benefit.9,14  
 While ‘medical reversal’ is an appropriate term for the phenomenon that it 
represents, it is conceptually clinically oriented and implies the cessation of the reversed 
practice. The term may not always be appropriate as reversal occurs in non-medical 
fields, such as public health, and a reversal of evidence does not guarantee de-adoption: 
many practices continue after the evidence for them is contradicted.26,46 We propose a 
new term, “evidence reversal” (ER), to describe the phenomenon in both medical and 
non-medical fields and, more appropriately, when new evidence that is stronger than 
preceding evidence contradicts the established evidence for a practice. 
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 Reversal in a medical or clinical context is very common.1 The percentage of 
studies that investigate an established clinical practice and subsequently lead to reversal 
may be as high as 40%.4 Although the term for the phenomenon is still being diffused 
throughout the medical community, all physicians are familiar with the concept of 
reversal through the ever-changing guidelines for clinical practice.  
 The desirable progression of medicine is for newer and better interventions to 
replace older and less effective interventions.2 This replacement of therapies is ideal 
because it implies that at any given time, patients are given a standard of care that is the 
best available treatment at the time.2 However, despite reversal of evidence and 
subsequent de-adoption being expected, there are four implied harms to patients and the 
health care system as a whole. The first implication of reversal in a medical context is 
that the patients who were treated with the reversed practice were placed at a greater risk 
for, or actually experienced, unnecessary harm for little to no benefit.2 The second is a 
risk that health care resources are being wasted because treatments that are unnecessary 
or of low value are being utilized before they can be reversed.2,3 The third is an 
undermining of the trust in the medical system that is held by the public and by those 
who practice medicine.2 And the fourth risk associated with reversal is the difficulty in 
de-adopting established practices from the medical community.2,28  
 In considering the challenge of de-adoption, beyond the medical community there 
exists the same difficulty in removing a paradigm from common belief, no matter what 
evidence may arise to contradict it. An example of the difficulties inherent in removing a 
consistently and clearly disproven theory from the view of the public is the persistence of 
the belief that vaccines cause autism.47 In spite of evidence to contradict and deny the 
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claim, the belief remains strong enough that there have been lowered rates of childhood 
vaccination and an increase in the incidence of vaccine-preventable diseases in recent 
years.47   
 In order to curtail the harms of unnecessary reversal, by minimizing early 
conclusions that are based on insufficient evidence thereby preventing the premature 
uptake of new practices and theories, we must first have an understanding of the way that 
the phenomenon has been discussed and researched. In this systematic overview review, 
we explore how the concepts surrounding evidence reversal have been explored in the 
medical and non-medical literature. We create a compendium of terminology and 
definitions that relate to evidence reversal with the goal of bringing a degree of cohesion 
to this new and largely un-explored field.  
 
2.1  METHODS 
 In 2014, Sutton and colleagues conducted a systematic literature review of the 
terminology surrounding evidence reversal as part of her thesis.45 This systematic review 
was conducted with the purpose of finding how reversal had been discussed thus far in 
the scientific literature. As the term itself is new, and meta-research on the subject of the 
reversal of practices is sparse, we thought it best to update the search by Sutton et al. to 
include any new material from the two years since the search was last conducted. As this 
was an updated systematic review we aimed to use the same search methodology that was 
used in July of 2014. To this end, almost identical search strategies were applied to the 
same databases and sources that were searched.  
A modification to the original search strategies for PUBMED, OVID MEDLINE, 
and EMBASE databases was devised under the supervision of a medical librarian. The 
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modification was necessary as a small error in the strategies for these databases led to two 
terms – “result” and “disinvest*” – being left out of the searches. After discussion, it was 
decided that the use of the term “result” would return too many unrelated citations, but 
“disinvest” would be added to the searches for these databases because it was highly 
relevant to reversal and returned a small and manageable number of citations.  
2.1.1  Search strategy 
 A systematic review of the two-year period from January 1st, 2014 until July 6th, 
2016 was conducted of eight scientific and gray literature databases including: 
PUBMED, Ovid MEDLINE, EMBASE, CINAHL, Web of Science, the Dissertations and 
Thesis Database, The Canadian Health Research Collaboration (CHRC), and GOOGLE 
ScholarTM. In addition to this systematic searching, hand searching was conducted for the 
last two years for 27 blogs and websites and six journals.  
 Databases were searched using a combination of relevant subject headings and 
keywords including: evidence-based practice, patient care management, guidelines, 
clinical practice, practice guideline, physician’s practice pattern, evidence-based, and 
disinvest*. In addition, searching by proximity was utilized using terms such as 
publication, evidence, practice, guideline*, medical, standard, unexpected, or surprising, 
paired with terms like revers*, change, contradict*, divest, or de-implement*. For the full 
search strategies for each database including number of returned citations, please see 
APPENDIX A. 
2.1.2  Screening and inclusion criteria 
 All returned citations were imported into EndNote for screening, except for those 
collected from the CHRC, which were imported into, and screened in, Microsoft Excel. 
Screening was conducted at three levels: title, abstract, and full text. Due to time 
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constraints and the breadth of the search strategy, which was developed for high 
sensitivity and inclusion, screening was not conducted in duplicate. All new citations 
retrieved for the update of the search were screened by RQ, and the citations returned by 
DS were not duplicated. However, agreement was reached for final inclusion of articles 
and disagreements were settled by discussion.  
 To be included in this systematic overview review, all articles had to meet two 
criteria: they must have made some reference to the process of reversal or related 
concepts – according to our operational definition of ER – and they must have been a 
review article. Systematic reviews, meta-analyses, evidence syntheses, reviews, and 
collections of studies were included. All reviews pertaining to the phenomenon of new 
and stronger evidence contradicting current practice were included. These included direct 
and indirect references to evidence reversal including: medical reversals, changes in 
clinical practice guidelines or standards of care, and the disinvestment, de-
implementation, or de-adoption of practices.  
2.1.3  Quality assessment 
Data extraction was performed independently with two authors (RQ and DS) 
verifying the other’s work on a random subset of articles. Discrepancies were resolved 
through discussion.  
 Quality assessment of included reviews was done using the AMSTAR rating tool. 
The AMSTAR (A Measurement Tool to Assess Systematic Reviews) rating system is an 
instrument for assessing the methodological quality of systematic reviews.48 It consists of 
11 items and has been validated as a reliable quality assessment tool.49 The greater an 
article’s score out of 11, the greater the confidence in the findings of that review or group 
of reviews.48,49   
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Two out of the eleven items on the AMSTAR instrument (“Appropriate pooling 
of findings” and “Likelihood of publication bias”) were not applicable to the articles 
included in our review because pooling of results across different Populations, 
Interventions, Comparators, Outcomes, Timing and Study Designs (PICOTS) is illogical, 
therefore it was determined that deviations from high methodological practice would not 
appreciably bias results. As a result of this modification, the maximum number of points 
that a review could achieve on AMSTAR was nine. 
 
2.2  RESULTS 
 Systematic searches of the scientific and grey literature databases, and all hand 
searching of journals, blogs, and websites yielded 8117 unique citations. These citations 
were screened for exclusion criteria, resulting in 27 articles selected for inclusion after 
title, abstract, and full text screening. Five of these articles (from 2014) were already 
found from the search conducted two years ago. Duplication of these articles was 
expected and their inclusion validates the replication of previous search methods. 
Because five of these articles were already found, they were no longer counted as a part 
of the results in this review update. Therefore, 22 new articles were identified for 
inclusion in the systematic review. A further 8 articles were collected after screening the 
bibliographies, cited by, and related articles of the 22 identified via the database searches. 
Therefore, 30 new articles were added to the overall review through this update.  
Combining these 30 new articles with the 57 retrieved from the 2014 search 
resulted in a total of 87 articles for inclusion in the final review. Please refer to Figure 2.1 
PRISMA Flow-Chart for details of the article selection process used for this systematic 
review update (2014-July 2016).  
Riaz	Qureshi	 	 	
Chapter	II	 	 Unlocking	Evidence	Reversal	
29	
Figure 2.1 PRISMA flow diagram of study selection 
 
The PRISMA flow-chart for the full review (i.e. the manuscript submitted for 
publication created by combining the original review and this update) may be found in 
Appendix A. Apart from the PRISMA diagram outlining the screening performed in this 
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update, the remaining results and discussion of findings presented are those of the full 
review, representing the findings from all 87 included articles. 
2.2.1  Description of studies 
 The most common type of article that we found discussing evidence reversal was 
“collection of studies” (n = 58). These collections were mostly narrative and included 
letters to the editor, editorials, and recommendations for clinical practice based on new or 
important trial results. The majority of these collections of studies presented hand-picked 
or selected examples from journals or other reviews that the authors were discussing. 
Systematic reviews were the next most common type of article that we found (n = 24). 
The majority of articles have been published since 2011 (n = 71) with only a handful 
published in 2010 or before (n = 16).  
 
Table 2.1 Characteristics of included studies Characteristic	 No.	(%)	of	87	Articles	Year	of	Publication	 		2001-2005	 7	(8)		2006-2010	 9	(10)		2011-2015	 59	(68)		2016	 12	(14)	Type	of	Article	 		Collection	of	Studies	 	 58	(67)		Systematic	Review	 	 24	(28)		Overview	Systematic	Review	 	 2	(2)		Systematic	Scoping	Review	 1	(1)		Secondary	Data	Analysis	and	Review	 	 1	(1)		Recursive	Cumulative	Meta-Analysis		 1	(1)	Relationship	to	Reversal	*	 		Phenomenon	of	Reversal	 32	(37)		Consequence	of	Reversal	 35	(40)		Target	of	Reversal	 79	(91)		Potential	Predictor	of	Reversal	 8	(9)	AMSTAR	Quality	Rating	 		Very	Low	Quality	(Score	of	0	to	2)	 63	(72)		Low	Quality	(Score	of	3	to	5)	 21	(24)		High	Quality	(Score	of	6	to	8)	 3	(3)		Very	High	Quality	(Score	of	9)	 0	(0)	
* Percentages do not sum to 100% due to the appearance of multiple terms within individual articles 
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2.2.2  Terminology related to evidence reversal 
 The operational definition for evidence reversal that was used to find relevant 
articles is: when new evidence – better powered, controlled, or designed than its 
predecessors – contradicts previously established claims. We found 50 unique sets of 
terms related to evidence reversal that we collated into four broader categories: a) terms 
for the phenomenon of ER, those that describe the event of new and better evidence 
contradicting older; b) terms for the consequences of reversal, the processes undertaken 
to remove a practice that has been reversed; c) terms for the targets of reversal or 
practices that are likely to be reversed in the future; and d) terms for potential predictors 
of ER. Table 2.2 presents the full list of identified terms and their definitions. Table 2.3 
presents the frequency of the use of terms and how they relate to evidence reversal. 
APPENDIX B provides the complete data extraction for all included articles. 
 
Table 2.2 Terms and associated definitions for evidence reversal 
Year Term used Definition(s) 
2001 Uncertainty 50 “How much the treatment effect has changed over time and how much 
the pooled treatment effect will change the future.” 50 
2002 No Articles No Articles 
2003 Discrepancy 51 “Magnitude of the genetic effect as it changes over time.” 51 
2004 Ineffective or 
harmful 
interventions 52 
“Treatments previously commonly practices, but not known to not work 
or cause harm.” 52 
Unfavourable or 
favourable shifts 
over time 53 
“Changes in whether results become less or more favourable for the 
experimental intervention over time.” 53 
2005 Contradicted 8 “Subsequent research contradicts efficacy claim.” 8 
Initially stronger 
effects 8 
“Subsequent research shows smaller magnitude of efficacy claim.” 8 
Proteus 
Phenomenon 54,55 
“Rapid, early succession of very contradictory conclusions.” 54 
“Extreme between-study opposing estimates of effect in the results of 
early studies followed by studies with diminishing between-study 
variance.” 55 
2006 Contradicted 56 “Diminishing effects for the strength of research findings and rapid 
alternations of exaggerated claims and extreme contradictions.” 56 
Proteus 
Phenomenon 56 
“Rapid alternation between exaggerated claims and extreme 
contradictions in early studies followed by studies with diminishing 
effects for the strength of research findings.” 56 
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2007 Change in evidence 
57 
“Quantitative changes include differences of statistical significance or 
≥50% effect change in magnitude for important outcomes. Qualitative 
changes include differences in definition of effectiveness, new data on 
harm, and caveats about previous evidence.” 57 
Disinvestment 58 “The processes of withdrawing (partially or completely) resources from 
any existing healthcare practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain 
relative to their cost, and thus are not efficient health resource 
allocations.” 58 
Inconsistency 59 “Inconsistency occurs when there is large between-study heterogeneity 
(diversity) in the magnitude of the genetic effects.” 59 
Non-replication 59 “Occurs when the GWA (Genome Wide Association) study proposes 
that there is a gene-disease association, but the accumulation of data 
from subsequent studies find no genetic effect.” 59 
2008 Sacred Cows 31 “Practices are considered routine and beyond dispute.” 31 
“A clinical practice despite research that shows that the practice is not 
helpful and may even be harmful to the patients we serve.” 31 
2009 Assess new 
intervention – 
displace old 60 
“When a new intervention is presented to the relevant committee(s)† for 
regulatory assessment, and is considered a potential replacement for (an) 
established comparator(s) for that indication, then that comparator for 
that patient indication is automatically considered and assessed for 
disinvestment” 60 
Class II 
Recommendation 61 
“Class II: conditions for which there is conflicting evidence and/or a 
divergence of opinion about the usefulness/efficacy of a procedure or 
treatment.” 61 
“Class IIa: weight of evidence/opinion is in favour of 
usefulness/efficacy.” 61 
“Class IIb: usefulness/efficacy is less well established by 
evidence/opinion.” 61 
Class III 
Recommendation 61 
“Class III: conditions for which there is evidence and/or general 
agreement that the procedure/treatment is not useful/effective and in 
some cases may be harmful.” 61 
False positive result 
62 
“Report a treatment effect when in reality there is not effect.” 62 
Ineffective, 
harmful, or non-
cost-effective 
interventions 60 
“Ineffective, non-cost-effective or harmful interventions.” 60 
Legacy items 60 “Long-established technologies that have never had their cost-
effectiveness assessed – look for coupling with other identification items. 
Automatically considered and assessed for disinvestment.” 60 
Technology 
development 60 
“When an intervention has evolved to the point that it differs markedly 
from the initial or prototype intervention that was originally assessed or 
funded, then the initial intervention should be reviewed (e.g., 256-slice 
compared with four-slice computed tomography).” 60 
2010 Snake oil 63 “Nutritional supplements that are not worth it (inconclusive, slight, or no 
evidence of efficacy).” 63 
2011 False positive and 
inflated results 64 
“Report a treatment effect when in reality there is no effect.” 64 
“RRs were in opposite direction, larger, more than twice as large, more 
than 4 times as large, or different beyond chance in the highly cited vs. 
the largest study and in the highly cited study vs. the meta-analysis.” 64 
Medical reversal 1,2 “The phenomenon of a new trial – superior to predecessors because of 
better design, increased power, or more appropriate controls – 
contradicting superior clinical practice.” 1 
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“The phenomenon of a new trial – superior to predecessors because of 
better design, increased power, or more appropriate controls – 
contradicting superior clinical practice.” 2 
“A medical practice falls out of favour not by being surpassed, but when 
we discover that it did not work all along, either failing to achieve its 
intended goal or carrying harms that outweighed the benefits.” 2 
Recommendations 
for practice 65 
“Lack or presence of evidence” 65 
Sacred cows 32 “Practices are considered routine and beyond dispute.” 32 
“A clinical practice despite research that shows that the practice is not 
helpful and may even be harmful to the patients we serve.” 32 
2012 Disinvestment 28 “The process of withdrawing health resources from any existing 
healthcare practices, procedures, technologies and pharmaceuticals that 
are deemed to deliver no or low health gain for their cost and thus [do] 
not [represent] efficient health resource allocation.” 28 
“The cessation or restriction of potentially harmful, clinically ineffective 
or cost inefficient practices.” 28 
“The process of taking resources from one service in order to use them 
for other purposes (i.e. reallocation of resources).” 28 
Improper use 28 “Any existing healthcare practices, procedures, technologies and 
pharmaceuticals that are deemed to deliver no or low health gain for their 
cost and thus [do] not [represent] efficient health resource allocation’.” 28 
Low-value 
practices 66 
“Ineffective and/or unsafe services, treatments not proven to be clinically 
effective.” 66 
Medical reversal 
3,26 
“Established standards must be abandoned not because a better 
replacement has been identified but simply because what was thought to 
be beneficial was not.” 3 
“Oftentimes, years after a practice was introduced, the medical 
community puts it to the test in large, well done randomized trials. 
Empirical evidence suggests that when this happens, nearly half of those 
practices are contradicted. We call this phenomenon ‘medical reversal’.” 
26 
Negative list 28 “[practices] that have been superseded or demonstrated to 
be ineffective or harmful.” 28 
Obsolete/outmoded/a
bandoned 
technologies 28 
“Those that have been superseded or demonstrated to be ineffective or 
harmful.” 28 
POEM likely to 
change clinical 
practice 67 
“A study that is valid (avoids important biases), reports patient-important 
outcomes (such as morbidity, mortality, or quality of life) and changes 
clinical practice.” 67 
Research updates 
most likely to 
change clinical 
practice 68,69 
“Research updates most likely to change clinical practice.” 68,69 
Services not 
medically 
necessary 28 
“Any existing healthcare practices, procedures, technologies and 
pharmaceuticals that are deemed to deliver no or low health gain for their 
cost and thus [do] not [represent] efficient health resource allocation.” 28 
Things providers 
and patients should 
question 70 
“Wasteful or unnecessary medical tests, treatments and procedures” 70 
Unnecessary 
medical tests, 
treatments, and 
procedures 70 
 
“Wasteful or unnecessary medical tests, treatments and procedures” 70 
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Wasteful medical 
tests, treatments, 
and procedures 70 
“Wasteful or unnecessary medical tests, treatments and procedures” 70 
2013 Disinvestment 71 “The complete or partial withdrawal of resources from healthcare 
services and technologies that are regarded as unsafe, ineffective or 
inefficient.” 71 
Ineffective 
technologies 71 
“Healthcare services and technologies that are regarded as unsafe, 
ineffective or inefficient.” 71 
Low-value 
practices / health 
care 72–76 
“Clinical decisions that are of little value to patients, amenable to 
improvement through standardization, and actionable by front-line 
providers.” 72 
“Ineffective or lack evidence on their effectiveness, negative risk-benefit 
balance, more cost-effective alternatives exists, obsolete due to the 
introduction of new technologies.” 73 
“Interventions that robust evidence reveals are of no benefit, or even 
harmful.” 74 
“Health care services that provide little or no benefit – whether through 
overuse or misuse.” 75 
“…Not clinically effective for a given indication. It may be unsafe for 
everyone, or for subgroups of patients with risk factors. It may have a 
poor risk-benefit profile overall, or when used inappropriately.” 76 
Medical reversal 
4,35,36,77  
“Reversal was designated when a current medical practice was found to 
be inferior to a lesser or prior standard.” 4 
“The phenomenon of a new superior trial that contradicts current clinical 
practice.” 36 
“Medical reversal happens when new trials – better powered, designed or 
controlled than predecessors – contradict current standard of care.” 77 
“Modifications or even retractions, of important medical practice 
recommendation… [which] challenge traditional medical opinion.” 35 
Obsolete 
technologies 71 
“Healthcare services and technologies that are regarded as unsafe, 
ineffective or inefficient.” 71 
Overdiagnosis 78 “Waste of resources on unnecessary care” 78 
Overused or 
misused tests and 
treatments 79 
“Unnecessary tests and procedures that don’t benefit the patient and can 
even cause harm.” 79 
POEM likely to 
change clinical 
practice 80 
“A study that is valid (avoids important biases), reports patient-important 
outcomes (such as morbidity, mortality, or quality of life) and changes 
clinical practice.” 80 
Research updates 
most likely to 
change practice 81–
84 
“Research updates most likely to change clinical practice.” 81–84 
 
 
Sacred cows 33 “Practices are considered routine and beyond dispute.” 33 
“A clinical practice despite research that shows that the practice is not 
helpful and may even be harmful to the patients we serve.” 33 
Snake oil 85 “Nutritional supplements that are not worth it (inconclusive, slight or no 
evidence of efficacy).” 85 
Too much medicine 
78 
“Waste of resources on unnecessary care” 78 
Unproven therapies 
34 
“No proven value by current Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) guidelines, US Preventive Task 
Force Services criteria, or other similar criteria.” 34 
Waste 75 “ Inappropriate overuse of an otherwise effective intervention.” 75 
 
 
Riaz	Qureshi	 	 	
Chapter	II	 	 Unlocking	Evidence	Reversal	
35	
2014 Change in 
treatment 
guidelines 86 
“New RCT findings.” 86 
Contradicted 
established medical 
practices 44 
“When large, well-done randomized trials have contradicted current 
medical practice.” 44 
De-implementation 
44 
“Abandonment of medical interventions.” 44 
“Stopping practices that are not evidence-based.” 44 
Inappropriate care 
87 
“That relating to the use or non-use of a health service intervention based 
on the evaluation of (a) evidence of effectiveness; and/or (b) economic 
implications; and/or (c) other health system impacts; and/or (d) 
consideration of ethical implications and societal values.” 87 
Medical reversal 88 “A phenomenon in which ‘a medical practice is found to be inferior to 
some lesser or prior standard of care.’” 88 
POEM likely to 
change clinical 
practice 89 
“A study that is valid (avoids important biases), reports patient-important 
outcomes (such as morbidity, mortality, or quality of life) and changes 
clinical practice.” 89 
[Sacred Cows] 
Practices not 
supported by the 
evidence 30 
“Practices are considered routine and beyond dispute.” 30 
“A clinical practice despite research that shows that the practice is not 
helpful and may even be harmful to the patients we serve.” 30 
Snake oil 90 “Nutritional supplements that are not worth it (inconclusive, slight or no 
evidence of efficacy).” 90 
Research updates 
most likely to 
change practice 91–
93 
“Research updates most likely to change clinical practice.” 91–93 
Research waste 94 “Avoidable waste or inefficiency in biomedical research.” 94 
Unnecessary 
treatments, tests, 
and procedures 95 
“Do not add value to care … potentially expose patients to harm, leading 
to more testing to investigate false positives and contributing to stress for 
patients … increased strain on the resources of our health care system.” 
95 
Unproven medical 
practice 30 
“Many medical practices are largely untested or have insufficient 
evidence unable to support or refute interventions.” 30 
2015 Abandonment / 
abandon* 96,97 
“Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
[Change / decline / 
change / drop in] in 
use 96,97 
“Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Contradict* 96,97 “Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Clinical redesign or 
re-prioritization 97 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
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De-adoption / de-
adopt* 96,97 
“Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
De-commission / 
de-list 97 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Decrease use / 
reduc* 96,97 
“Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
De-funding or 
resource release 97 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Discontinuation / 
discontinu* 96,97 
“Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
De-implementation 
/ de-implement* 
97,98 
“Can involve overuse, underuse, and/or misuse of health services, 
products, and resources.” 98 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Disinvestment / 
disinvest 96,97,99 
“Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
“The process of (partially or completely) withdrawing health resources 
from any existing healthcare practices, procedures, technologies, or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and thus are not efficient health resource allocations.” 99 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Do-not-do 97 “The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Harmful practices 
98,100 
“Can involve overuse, underuse, and/or misuse of health services, 
products, and resources.” 98 
“Low value, unnecessary, or harmful to patients.” 100 
Inappropriate care 
101 
“Treatments that evidence clearly shows should not be done routinely, or 
at all.” 101 
Ineffective 
[technology / 
practice] 97,99 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
“Ineffective technologies are usually identified by evaluating their 
effectiveness, safety, and cost-effectiveness. In addition, overuse or 
misuse of technologies can lead to ineffectiveness.” 99 
Low-value health 
care / services / 
practices 97,98,100,102 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
“Care that is avoidable/not necessary/of low value.” 102 
“Can involve overuse, underuse, and/or misuse of health services, 
products, and resources.” 98 
“Low value, unnecessary, or harmful to patients.” 100 
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Medical reversal 
96,97,103–105  
“Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
“When an accepted practice – a diagnostic test, medication, or procedure 
– is overturned. The practice is not replaced by something better, but 
shown to be inferior to a pre-existing, less intensive, or less invasive 
one.” 103 
“Reversal of medical practice requiring significant changes in standards 
of care, workflow, and decision making.” 104 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
“When a current practice is found to be no better than, or inferior to, a 
prior standard.” 105 
Misuse 96,97 “Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Obsole* 96,97,99 “Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
“Obsolete technology: Any health technology in use for one or more 
indications, whose clinical benefit, safety, and/or cost-effectiveness have 
been significantly superseded by other available alternatives or are not 
supported by evidence.” 99 
Opportunity cost 96 “Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
Overdiagnosis 96 “Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
Overtreatment / 
overmedicalization 
/ Medical over use 
96,97,106,107 
“Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
“The provision of health care when the “risk of harm exceeds its 
potential benefit,” when the benefits are negligible, or when fully 
informed patients would forego care.” 107 
“Treatment of overdiagnosed conditions, or treatment that has minimal 
evidence of benefit or is excessive (in complexity, duration, or cost) 
relative to alternative accepted standards.” 106,107 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
POEM likely to 
change clinical 
practice 108 
“A study that is valid (avoids important biases), reports patient-important 
outcomes (such as morbidity, mortality, or quality of life) and changes 
clinical practice.” 108 
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Practice-changing 
evidence 109 
“Potential for practice change.” 109 
Reappraisal 96,97 “Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Reassess* or 
[evidence-based / 
health technology] 
reassessment 96,97 
“Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Recommendations 
for practice 110 
“New RCT findings.” 110 
Redeploy 97 “The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Refute 97 “The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Re-invest or 
substitutional re-
investment 97 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Relinquish* 97 “The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Remov* 97 “The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Replace 97 “The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Resource re-
allocation 96,97 
“Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Sacred Cows 111 “Clinical practices so rooted in tradition that they are resistant to change, 
despite reduced quality of care, patient outcomes, and greater costs 
compared with newer practices.” 111 
Selective 
disinvestment 98 
“Can involve overuse, underuse, and/or misuse of health services, 
products, and resources.” 98 
Stop* 97 “The discontinuation of a clinical practice after it was previously 
adopted.” 97 
Undiffusion 112 “Abandoning established practices found to be ineffective, disruptive, or 
the cause of net harm — or when better practices come along.” 112 
Waste 96  “Processes of withdrawing (partially or completely) health resources 
from any existing health care practices, procedures, technologies or 
pharmaceuticals that are deemed to deliver little or no health gain for 
their cost, and are thus not efficient health resource allocations.” 96 
Withdraw* or 
withdrawing from a 
service and 
redeploying 
resources 97 
 
 
“The discontinuation of a clinical practice after it was previously 
adopted.” 97 
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2016 
*As 
of 
July 
24th, 
2016 
Do-not-Do 
recommendations 
113 
“Clinical practices, identified during the development of guidance that 
should be discontinued or not used routinely.” 113 
Grade D 
Recommendation 
114 
“The USPSTF recommends against the service. There is moderate or 
high certainty that the service has no net benefit or that the harms 
outweigh the benefits. Discourage the use of this service.” 114 
Ineffective services 
115 
“Possibly ineffective or low-value services.” 115 
I statement 114 “The USPSTF concludes that the current evidence is insufficient to 
assess the balance of benefits and harms of the service. Evidence is 
lacking, of poor quality, or conflicting, and the balance of benefits and 
harms cannot be determined” 114 
Known uncertainty 
116 
“Uncertainties about the effects of treatments.” 116 
Low-value health 
care 115 
“Possibly ineffective or low-value services.” 115 
Medical reversal 
117,118 
“An accepted medical practice, often widely adopted, that is later found 
to be no better or worse than a previous standard of care.” 117 
“Medical reversals occur when the results of preclinical, observational 
and/or early phase studies fail to predict the results of subsequent 
randomized clinical trials, but the practice has already gained widespread 
acceptance.” 118 
POEM likely to 
change clinical 
practice 119 
“A study that is valid (avoids important biases), reports patient-important 
outcomes (such as morbidity, mortality, or quality of life) and changes 
clinical practice.” 119 
Practice-changing 
evidence 120 
“Potential for practice change.” 120 
Translation failure 
118 
“Translation failure occurs when the results of preclinical, observational 
and/or early phase studies fail to predict the results of well done (i.e. 
appropriately controlled, adequately powered, and properly conducted) 
phase III or randomised clinical trials.” 118 
Trials likely to 
change practice 121 
“New RCT findings.” 121 
Unnecessary waste 
115 
“Ineffective or low- value services, which are possibly provided at the 
expense of the social health insurance in Austrian primary care.” 115 
 
 
 Sixteen reviews used the term “Medical Reversal”, and the definitions that were 
presented were nearly identical to our operational definition for evidence reversal.1–
4,26,35,36,77,88,96,97,103–105,117,118 The use of the term “contradicted,” in the context of 
established medical practices, also had a similar definition, but with a focus on the 
comparison of initial conceptual studies and subsequent research, as opposed to evidence 
reversal which compares new evidence to previous evidence.8,44,97 Another term for the 
comparison of initial conceptual, and often extreme, results with subsequent research – 
but one that is used exclusively in the context of genome wide association studies – is the 
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“Proteus Phenomenon.”54–56 Other terms that we found referring to the phenomenon of 
ER include: “change in evidence” 57; “opportunity cost” 96; “overdiagnosis” 78,96; 
“practice changing evidence” 109,120; “refute” 97; “translation failure” 118; and “favourable 
/ unfavourable shifts over time.”53 Each of these terms describes the phenomenon of new 
evidence coming to light that changes a previously held belief about an established 
practice.  
Separate from terms that describe the phenomenon of evidence reversal are terms 
for the processes of reversal, or the actions that should take place after a reversal has 
occurred. These terms include: “abandonment” 96,97; “assess new interventions – displace 
old or replace” 60,97; “change in treatment [guidelines / practice]” 86,97,104; “clinical 
redesign or reprioritization” 97; “de-adoption or dis-adoption” 96,97; “decommission or de-
list” 97; “[decrease / decline / change / drop in] use” 96,97; “defunding or resource release” 
97; “de-implementation” 44,97,98; “discontinuation” 96,97; “disinvestment” 28,58,71,96–99; 
“overtreatment, medical overuse, overuse, misuse, or ‘too much medicine’” 78,96,97,106,107; 
“reassess*, [evidence-based / health technology] reassessment, or re-appraisal” 96,97; 
“recommendations for practice” 65,110; “re-invest, substitutional re-investment, re-
allocation, or redeploy” 96,97; “remov* or stop*”97; “undiffusion” 112; and “withdraw, 
withdrawing from a service and redeploying resources, or relinquish.”97   
Another category of terms that are related to reversal, but do not refer to the 
phenomenon or its consequences are those that describe targets. These terms refer to 
practices that are known to be reversals or are likely to be reversed and are therefore 
targeted for removal. These terms include: “Class II / IIa / IIb/ III recommendation” 61; 
“do-not-do recommendations” 97,113; “grade D recommendations” 114; “I statement” 114; 
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“[inappropriate / improper] [care / use]” 28,87,97,98,101; “[Ineffective / harmful / non-cost-
effective] [interventions / technologies]” 52,60,71,97–100,115; “legacy items” 60; “low-value 
[practices / health-care / services / intervention]” 66,72–76,97,98,100,102,115; “negative list” 28; 
“[obsolete / outmoded / abandoned] technologies” 28,71,96,97,99; “[overused / misused] tests 
and treatments” 79; “[research updates most / trials / POEMS] likely to change clinical 
practice” 67–69,80–84,89,91–93,108,119,121; “sacred cows” 30–33,111; “snake oil” 63,85,90; “technology 
development” 60; “things providers and patients should question or practices not 
supported by evidence” 30,70; “unnecessary medical [tests / treatments / procedures], 
unnecessary [tests / treatments / procedures], or services not medically necessary” 28,70,95; 
“unproven [therapies / medical practice]” 34,44; and “waste, research waste, unnecessary 
waste, or wasteful medical tests, treatments, and procedures.”70,75,94,96,115  
The final category of terms that we propose is related to evidence reversal is 
potential predictors of future reversal. These terms all refer to red flags in clinical 
research: their presence could bring the efficacy and strength of the evidence surrounding 
the investigated practice into question. Potential predictors of future reversal include: 
“[Discrepancy / inconsistency / uncertainty] or known uncertainty” 50,51,59,116; “[false 
positive / inflated] results” 62,64; “initially stronger effects” 8; and “non-replication.”59  
 
Table 2.3 Frequency of terms and their relation to evidence reversal 
Term Set a No. (%) of 
87 Articles b 
Year of First 
Appearance 
Relationship 
to Reversal 
References 
Abandonment / abandon* 2 (2) 2015 Consequence 96,97 
Assess new interventions – 
displace old or replace 
2 (2) 2009 Consequence 60,97 
Change in evidence  1 (1) 2007 Phenomenon 57 
Change in treatment guidelines / 
practice 
3 (3) 2014 Consequence 86,97,104 
Class II recommendation 1 (1) 2009 Target 61 
Class III recommendation 1 (1) 2009 Target 61 
Clinical redesign or re-
prioritization 
1 (1) 2015 Consequence 97 
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Contradicted / contradict* / refute 
/ contradictory result 
5 (6) 2005 Phenomenon 8,44,56,96,97 
De-adoption / de-adopt* / dis-
adoption 
2 (2) 2015 Consequence 96,97 
Decommission / de-list 1 (1) 2015 Consequence 97 
[Decrease / decline / change / 
drop in] use or reduc*  
2 (2) 2015 Consequence 96,97 
Defunding or resource release 1 (1) 2015 Consequence 97 
De-implementation / de-
implement* 
3 (3) 2014 Consequence 44,97,98 
Discontinuation / discontinu* 2 (2) 2015 Consequence 96,97 
Discrepancy / inconsistency / 
uncertainty or known uncertainty 
4 (5) 2003 Potential 
Predictor 
50,51,59,116 
Disinvestment / disinvest*  7 (8) 2007 Consequence 28,58,71,96–99 
Do-not-do recommendations 2 (2) 2007 Target 97,113 
[False positive / inflated] results 2 (2) 2009 Potential 
Predictor 
62,64 
Grade D recommendations  1 (1) 2016 Target 114 
I statement 1 (1) 2016 Target 114 
[Inappropriate / improper] [care / 
use] 
5 (6) 2014 Target 28,87,97,98,101 
[Ineffective / harmful / non-cost-
effective] [interventions / 
technologies / practices] 
8 (9) 2004 Target 52,60,71,97–
100,115 
Initially stronger effects 1 (1) 2005 Potential 
Predictor 
8 
Legacy items 1 (1) 2009 Target 60 
Low-value [practices / health care 
/ services / intervention] 
11 (13) 2012 Target 66,72–
76,97,98,100,102,
115 
Medical reversal / reversal 16 (18) 2011 Phenomenon 1–
4,26,35,36,77,88,9
6,97,103–
105,117,118 
Negative list 1 (1) 2012 Target 28 
Non-replication 1 (1) 2007 Potential 
Predictor 
59 
[Obsolete / outmoded / 
abandoned] technologies 
5 (6) 2012 Target 28,71,96,97,99 
Opportunity cost 1 (1) 2015 Phenomenon 96 
Overdiagnosis 2 (2) 2013 Phenomenon 78,96 
Overtreatment or medical overuse 
or “too much medicine” or 
overuse or misuse 
5 (6) 2013 Consequence 78,96,97,106,107 
[Overused / misused] tests and 
treatments 
1 (1) 2013 Target 79 
Practice changing evidence 2 (2) 2015 Phenomenon 109,120 
Proteus phenomenon 3 (3) 2005 Phenomenon 54–56 
Reassess* or [evidence-based / 
health technology] reassessment 
or re-appraisal 
 
2 (2) 2015 Consequence 96,97 
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Recommendations for practice  2 (2) 2015 Consequence 65,110 
Re-invest or re-allocation or 
substitutional re-investment or 
redeploy 
2 (2) 2015 Consequence 96,97 
Remov* or Stop* 1 (1) 2015 Consequence 97 
[Research updates most / trials / 
POEMS] likely to change clinical 
practice 
15 (17) 2012 Target 67–69,80–
84,89,91–
93,108,119,121 
Sacred cows 5 (6) 2008 Target 30–33,111 
Snake oil 3 (3) 2010 Target 63,85,90 
Technology development 1 (1) 2009 Target 60 
Things providers and patients 
should question or practices not 
supported by evidence 
2 (2) 2012 Target 30,70 
Translation failure 1 (1) 2016 Phenomenon 118 
Undiffusion 1 (1) 2015 Consequence 112 
Unfavourable or favourable shifts 
over time 
1 (1) 2004 Phenomenon 53 
Unnecessary medical [tests / 
treatments / procedures] or 
unnecessary [tests / treatments / 
procedures] or services not 
medically necessary 
3 (3) 2012 Target 28,70,95 
Unproven [therapies / medical 
practice] 
2 (2) 2013 Target 34,44 
Waste or research waste or 
unnecessary waste or wasteful 
medical tests, treatments and 
procedures 
4 (5) 2012 Target 70,75,94,96,115 
Withdraw* or withdrawing from a 
service and redeploying resources 
or relinquish 
1 (1) 2015 Consequence 97 
a *wildcard notation signifies multiple endings for the given term 
b Percentages do not total 100 due to the appearance of multiple terms within individual articles 
 
 
2.2.3  Quality Assessment 
 The overall confidence in findings of included articles was very low with a mode 
score of ‘1’, a median score of ‘2’, and a mean score of ‘2’. Most of the included articles 
declared conflicts of interest, but none of them described the potential conflicts of the 
examples that they presented. This led to the “conflicts of interest” item being uniformly 
not present among the included articles. The next four AMSTAR items that were the least 
present among included articles were: “list of included and excluded studies” (1%), 
“publication status in inclusion” (8%), “quality of included studies” (11%), and 
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“appropriate conclusions” (11%). The most present AMSTAR item among included 
articles was “characteristics of included studies” (85%). The majority of articles 
presented study characteristics in a non-table format (n = 47). The two AMSTAR items 
that had the greatest uncertainty were “study selection and data extraction in duplicate” 
and “comprehensive literature search,” the presence of which was unclear in 60% of 
included articles. APPENDIX C contains the full AMSTAR evaluation for all included 
articles. 
 
 
Figure 2.2 AMSTAR quality assessment 
 
 
2.3  DISCUSSION 
 In this systematic overview review, we expected to find a wide range of terms for 
the phenomenon of evidence reversal because the term “Medical Reversal” has only been 
						Percent	of	Ratings		
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in use since 2011, but the phenomenon has been present for longer.1 We found 50 unique 
sets of terms. The true number of terms was greater (179), but some terms were 
synonymous and were therefore grouped together (e.g. “[ineffective / harmful / non-cost-
effective] [interventions / technologies]” are six possible unique terms, but one unique 
set). Furthermore, we were interested to find that not all of these sets of terms had the 
same relation to evidence reversal. We set out to understand how the phenomenon had 
been explored thus far, both inside and outside of the academic literature, and based on 
our findings we propose that there are four essential facets to the evidence reversal 
discussion and meta-research. 
The first facet is research about the phenomenon itself: research surrounding the 
event of new evidence contradicting what was previously found and believed about a 
given practice or theory. The second facet is research around the processes and 
consequences of evidence reversal: the difficulties inherent in, and methods by which 
practices are de-implemented. The third facet of studying evidence reversal is identifying 
and declaring the targets for evidence reversal: the practices, health-care, and services 
that are known or suspected to be of low value. The fourth facet of this area of meta-
research is studying the potential predictors of future reversal: the characteristics of 
research that may lead to reversal of a practice in the future. 
        In order to reduce the impact of evidence reversals, the two most important areas 
of research are the latter two facets: identifying the targets of ER for removal and the 
potential predictors of ER for prevention. These areas of meta-research will take time and 
a concerted effort on behalf of the meta-research community. The first step to reduce the 
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impact is to bring cohesion to the first two facets of ER: studying the phenomenon of ER 
as well as the processes and consequences of ER. 
        The 26 unique sets of terms describing the phenomenon and consequences of ER 
suggest that there is currently no cohesion in this field of meta-research. While terms 
such as “Medical Reversal” and “De-implementation” are used most often, there are 
many other terms that have similar definitions but have slight contextual differences. For 
example: “Unfavourable or favourable shifts over time,” defined as “Changes in whether 
results become less or more favourable for the experimental intervention over time” 53; 
“Change in Evidence,” defined as “Quantitative changes include differences of statistical 
significance or ≥50% effect change in magnitude for important outcomes. Qualitative 
changes include differences in definition of effectiveness, new data on harm, and caveats 
about previous evidence” 57; or “Translation Failure,” defined as “When the results of 
preclinical, observational and/or early phase studies fail to predict the results of well-done 
(i.e. appropriately controlled, adequately powered, and properly conducted) phase III or 
randomised clinical trials.”118 This variety of terms causes unnecessary confusion and 
increases the difficulty for those who wish to understand the processes involved. This 
difficulty was evident while designing database specific search strategies as there are no 
subject headings that are specific to evidence reversal. 
In 2015, Niven et al. proposed the term “De-adoption” as a unifying term for the 
process of removing a practice from use. We agree that this would be a good term to 
describe the consequences of reversal in an all-encompassing context, as opposed to the 
most frequently cited term for the process  – disinvestment – which was more often used 
in a monetary/economical context. In adopting the term “de-adoption” for the process and 
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consequences of evidence reversal, there is still the confusion created by the many terms 
for the phenomenon. Although it has not been used before in the literature, we propose 
the term Evidence Reversal as a unifying term because it represents finding contradictory 
evidence for any established practices or beliefs in both medical and non-medical fields, 
unlike the current most commonly used term, “Medical Reversal,” which is restricted to 
the field of medicine and clinical practice. 
2.3.1  Significance and future directions 
The significance of this review for the field and for this thesis lies in the proposed 
unity that the term Evidence Reversal would bring to this area of meta-research. Previous 
research in the field of reversals has been focused on the medical literature and clinical 
practices. As a term for the phenomenon, “medical reversal” is clinically oriented and 
carries an implication of cessation of practice. This systematic overview review expands 
the definition from “medical reversal” to “evidence reversal,” thereby encompassing both 
medical and non-medical practices, and providing an appropriate term for when the 
evidence has been reversed, but the practice continues to be used.  
The next step for resolving the large collection of terms and definitions would be 
to form a common language framework using input from content experts in medical 
reversal, disinvestment, and meta-research through the Delphi Method to reach consensus 
on subject headings and how they should be defined. Once created, the framework will 
promote consistent use of terms and concepts to maximize comparability, repeatability, 
and quality of evidence, which will allow universal discussion and higher quality reviews 
in the future, thus advancing the field of evidence reversal in a more structured way.  
This review will inform the development of such a framework because it has 
revealed that although exploration of reversals as a field of research has only recently 
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begun, there are many different terms that have similar definitions. This discrepancy 
suggests that the best way to approach ER may be through a simplified definition such as: 
“when newer and stronger evidence contradicts a previously held belief that was based on 
older or weaker evidence.”  
2.3.2  Strengths and limitations 
This review was very thorough and the search strategies and methodologies 
employed gave the results a very high sensitivity to capture all of the relevant material. 
As the purpose of this review was to explore the literature and capture the different ways 
that reversal has been described, our broadly defined inclusion criteria allowed us to 
capture what should be the vast majority of relevant articles related to evidence reversal.  
The high sensitivity of our search is also one of its weaknesses. This review was 
very labour intensive and thus, screening was not conducted in duplicate and inclusion 
may have been more subjective than is typically desirable for a systematic review. While 
there was a six-month period of overlap between the original searches and this update 
(from January 2014 until July 2014), agreement was not calculated for any of the 
screening levels (i.e. title, abstract, full-text). However, the articles for final inclusion 
were agreed upon between authors (RQ and DS), with all disagreements resolved through 
discussion.  
The quality of articles included in this review was very low and the focus was 
largely on collections of studies instead of systematic reviews. The median AMSTAR 
rating was 2/9, which would suggest very low confidence in the conclusions and 
recommendations of this review. However, as the purpose of this review was to explore 
the terminology and definitions of the field, and not the conclusions or findings made by 
any particular articles, this poor quality of included studies should not have an effect on 
Riaz	Qureshi	 	 	
Chapter	II	 	 Unlocking	Evidence	Reversal	
49	
the quality of this review. Rather, such consistently low quality of research into the field 
should instead suggest that more high-quality research be conducted to verify or disprove 
the phenomenon of evidence reversal.  
While the quality of included studies may not necessarily affect the quality of the 
conclusions that this review makes, one limitation that must be considered lies with the 
definitions of some of the included terms. Many of the included reviews used multiple 
terms but did not provide all of the corresponding definitions. As a result, our table of 
terms and definitions has much overlap between the definitions given for different terms 
from the same article (e.g. Niven et al. only provided a definition for “de-adoption,” 
though they found over 40 terms related to the process, many of which we considered to 
be unique and were separated into different term sets).97 This limits the strength of our 
results because some of the sets of terms that we found do not have distinct definitions, 
despite the terms themselves being unique – even to the point of having different 
relationships to reversal (e.g. “Re-appraisal” and “Contradict*” which are respectively 
terms for a consequence and the phenomenon of reversal, were both found in the review 
article by Niven et al., but neither was defined in its own right, so both are assigned the 
only relevant definition provided by the article: the definition for de-adoption “The 
discontinuation of a clinical practice after it was previously adopted” 97).  
 
2.4  CONCLUSION 
 Evidence reversal, though not a new phenomenon, has only recently been named. 
There are many different terms for the phenomenon of reversal as well as the 
consequences and process that follow identifying practices that are targeted for reversal. 
Given the similarities between definitions for the various terms, the best way to proceed 
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with discussion of evidence reversal is under a simplified and all-encompassing 
definition. Consensus should be reached on which terms are most appropriate so that 
subject headings can be developed and cohesion can be brought to this emerging field of 
meta-research. Once there is unity in the theoretical aspects of ER, then researchers can 
start to investigate more tangible aspects including identifying the targets of reversal and 
characteristics of initial evidence that may be potential predictors of future reversal.   
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CHAPTER 3 
 
 
 
 
 
An exploration of characteristics associated with Evidence 
Reversal: Methods – Part I 
 
Rationale & Methods of Database Generation 
 
 
 
 
 
Riaz Qureshi 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Summary: This chapter presents the methods used to construct the database upon 
which we conduct all of our exploratory analyses. The rationale for our 
approach is presented first, followed by explanations of our screening and data-
extraction methods. More detailed protocols with exact descriptions of the 
decision-making processes at each stage are presented in Appendices D and E.   
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CHAPTER	3	
3.0  A QUANTITATIVE APPROACH TO REVERSAL 
 Evidence reversal is the phenomenon whereby new and better evidence 
contradicts a previously held belief about an established practice or standard of care that 
was based on weaker evidence. In its current state, the meta-research surrounding the 
field of medical reversals and evidence reversals remains disorganized and unnecessarily 
complicated. Since the field is new, there are many different terms and areas of research 
being explored. In our systematic overview of the literature, we found 87 articles that 
could be characterized into four broader categories of research surrounding reversal: 
research about the instance of reversal or contradictory findings, research about the 
consequences or recommendations for practice change after something has been reversed, 
research about the practices that are low value and should be targeted as reversal, and 
research about the characteristics of practices and early research that increases the 
likelihood of later reversal.122    
 Between these four facets of reversal research we found 50 unique sets of terms 
that have been used in the literature. The phenomenon of reversal was most often denoted 
as “medical reversal” and “contradicted / contradict* / refute / contradictory result” while 
“disinvestment” and “overtreatment, medical overuse, ‘too much medicine,’ overuse, or 
misuse” were primarily used to describe the consequences of reversal.122 We found that 
the practices targeted as reversals were most often referred to as “low-value [practices / 
healthcare / services / interventions]” or “[research updates most / trials / POEMS] likely 
to change clinical practice,” and that discussion of potential predictors of future reversal 
included research characteristics such as “discrepancy,” “inconsistency,” “uncertainty,” 
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“known uncertainty,” “false positive or inflated results,” “initially stronger effects,” and 
“non-replication.”122  
 Despite being a quickly expanding field, the vast majority of research pertaining 
to evidence reversal has been qualitative: we found that the most common type of review 
article discussing an aspect of reversal was “collection of studies,” which were primarily 
narrative and included letters to the editor, editorials, and recommendations for clinical 
practice.122  	
3.1  THE CAUSES AND CHARACTERISTICS OF REVERSAL 
The phenomenon of evidence reversal is complex and there are two different 
directions from which the problems posed by unnecessary reversals can be approached. 
One approach is an analysis of the characteristics of original research that leads to the 
premature adoption of practices that will later be reversed. Such an analysis would 
provide insight into the causes of reversal and could lead to the generation of a predictive 
model for the likelihood of reversal in the future. The other approach would be an 
analysis of the characteristics of trials that find contradictory evidence against established 
practices and beliefs. Such an analysis would not provide a predictive model, but could 
elucidate the characteristics of research that are associated with reversing previous 
evidence. 
In his paper about the high prevalence of research findings that are false or 
inaccurate, Ioannidis touched on several important characteristics of research that could 
contribute to future reversal – in relation to the first approach – including: increased 
financial interests or prejudices, the non-declaration of conflicts of interest, and the 
novelty of a research field.23,39 Beyond these contributing factors, other characteristics of 
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research that may be associated with risk of reversal include: the use and support of 
traditional practices that have never been tested using randomized controlled trials, the 
overgeneralization of pathophysiological models to untested indications and populations, 
and implementing interventions and practices based on their effects on surrogate 
outcomes.1,22,30,33,35,36 Furthermore are the common problems with study design and 
conduct that can affect the validity and fragility of research findings which include, 
among others: small sample size, low numbers of events, use of restricted populations, 
biased data collection and assessment, as well as the validity of measures used to assess 
an outcome. All of these characteristics may be applicable to evidence reversal in 
assessing the risk of future reversal based on initial studies. 
The second approach is also important as the analysis and understanding of the 
characteristics of contradictory evidence is critical for the development of a framework of 
reversibility. By ‘framework of reversibility,’ we mean a conceptual framework of study 
characteristics that are associated with the contradiction of beliefs about current medical 
practices that can be used to guide future research and practice. In particular, a 
framework outlining the prevalence of study characteristics and degrees of association 
that trials may have with evidence reversal would be valuable to researchers and policy 
makers in guiding trial design to test current standards of care and the adoption or de-
adoption of practices. 
 
3.2  A DATABASE OF “REVERSALS” AND “CONFIRMATIONS” 
 Prasad et al.’s 2013 study, ‘A decade of reversal,’ was a review of all original 
articles published in the New England Journal of Medicine between 2001 and 2010.4 
After screening 2044 articles, they determined that approximately 65% (1344/2044) 
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concerned a medical practice, 27% (363/1344) of which tested an established practice, 
and of those, 40% (146/363) were declared medical reversals: finding the practice no 
better or worse than originally believed.4  
While this was the first systematic attempt to quantify reversal, the study had 
several limitations, particularly with respect to how reversals were characterized. One 
element that was not included was the quality of studies. A study was classified as a 
medical reversal if the original study authors declared that their findings contradicted 
current practice, and all original research articles, regardless of the study design, were 
included in their review. However, the element of study quality is inherent to the 
definition of reversal (i.e. a study must be better quality than its predecessor to reverse 
that previously established practice). We sought to improve upon this limitation by 
including only randomized controlled trials, which are assumed to represent higher 
quality of evidence than other study designs for testing interventions.123 However, our 
classification of reversal or reaffirmation was still largely based on what was presented 
by the authors of each respective RCT included in our database.  
Another limitation of ‘A decade of reversal’ was that the statistical analyses were 
primarily descriptive of the sample of studies that they had collected: percentages of trials 
that examined new versus existing medical practices, the distribution of study designs, 
the percentages of trials that had conclusions that were positive versus negative or no 
difference between comparators, and the prevalence of studies that were classified as: 
‘reversal,’ ‘confirmation,’ ‘replacement,’ or ‘back to the drawing board’.4 Prasad et al. 
also qualitatively described each study that they considered to be reversals. However, no 
analyses of association of characteristics with reversals were conducted. 
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Table 3.1 outlines the features of ‘A decade of reversal’ and directly compares 
them to the approach taken in this thesis. 
 
Table 3.1 Comparing our approach to Prasad et al.’s ‘A decade of reversal’ 
‘A decade of reversal’ Expanded study outlined in this thesis 
• NEJM (2001-2010) 
• All original research studies 
• Includes studies of both new and 
established standards 
• Descriptive statistics (study design) 
• Qualitative descriptions of ‘reversals’ 
• NEJM (2000-2016) 
• Randomized Controlled Trials (subset of all original 
research studies) 
• Includes only trials testing established practices 
• Descriptive statistics (study design) 
• Descriptive statistics (study results, methodology, and 
quality) 
• Exploratory analyses of association of trial 
characteristics with reversal of evidence using 3 
logistic regression approaches 
• Univariable 
• Multi-variable 
• Backwards-stepwise model selection 
  
To construct our database of reversals and reaffirmations, we first collected all of 
the same characteristics assessed by Prasad et al. To expand upon their analyses and to 
further explore the characteristics of study design that may be associated with reversal, 
we also conducted an extensive quality assessment for each included trial using several 
different approaches. The inclusion of each of the individual components of these 
assessments, as well as their overall judgements allows us to quantitatively explore the 
characteristics of reversal to a greater degree than possible in ‘A decade of reversal.’   
 
3.3  SCREENING 
We collected and screened all articles published as original research studies in the 
New England Journal of Medicine (NEJM) from January 2000 until December 2016. The 
NEJM was selected because it was the most cited journal in the medical sciences at the 
time: based on the 5-year Hirsch Index for Medical Journals.124 The use of a single 
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journal was also necessary to restrict the project to a manageable size, given the time 
constraints of a two-year program.  
Collected articles were screened in three consecutive stages on the basis of 
published abstracts and full-text articles. The first two levels of screening were not 
conducted in duplicate, but the third level was screened in duplicate (RQ, DS). 
 In order to be included in this review, articles must have met three criteria: 1) they 
must evaluate a medical practice; 2) they must be a randomized controlled trial; and 3) 
they must evaluate an established practice or current standard of care.  
As we planned to analyse the characteristics of studies that are likely to be 
associated with reversal, it necessitated two further inclusion criteria beyond the 
collection of all studies of medical practices: that of RCT study design – the established 
gold standard for testing the effect of interventions and consequently assumed higher 
quality than observational study designs – and that of established practices so as to create 
a dichotomous outcome upon which to build a logistic regression: contradiction (i.e. 
reversal) or confirmation (i.e. reaffirmation) of the current practice. 
There were no restrictions placed on medical field or setting: all articles that met 
the above three criteria were included, regardless of their domain. For full descriptions of 
how decisions were made for each of the three inclusion criteria, including article 
excerpts to support the description of methods, please see APPENDIX D.  
3.3.1 Medical practice 
 As per the methods described by Prasad et al., articles that tested a medical 
practice were defined as “any investigation that assesses a screening, stratifying, or 
diagnostic test, a medication, a procedure or surgery, or any change in health care 
provision systems”.4   
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Besides medical practices, there were several other subject areas that appeared in 
the NEJM including research articles pertaining to molecular basis of disease, 
pathophysiology of disease, and animal studies. Articles addressing these subjects were 
excluded as they did not fit the pre-specified definition of medical practice. 
3.3.2 Randomized controlled trial 
 On the basis of their abstracts and methods, the study design of an article was 
classified as randomized controlled trial (RCT), prospective controlled (but non-
randomized) intervention study, observational study (prospective or retrospective), case-
control study, or other methods (including reviews, case series, and case studies). Only 
RCTs were included in this review; all other study designs were excluded in an effort to 
create a database of higher quality studies.  
3.3.3 Current standard of care or existing practice 
 The classification of whether or not a trial tested an existing practice was made on 
the basis of the abstract, introduction, and discussion sections of the papers. While no 
literature searches were conducted to verify each practice as being currently in use, as this 
would have been infeasible given the number and extent of searches that would have 
been necessary, this inclusion criterion was screened by two authors (RQ, DS) who had 
access to practicing health care providers, and all disagreements were resolved through 
consensus, and when necessary by consultation with a health care provider. We believe 
this to be a fair replication of Prasad et al.’s methods for determining whether a practice 
was new or existing, though they were not explicit in describing the criteria used to 
determine whether a practice was new or existing.  
Some trial authors were clear in their description of a practice’s prior use, while 
some chose to downplay or overemphasize the use of a practice. As such, while we felt 
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that the majority of trials were correctly designated as testing new or existing practices, 
there were some trials that were contentious and required discussion between RQ, DS, 
and JM. 
 
3.4  DATA EXTRACTION 
As we sought to explore the characteristics of studies that may be associated with 
reversal, our extraction included any characteristics that we believed may have some 
relevance to the phenomenon. Thus, the extraction for each RCT included: general 
identifying information, study design and methodology, study results, overall 
conclusions, conflicts of interest, PICOTS assessment, Risk of Bias assessment, and 
overall GRADE rating. Table 3.2 presents each of the characteristics included in the 
database.  
 
Table 3.2 Database characteristics extracted and automatically completed for each 
included trial 
Extraction Section Characteristics Extracted Automated Characteristics 
General information • Authors 
• Title 
• DOI 
• Date of publication 
• Registered/protocol published 
• Registration number/protocol citation 
• Year of trial initiation 
• Year of trial registration 
• Year of trial completion 
• Year of publication 
• Years between start and 
registration 
• Years between registration and 
publication 
• Years between completion and 
publication 
• Years since publication 
 
Study design and 
methodology 
• Population 
• Intervention 
• Comparison 
• Primary outcome 
• Primary outcome: 
favourable/unfavourable? 
• Secondary outcomes 
• Duration of follow up 
• Sample size 
• Required sample size 
• Delta used to calculate sample size 
• Whether each of the above elements 
matches the protocol  
None 
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Study results • Total loss to follow up  
• Loss to follow up in intervention group 
• Loss to follow up in comparison group 
• P-value for primary outcome 
• Statistical significance of P-value 
• Point estimate for effect measure 
• Confidence interval around point 
estimate 
• Measure of effect 
• Type of outcome 
• Events in intervention group 
(dichotomous) 
• Number of subjects in intervention 
group 
• Events in comparison group 
(dichotomous) 
• Number of subjects in comparison 
group 
• Intervention group mean (continuous) 
• Intervention group standard deviation 
(continuous) 
• Comparison group mean (continuous) 
• Comparison group standard deviation 
(continuous) 
• Percent of sample size lost to 
follow up 
• Intervention group rate and 
confidence interval 
(dichotomous) 
• Control group rate and confidence 
interval (dichotomous) 
• Absolute risk difference and 
confidence interval 
(dichotomous) 
• Number needed to treat and 
confidence interval 
(dichotomous) 
• Total number of events 
(dichotomous) 
• Relative risk reduction 
(dichotomous) 
• Fragility index (dichotomous) 
• Standardized effect size and 
confidence interval (continuous 
and dichotomous) 
• Adequacy of power (continuous 
and dichotomous) 
 
Overall conclusions • End point conclusions 
• Justification for conclusion 
• Does the article contradict current 
medical practice? 
• Justification for contradiction or 
confirmation 
• Primary outcome reported in abstract 
conclusion 
• Abstract conclusion based on subgroup 
analyses 
• Abstract conclusion based on 
secondary outcomes 
• If reversal: what category? 
• Personal judgement on whether trial is 
a reversal 
• Is the article a reversal or a 
reaffirmation? 
 
Conflicts of interest • Funding designation 
• Sources of funding 
None 
PICOTS assessment • Sufficiency or Insufficiency of each of 
the following characteristics 
o Population 
o Sample size 
o Intervention 
o Comparison 
o Outcomes 
o Type of outcome (hard, surrogate, 
composite) 
o Follow up 
o Study design 
o Study purpose/question 
 
None 
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• Justification for the designation 
applied to each of the above 
characteristics 
• Overall sufficiency of PICOTS 
ROB assessment • The likelihood of risk of bias in each 
of the following characteristics 
o Sequence generation 
o Allocation concealment 
o Blinding 
o Incomplete outcome data 
o Selective outcome reporting 
o Other design areas 
• Justification for the designation 
applied to each of the above 
characteristics 
• Overall likelihood of risk of bias 
None 
GRADE assessment None • General risk of bias (Overall 
likelihood of risk of bias) 
• Directness and applicability 
(Overall sufficiency of PICOTS) 
• Imprecision of results (Adequacy 
of power) 
• Modified risk of publication bias 
(Selective outcome reporting 
bias) 
• Total number of downgrades 
• Overall quality of evidence 
 
 
Data extraction was completed by three extractors: RQ (years: 2000, 2001, 2002, 
2003, 2004, 2006, 2008, 2010, 2012, 2014, 2016), DS (years: 2005, 2007, 2009, 2011, 
2013, 2015), and Dr. Leonardo Guizzetti, who was also trained and contributed to data 
extraction for 2006.  
To guide the data extraction process, a protocol for this review, outlined by Sutton 
et al. was followed.45 This protocol outlined the components and processes followed for 
each characteristic in the database. The use of the protocol and a random test-set of trials 
before completing extraction minimized potential differences between extractors. The full 
table of data-extraction and analysis elements for the database can be found in 
APPENDIX E.  
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3.4.1 General information 
 General information collected from each study was primarily used for 
identification, although characteristics such as the dates of publication, trial registration, 
initiation, and completion were also used to inform the PICOTS assessment.  
3.4.2 Study design and methodology 
 Characteristics of the study design and methodology that were extracted include: 
population, intervention, comparison, primary outcome, secondary outcomes, duration of 
follow-up in weeks, actual sample size, and the required sample size to meet author 
specified power level, significance level, and specified differences between point 
estimates of measures of effect. Furthermore, each of these characteristics was compared 
with the trial protocol or registration (if available) to inform the PICOTS assessment. 
It is important to address the selection of intervention, comparison, and primary 
outcome because they formed the basis for the characteristics of the study results. All 
three of these characteristics were attributed based on the authors’ designation. In some 
cases, the designation was not explicit or multiple options were available, in which case 
pre-specified rules were followed, as outlined in the data extraction protocol 
(APPENDIX E).  
3.4.3 Study results and overall conclusions 
 Characteristics of the study results that were extracted include: loss to follow up, 
significance, point estimate and confidence intervals of measures of effect for the primary 
outcome (if provided), as well as the raw findings pertaining to the primary outcome: 
numbers of subjects in each group and numbers of events, for dichotomous outcomes, 
and means/medians and standard deviations/interquartile ranges for continuous outcomes.  
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In addition to the extracted characteristics, the Excel database was encoded to 
automatically calculate clinical measures including: point estimates and confidence 
intervals for the absolute risk difference (ARD), number needed to treat (NNT), the 
relative risk reduction (RRR), and a standardized effect size for dichotomous and 
continuous outcomes. The Fragility Index and reverse Fragility Index were respectively 
calculated for each eligible trial using a web application and the R – 3.3.3 ‘Fragility 
Index’ package.  
 The overall conclusions of the included trials were taken from the discussion or 
the conclusion of the abstract and pertain to the main finding for the primary outcome. 
Similarly, the classification of the trial as contradicting current medical practice was 
taken from the authors’ conclusions, recommendations, and background in describing the 
current beliefs surrounding the practice in question.  
If a trial was determined to contradict a previously established and currently used 
practice, the type of reversal was specified as one of several predetermined categories 
including when the practice was found to be harmful; not effective; less effective than 
currently believed, but still beneficial; or beneficial if thought to be harmful/not 
effective/inferior to a different practice. 
3.4.4 Conflicts of interest 
 The conflicts of interest included all sources of funding reported by the authors. If 
sources of funding or other potential conflicts of interest were stated, they were classified 
as non-industry or industry.  If any of the sources of funding were from an industry 
company (e.g. pharmaceutical makers), then the conflicts were classified as industry. 
However, if a company provided only the intervention and this was declared in the paper 
(i.e. the authors explicitly stated that the company only provided drugs/devices and not 
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any funding or further support), then the designation was based on the other sources of 
funding and potential conflicts.  
3.4.5 PICOTS assessment 
 A PICOTS (population, intervention, comparison, outcome, timing, study design) 
assessment was conducted to determine the sufficiency of the study methodology that 
was extracted previously. Each component of trial methodology was classified as 
sufficient or insufficient with regards to its adequacy for reaching an answer for the 
primary outcome and overall study question, as well as its similarity to the trial 
protocol/registration (if available). The general guideline that was followed led to a 
designation of sufficient as being appropriate if the relevant information was itemized or 
stated in the article or its protocol. If the information was not present or was 
inappropriately different from the protocol (when available) then the component was 
designated as insufficient. An overall assessment of the PICOTS was generated on the 
basis of the sufficiency of the individual components. APPENDIX E contains detailed 
instructions to guide the designation of each component as sufficient or insufficient. 
3.4.6 Risk of Bias assessment 
 A risk of bias (ROB) assessment was conducted to determine the overall risk of 
bias for each trial. The ROB tool was developed from the Cochrane Handbook, Chapter 8 
and each item is given a designation on a 4-point scale: ‘definitely low risk of bias,’ 
‘probably low risk of bias,’ ‘probably high risk of bias,’ or ‘definitely high risk of 
bias.’125 The ROB assessment is similar to a PICOTS in that it requires one to judge a 
study’s design, however it covers different aspects of methodology where biases may be 
introduced including: treatment sequence generation, allocation concealment, blinding to 
intervention groups, handling of incomplete outcome data, whether outcomes were 
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selected and switched or pre-specified, and other general issues with study design (e.g. 
early termination, industry influence, extreme baseline imbalance).  
The general guideline that was followed for the ROB assessment was that if direct 
evidence to inform the decision was provided in the article, then ratings of “definitely low 
risk of bias” or “definitely high risk of bias” were appropriate options. However, if the 
relevant information was not explicitly reported in the article but could be inferred, or 
there was insufficient information to permit judgement, then ratings of “probably low risk 
of bias” or “probably high risk of bias” were appropriate options. A rating of “definitely 
high risk of bias” was assigned to a domain when there was direct evidence that bias 
could have been introduced in that design element. An overall assessment of the ROB 
was generated on the basis of the individual domains. APPENDIX E contains detailed 
instructions to guide the rating of each component’s risk of bias. 
3.4.7 GRADE assessment 
 Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) is a well-established tool to help determine the overall quality of evidence that 
a study provides.126 There are five domains including general risk of bias, directness and 
applicability, imprecision, risk of publication bias, and inconsistency of findings.126 All 
studies included in our review had an initial GRADE rating of ‘high quality evidence’ 
because under the GRADE framework, trials are considered to start at the highest level of 
evidence as opposed to observational studies, which begin at a low level of evidence.123   
The GRADE assessment in the database was coded to automatically complete for 
each trial based on the previously extracted characteristics. The GRADE ‘risk of bias’ 
was taken from the overall ROB assessment. ‘Directness and applicability’ was 
autocompleted with the overall PICOTS assessment. ‘Imprecision’ was automatically 
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characterized as ‘sufficient’ or ‘insufficient’ based on the adequacy of the trial’s power. 
A modified ‘risk of publication bias’ was based on the risk of bias for outcomes selection 
(within the ROB assessment) using reporting bias as a proxy for publication bias.  
We did not include the GRADE domain of ‘inconsistency’ in our assessment 
because it is specifically used for describing the heterogeneity of results across multiple 
trials on the same topic. As we collected all original RCTs of medical practices, with no 
restriction on type or field of practice, it was impossible to describe the degree of 
consistency across the evidence. Therefore, we made the simplifying decision to not 
assess the inconsistency of included trials.  
Another simplifying assumption that we made in our GRADE assessment was the 
inability to increase quality of evidence rating through inflating factors. The GRADE 
framework allows studies to increase their quality rating if they exhibit: a large or very 
large effect size, a dose-response relationship, or if the presence of residual confounding 
would reduce the demonstrated effect or suggest a spurious effect if no effect was 
observed.127 However, this upgrading of the evidence is primarily only applied to 
observational studies and though it is theoretically possible to upgrade the quality rating 
of RCTs, the GRADE Working Group remark that they “have yet to find a compelling 
example of such an instance.”127 Also, by including only RCTs, each article was 
automatically categorized as the highest quality of evidence initially. For these reason, we 
decided that for our GRADE assessment, trials – and consequently all included studies in 
this review – would not be able to receive any upgrading of evidence as proposed within 
standard GRADE methodology.  
 
Riaz	Qureshi	 	 	
CHAPTER	III		 An	Exploration	of	Trial	Characteristics:	Methods	I	 	 	
67	
3.5  CONCLUSIONS 
Prasad et al.’s review from 2013 provided a starting point from which we sought 
to further explore the characteristics of research that may be associated with reversal. To 
this end, we independently replicated and also further expanded their methodology to 
allow for more in-depth analyses of quality, methodology, and the findings of RCTs that 
test established practices and may lead to evidence reversal.  
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Chapter Summary: This chapter presents the methods used for all of our planned analyses 
and additionally serves as a protocol to guide the analyses as it was written 
before the analyses were conducted. The planned reproduction and expansion 
of ‘A decade of reversal’ is presented first, followed by an explanation of our 
exploratory logistic regression analyses. The Stata do-files for setting up the 
database and conducting the analyses are presented in Appendices F and G.   
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CHAPTER 4 
4.0  STATISTICAL ANALYSES PLAN 
 The ‘Decade of Reversal’ study by Prasad et al. was a landmark review in the 
field of medical and evidence reversal as it was the largest and most comprehensive study 
to specifically address the phenomenon.4 Given its importance, and their focus on the 
years 2001 to 2010, an independent replication of the study, together with a further 
expansion to include more recent articles (2000 to 2016), is needed to assess 
reproducibility and to add power. Furthermore, reproducing the review provides an 
opportunity to expand the breadth of analyses to identify trial characteristics that may be 
associated with reversal, potentially providing the necessary data to create an evidence-
informed framework of reversibility to guide future research.   
 After screening all articles published in the New England Journal of Medicine 
between January 2000 and December 2016, the characteristics of included articles were 
extracted into an excel database as described in Chapter 3 and APPENDICES D and E. 
All descriptive statistics were calculated using Stata 13, as were all regression analyses. 
The Stata do-files for importing and setting up the excel database and then conducting the 
analyses described in this chapter can be found in APPENDIX F and APPENDIX G, 
respectively.  	
4.1  ANALYSES IN ‘A DECADE OF REVERSAL’ 
 The 2013 review was conducted to identify medical practices that offer no net 
benefits. The authors reviewed all articles published in the NEJM between 2001 and 
2010, and classified them according to whether they addressed a clinical practice, 
whether they tested a new therapy or an existing therapy, whether the final results and 
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conclusions were positive versus negative or no difference (i.e. whether they found a 
significant effect favouring their intervention or control group, or found the groups were 
not statistically different), and whether the results constituted evidence “replacement,” 
“back-to-the-drawing-board,” “reaffirmation,” or “reversal.”4  
 The analyses that Prasad et al. conducted in ‘A decade of reversal’ were primarily 
descriptive. In their results they described: the proportion of articles addressing a medical 
practice (65.8%); the proportion of medical practices that were new versus existing (73% 
and 27%, respectively); the proportions of different study designs (67.7% RCTs, 16.4% 
prospective controlled but non-randomized studies, 8.7% observational studies, 3.2% 
case-control studies, and 3.9% studies with other methods); the proportions of studies 
reaching conclusions that were positive (significant difference in favour of intervention) 
versus negative (significant difference in favour of control or non-significant difference) 
between comparators (70.5% and 29.5%, respectively); as well as the overall proportions 
with conclusions that constituted replacement, back to the drawing board, reaffirmation, 
or reversal (56.3%, 12.3%, 10.9%, and 10.3%, respectively).4  
 In addition to the above descriptive statistics, Prasad et al. specified the most 
common study type, the proportions of reaffirmations and reversals among studies that 
tested existing medical practices, the proportions of study types among articles that 
constituted reversals, and the statistical likelihood that articles testing new or existing 
practices would find the practice to be beneficial or ineffective. The remainder of the 
results presented in the review were qualitative descriptions of selected reversals and a 
limited exploration of their trends; namely the narrative shared by many reversals, which 
entails the acceptance of a practice or standard – despite a weak evidence base – due to 
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support from prominent members of the medical community and a faith in the 
pathophysiologic mechanism, which is subsequently undermined when adequately tested 
by properly conducted randomized controlled trials.4 
 
4.2  INDEPENDENTLY REPRODUCING AND EXPANDING 
ANALYSES OF ‘A DECADE OF REVERSAL’ 
In an effort to independently reproduce, expand, and update ‘A decade of 
reversal,’ we attempted to classify articles into the same categories over the same years as 
in Prasad et al., with an additional 7 years of trials. We replicated their methodology as 
accurately as we could from the description provided in the article. However, we also 
wanted to improve upon their methods by assessing the characteristics of studies that may 
be associated with reversal. To this end, we only extracted data for articles that were 
classified as randomized controlled trials (RCTs) as they are assumed to provide a higher 
quality of evidence than observational studies, and generally provide conclusions that are 
more robust.  
 The baseline analyses of our database of RCTs will include independent 
reproduction of all descriptive statistics presented in ‘A decade of reversal.’ This will 
include: the proportion of articles that address a medical practice, the proportion of 
medical practices that were new versus existing, the proportions of different study 
designs testing medical practices, the proportions of article conclusions being positive 
(significant) versus negative (non-significant difference) between comparators, and the 
proportions of reaffirmations and reversals among trials that tested established practices. 
There are several descriptive statistics that were not conducted because articles 
that were classified as testing “new” practices were excluded from our study and have no 
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further data extracted beyond that collected to inform the first two levels of screening 
(outlined in Chapter 3, Section 3.3). Further, the “study type” of all included articles for 
our study is “RCT,” and thus descriptive statistics relevant to other study designs do not 
apply to our study sample. We will not describe: the overall proportions of studies 
designated as “replacement” or “back to the drawing board,” the most common study 
type, the proportions of study types among articles that constituted reversals, and the 
statistical likelihood that a trial testing new practices would find the practice to be 
beneficial or ineffective.  
 
4.3  EXPANDED ANALYSES: DESCRIPTIVE STATISTICS 
Prasad et al. explored the presence of reversal within the NEJM and described 
several characteristics of the articles that they found. Our goal was to expand the analyses 
conducted in ‘A decade of reversal.’ Consequently, we collected additional 
characteristics about the included trials, which allowed us to provide improved 
description of the sample of trials and characteristics that may be associated with 
reversal. In addition to independently reproducing the descriptive statistics presented by 
Prasad et al., as outlined above in section 4.2, we also report other descriptive statistics 
for our sample as would be found in an observational study or trial. These will be 
reported for the overall sample and according to whether the trial contradicted or 
supported the practice that it was examining (i.e. reversal vs. reaffirmation). 
In our tables of sample characteristics, we will report: proportion of trials that 
were registered; proportion of those registered that had an accessible protocol or 
registration; mean number of years between trial start and registration of those where the 
protocols/registrations were accessible; the proportion of trials that had a primary 
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outcome that was focused on harm; mean duration of follow up; mean sample size 
achieved; mean required sample size; mean percentage lost to follow up; proportion that 
had significant primary outcomes (with a P-value ≤ 0.05); proportions of studies using 
different measures of effect; proportion with a primary outcome that was dichotomous; 
proportions of studies with primary outcomes that are based on hard, composite, or 
surrogate outcomes; proportions of studies that reported abstract conclusions based on 
their primary outcome, subgroup analyses, or secondary outcomes; proportions of studies 
belonging to each category of ‘reason for reversal;’ proportions of studies with each 
overall PICOTS designation; proportions of studies with each overall ROB designation; 
and proportions of studies with each overall GRADE level of evidence.  	
4.4  EXPANDED ANALYSES: LOGISTIC REGRESSION 
While descriptive statistics are valuable in characterizing a sample of studies that 
may lead to evidence reversal, the conclusions that can be drawn from such analyses are 
limited. A multivariable logistic regression of the characteristics of these studies would 
provide a greater understanding of the degree to which they are associated with reversal. 
Logistic regression will be used for this analysis because it is the most widely used model 
for binary outcomes in clinical and epidemiological applications.128 This quantitative 
approach to assessing the characteristics of trials will contribute to the generation of a 
framework of reversibility to help guide future research in the field. 
The multivariable logistic regression model assumes that multiple covariates are 
related to the outcome in an additive fashion on the log scale.128 Other assumptions about 
the covariates and outcome include: the model is fitted correctly; the outcome follows a 
binomial distribution; the mean expected outcome for a given set of covariates (E[y|x] = 
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P(x)) is given by the logistic function; values of the outcome are statistically independent 
(i.e. truly binary); all observations are independent; and the requirement of large sample 
sizes.  
To ensure the model has appropriate fit, Pearson and Hosmer-Lemeshow (HL) 
goodness-of-fit tests will be performed. If either goodness-of-fit test suggests that the 
model is not appropriate (P-value ≤ 0.05) then the least non-significant covariate will be 
removed and the goodness-of-fit retested, until the model is appropriate. The outcome of 
the model (reversal versus reaffirmation) is binary and the requirement of large sample 
sizes will be assumed met for all univariable analyses, as there will be more than 10 
reversals (cases) per covariate given the sample size of 611 trials. However, there will be 
reduced power for the overall multivariable regression as controlling for several 
categorical covariates will lower the number of trials with each specific designation. An 
assumption that may not be met is the independence of all observations, as some trials 
included in the database are related. As all RCTs from 2000-2016 that met the inclusion 
criteria are in the database, some included trials are secondary analyses of earlier trials 
(which may also be included), or multiple publications on different outcomes of the same 
trial (e.g. publication of intermediary analyses and final outcome data). However, the 
simplifying assumption of independence between observations will be applied as only a 
small proportion of the 611 included trials are not independent.   
This project presents a comprehensive study of RCTs published in the NEJM, but 
it is neither a meta-analysis, nor a meta-regression. Rather, the sample of trials that have 
been collected will be treated as ‘individuals’ in assessing the relation of their 
characteristics to a known outcome. In this sense, an analogous study design to the 
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overall approach could be described as a repeated cross-sectional study. A case-control 
design would not be an appropriate analogue, as a sample of reversals and reaffirmations 
was not selected at the start of the trial based on their outcome. Neither would a cohort 
design be an appropriate analogue because there are different ‘subjects’ each year and 
there are no repeated measures of the same ‘individuals.’ A repeated cross-sectional study 
design is the most appropriate as the database is a sample of trials each year for the past 
17 years – selected on the basis of inclusion criteria that were designed to refine the 
sample to one most likely to have the outcome of interest – and extracted relevant 
characteristics for which the relation to the outcome of interest (determined after 
inclusion in the study) will be described. The implication of this ‘approach’ is that we 
cannot infer causality or influence of the characteristics on the outcome, only the degree 
to which they are associated, because all of the data for the characteristics and the 
outcome is collected at the same time.    
4.4.1 Overall logistic regression 
 In order to assess the strengths of associations that the characteristics of trials may 
have with reversal, potentially important characteristics will be included as covariates in a 
multivariable logistic regression on the outcome of reversal (contradiction of established 
practice) or reaffirmation (confirmation of established practice). Table 4.1 presents the 
covariates that will be included in the overall logistic regression model, as well as their 
possible values. Section 4.5 describes the rationale for inclusion of each covariate in the 
model as well as the methods for describing and assessing their distribution and validity 
of inclusion in the model.   
In the logistic regression analyses of these characteristics, the associations of all 
individual covariates were first tested in univariable analyses. An overall logistic 
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regression model was then fitted with all potential predictors in a simple exploratory 
analysis, which was followed by a backwards-stepwise model selection. As an additional 
approach to assessing the covariates, we assessed the correlation of each covariate with 
the others. 
 
Table 4.1 The 15 covariates included in overall logistic regression  
Type of 
Covariate 
Covariate name Possible values 
Continuous 1. Percentage of participants lost to follow up 0.0 to 100 
2. Length of follow up 0 to (+ ∞) 
3. P-value 0.0 to 1.0 
4. Sample size 0.0 to (+ ∞) 
5. Standardized effect size 0.0 to (+ ∞) 
6. Year of publication 2000 to 2016 
Binary 7. Protocol registered • Yes 
• No 
8. Abstract conclusions based on primary outcome • Yes 
• No 
9. Abstract conclusions based on secondary 
outcome 
• Yes 
• No 
10. Abstract conclusions based on subgroup 
hypotheses 
• Yes 
• No 
Categorical 
(Ordinal) 
11. Overall PICOTS assessment • Sufficient 
• Somewhat insufficient 
• Clearly insufficient 
12. Overall ROB assessment • Definitely low risk of bias 
• Probably low risk of bias 
• Probably high risk of bias 
• Definitely high risk of bias 
13. Overall GRADE assessment • High 
• Moderate 
• Low 
• Very low 
Categorical 
(Nominal) 
14. Conflicts of interest  • Non-industry 
• Industry 
• None reported 
15. Type of outcome • Hard  
• Composite 
• Surrogate 
 
The logistic backwards-stepwise regression fits all explanatory variables to a 
model and then sequentially removes the covariates that are non-significant by a pre-
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specified level for removal.129 The model iteratively checks the significance of the least 
significant included covariate to see if it is less than the pre-specified level for exclusion 
from the model and re-estimates the fit after each removal until all include covariates are 
significant at the pre-specified level.129 This method theoretically produces the best fitting 
model from a set of potential predictors, but only when there is no prior subject matter 
knowledge to enable pre-specification of important covariates.130  
There are limitations to the use of backwards-stepwise model building – 
particularly with regards to the stability of the selection process in the presence of 
collinearity – such as over-fitting the model to the data, yielding highly biased R2 values 
and models that are not generalizable.130,131 However, as this analysis is exploratory, and 
we wished to determine if any of our pre-determined covariates have relationships with 
reversal – whether significant or not – and not necessarily to build the most appropriate 
predictive model, we deemed the backwards-stepwise approach acceptable. Our model 
selection criteria were lenient and we used a significance level of ‘0.5’ for dropping 
covariates from the model.130 Thus, if a covariate has a p-value > 0.5 it may be excluded 
from the model.131 The Hosmer-Lemeshow goodness of fit for the original model was 
compared to the final model generated with the backwards-stepwise method. 
 The results of the individual covariate analyses and overall logistic regression are 
presented as a table of the odds ratios, confidence intervals, and p-values for the 
relationship that each covariate has with the outcome of reversal. These associations 
between each covariate and the outcome were interpreted from the perspective of trial 
methodologists to inform the development of a framework which attempts to incorporate 
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the relationships discovered into a unified decision aid for directing future research and 
assessing generalizability for detecting past reversals or predicting future reversals.  
4.4.2 Logistic regression of multidimensional summary scores 
After the general logistic regression had been conducted with all of the covariates 
of interest, it was possible that one or more of the multidimensional summary 
components may have been found significantly associated with reversal. The overall 
GRADE, PICOTS, and ROB assessments are summary scores that are comprised of 
individual components – covering different aspects of study design and methodology. If 
any of these summary measures were found to be significantly associated with the 
contradiction of established practices, we planned to conduct multivariable logistic 
regressions of the component domains on the outcome to determine which of the 
components drives the significance of the overall measure.  
Table 4.2 outlines each of the three smaller logistic regressions that would have 
been conducted to assess the individual components of the multidimensional summary 
scores, if any of them had been significantly associated with the outcome in the overall 
logistic regression. These models also would have been assessed with Pearson and HL 
goodness of fit tests.  
 
Table 4.2 Model covariates for each of three separate summary score regressions 
Significant summary score Covariates Possible values 
PICOTS (8 components) • Population 
• Sample size 
• Intervention 
• Comparison 
• Outcomes 
• Follow up 
• Study design 
• Study purpose/question 
• Sufficient 
• Insufficient 
ROB (6 components) • Sequence generation 
• Allocation concealment 
• Blinding 
• Definitely low risk of bias 
• Probably low risk of bias 
• Probably high risk of bias 
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• Incomplete outcome data 
• Selective outcome reporting 
• Other design areas 
• Definitely high risk of bias 
GRADE (4 components) • General risk of bias • Definitely low risk of bias 
• Probably low risk of bias 
• Probably high risk of bias 
• Definitely high risk of bias 
• Directness and applicability • Sufficient 
• Somewhat insufficient 
• Clearly insufficient 
• Imprecision of results • Sufficient 
• Insufficient 
• Modified risk of publication 
bias 
• Definitely low risk of bias 
• Probably low risk of bias 
• Probably high risk of bias 
• Definitely high risk of bias 		
4.5  RATIONALE FOR COVARIATE INCLUSION 
The initial set of explanatory variables that were selected for inclusion in the 
model included a mix of continuous, binary, ordinal, and nominal categorical. There were 
15 covariates that we believed might be associated with the outcome of reversal or 
confirmation of practice because they have been previously identified as indicators of 
study quality and strength of evidence. Given that a common trend for many reversals 
involves high quality randomized controlled trials that contradict a practice implemented 
on a weak evidence base, we assumed that these common markers of study quality may 
represent good candidate markers with plausible mechanism for relationship with reversal 
or reaffirmation of established practices.  
When there is a high degree of loss-to-follow up within a trial, it can be difficult 
to interpret the effect of the intervention.132 Differential or non-random loss to follow up 
– in terms of numbers and reasons between comparison groups – is particularly 
challenging as it may affect the validity of trial conclusions, while a low loss-to-follow 
up can be indicative of good trial design and conduct.132  
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As experience in clinical research has developed, it has become apparent that 
interventions that were believed to have short-term effects will continue to elicit effects 
and impact patient outcomes in the long term (e.g. excess mortality among patients with 
sepsis admitted to the hospital, compared to the general population, remains for several 
years, yet most interventional sepsis studies use end-points of mortality at 28-days).133,134 
As a consequence, the study of clinical outcomes almost always requires longer lengths 
of follow up to find the true net effects of an intervention. Thus, duration of follow up is 
included as a continuous covariate because theoretically, the longer patients are followed, 
the more likely it is that the true net effect of a practice will be found and potentially 
reversed.  
While sample size is a predictor of significance, both the P-value and sample size 
were included in the overall model because practices that are established based on small 
studies may be overturned by large, adequately powered, trials, and thus these 
characteristics may have some relation to evidence reversal. Similarly, a standardized 
effect size was included in the model to allow comparison between the various measures 
of effect, both dichotomous and continuous, used by different trials.  
We investigated the year of publication as a potential predictor for two reasons. 
Firstly, Prasad et al. tested if there was a significant relationship between the percent of 
reversals over time using a linear regression. Even though they found that the percentage 
of reversals among articles that tested a standard was consistent across the decade (P = 
0.51), we still included year as a covariate because, theoretically, the risk of reversals 
may change as time progresses, and our study has increased the number of years from 10 
to 17. This assumption is logical because the longer that a practice has been implemented, 
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the more opportunities arise where it may be reversed and consequently practices may be 
significantly more likely to be reversed as time progresses.  
The sources for abstract conclusions (primary outcome, secondary outcomes, or 
subgroup hypothesis) were included in the overall model as dichotomous markers for 
potential reporting bias. The conclusions of the abstract should report the general 
interpretation of results and be consistent with the primary outcome reported in the 
abstract.135 Publications that make abstract conclusions based on subgroup analyses or 
secondary outcomes (i.e. selective reporting) may be trying to draw attention away from 
an unfavourable or insignificant primary outcome.136 
The overall PICOTS, ROB, and GRADE assessments were also tested in the 
model because they are summary measures of several multidimensional characteristics 
concerning study quality. We believe that designations of higher study quality may be 
associated with reversal because for a practice to be reversed there must be sufficient 
evidence to support the decision and poor quality studies are less likely to constitute 
sufficient evidence. This rationale is further supported by the definitions of medical and 
evidence reversal, which include the qualification that the new evidence claiming to 
reverse an established practice be superior to that which preceded it.1  
The designation of potential conflicts of interest and sources of funding were 
included in the model as trials with industry influence may be more likely to lead to 
confirmation. This is because all trials in our database test established practices. While 
industry trials of new practices are more likely to find significant differences, when 
testing interventions that are already adopted – particularly those created by their own 
company – they may be more likely to confirm what is believed than contradict it.137,138  
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Outcome type was the final covariate included in the overall model as its 
relationship with reversal is one of the trends seen among many reversals: practices 
implemented based on intervention effects on surrogate outcomes are subsequently 
reversed when the relevant ‘hard’ (clinically-relevant; patient-important) outcomes are 
tested.2,77 We included this characteristic because we expected that trials using surrogate 
outcomes or composite outcomes may be more likely to confirm the practices that they 
are testing, while trials investigating an intervention’s effect on hard, patient-important, 
outcomes may be more likely to lead to reversal.139  
In addition to the 15 included in the overall model, there are five covariates for 
which the relationship with reversal was only examined in univariable analyses. These 
are ‘years between trial start and registration,’ ‘years between trial end and publication,’ 
‘Fragility Index,’ ‘Total Number of Events,’ and ‘Adequacy of Power.’ These covariates 
are of interest because they are related to the confidence that can be expressed in a trial’s 
results, but must be assessed on their own because all but the Adequacy of Power have 
high degrees of missing data that cannot be meaningfully imputed, and the Adequacy of 
Power is an indicator variable of our devising that we do not feel comfortable influencing 
the potential relationships of other covariates.  
The two continuous covariates that measure the years between start and 
registration, and completion and publication, are indicators of reporting and publication 
biases as trials with large positive values indicate retroactive registration and long periods 
of non-publication. These two covariates were not included in the overall model because 
they only had numerical values when a registered protocol is accessible and have a 
designation of ‘N/A’ when there is no registration available. Consideration was given to 
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including them in the model with a binary indicator variable (the availability of a protocol 
or registration), but after deliberation with committee members, the decision was made to 
explore them on their own. The Fragility Index is an indication of how many events 
would be required to change the significance of a trial’s results.140 A lower Fragility 
Index suggests that a trial’s conclusions may have been different with a few more events 
in one group or the other and, consequently, that the results may be ‘fragile’ and more 
easily reversed.140 A Fragility Index value of ‘0’ may arise because of a difference in the 
statistical test used to determine significance, as the Fragility Index calculates p-values 
using the Fischer’s Exact Test.140 The total number of events is closely linked to the 
Fragility Index as it is calculated using the number of events and subjects in each group. 
However, investigating the relationship of total number of events is also of interest 
because it is a more familiar metric to the medical community and an established 
contributing factor to the power of a trial in making conclusions. The adequacy of power 
is a dichotomous indicator of whether or not a trial had sufficient power based on its 
actual sample size, its reported necessary sample size, and the desired delta between 
comparators (if reported).  
 
4.6  MISSING DATA 
The NEJM was selected as the journal upon which to conduct this review based 
on its 5-year impact factor (Hirsch-index).4 The NEJM is widely regarded as being one of 
the highest quality medical journals in the world and as such, maintains a high standard in 
the reporting and writing of the articles it publishes. However, even within this high 
impact journal, some elements of trial design and results were missing from the 
descriptions provided in the publication (as well as provided appendices and protocols).  
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In an effort to account for missing data, simple mean imputation was used for 
characteristics where appropriate. Each imputed characteristic underwent sensitivity 
analyses to test whether use of the imputed data significantly affected the resulting 
relationship. The amount of missing data for each covariate – before and after imputation 
– will be presented in Chapter 5 as the number of observations contributing to the result 
for each characteristic.  
Table 4.3 outlines the methods used for imputation of missing data for each of the 
covariates in the general model. There are several covariates for which there was no 
missing data, including: year of publication, whether the trial was registered, the end 
point conclusions, overall PICOTS assessment, overall ROB assessment, overall GRADE 
assessment, the reason for reversal, the designation of conflicts of interest, and the type of 
primary outcome. These are mostly covariates that were our judgements and 
interpretations of aspects of the trial – based on what the author had presented in their 
paper – and therefore cannot be missing because they are not directly taken from the 
publication.  
 
Table 4.3 The 15 covariates and proposed imputation methods for missing data 
Covariate Proposed method of imputation 
% Subjects lost to follow up Mean imputation with average % subjects lost to follow up 
P-value If raw data or effect measure for primary outcome is provided, the 
missing p-value will be imputed with a mean significant p-value for 
significant trials with a significant outcome confidence interval, and 
the mean non-significant p-value for trials with non-significant 
confidence intervals for their primary outcome 
Standardized effect size Standardized effect size is calculated using the raw trial data. For 
trials with dichotomous outcomes, the number of subjects and 
number of events for each group are used to calculate an absolute risk 
difference, which is used to generate a standard effect size. For trials 
with continuous outcomes, the mean and standard deviations for each 
group are used to generate a standard effect size.  
 
For trials with no raw data, missing effect sizes will be mean 
imputed. 
Length of follow up Mean imputation with average duration of follow up 
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Year of publication No missing data 
Abstract conclusion primary No missing data 
Abstract conclusion secondary No missing data 
Abstract conclusion subgroup No missing data 
Protocol registered No missing data 
End point conclusions No missing data 
Overall PICOTS assessment No missing data 
Overall ROB assessment No missing data 
Overall GRADE assessment No missing data 
Conflicts of interest No missing data 
Type of outcome No missing data 
 
 
4.7  DEVELOPING A FRAMEWORK OF REVERSIBILITY 
An initial framework of reversibility has been proposed by Sutton and Martin that 
focuses on specific components of the design, execution, and analysis of evidence by 
using indicators derived from trial design, methodology, and reporting.45 The framework 
– which includes the individual domains of a PICOTS, ROB, and modified GRADE 
assessment, as well as modified optimum information size, fragility index, duration from 
trial start to registration and from completion to publication, and sources of abstract 
conclusions – is proposed as a tool to inform the likelihood that a trial reverses an 
established practice.45 This framework may aid healthcare decision-makers in delaying 
the adoption of new practices or disinvesting established practices until the evidence has 
matured. Our expanded analyses will further the development of this framework as we 
explore the relationship that these characteristics and others have with the declaration of 
reversal.  
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Chapter Summary: This chapter presents the results of both descriptive analyses (the 
reproduction and expansion of those conducted in ‘A decade of reversal’) and 
the exploratory logistic regression analyses.   
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CHAPTER 5 
5.0  SCREENING 
 Three thousand five hundred and sixty original research studies published in the 
New England Journal of Medicine (NEJM) between January 1st, 2000 and December 31st, 
2016 were collected by two authors (RQ and DS).  These articles were screened at three 
levels for inclusion criteria using the abstract and full texts, leading to exclusions of: 834 
for not studying a medical practice, 964 for not being randomized controlled trials, and 
1147 for testing new practices.   
 
 Figure 5.1 PRISMA flow diagram for inclusion of trials 
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Screening for the first two levels was not conducted in duplicate, but the third tier 
– existing versus new practices – was duplicated and had an initial Kappa of 69% 
between the two authors (RQ and DS). After screening for exclusion criteria, 615 trials 
were included in the database. However, during data extraction, four trials were excluded 
for reasons that were not accounted for in the initial exclusion criteria. These trials were 
excluded primarily due to the lack of useable outcome data. One publication was an 
ICER (Incremental Cost-Effectiveness Ratio) analysis of a previously published trial. 
One trial was of a screening test, but provided no summary outcome data that could be 
used. One publication was an interim analysis of the participant’s baseline data and had 
no outcome data for either group. One trial did not present outcome data for each 
intervention group, but as summary data for the entire study group. Therefore, the 
database includes 611 randomized controlled trials of established medical practices. 
 
5.1  DESCRIPTIVE STATISTICS FOR INCLUDED TRIALS  
 Between 2000 and 2016, 3560 original research studies were published in the 
NEJM. The majority of studies (2726 [77%]) addressed a medical practice. Of the studies 
concerning a medical practice during these 17 years, we identified 1762 (65%) 
randomized controlled trials, 725 (27%) observational studies, 118 (4%) prospective 
controlled but non-randomized studies, 88 (3%) case control studies, and 33 (1%) studies 
of other design. Of the randomized controlled trials, 615 (35%) were determined to 
address an existing practice. Characteristics of the 611 included trials were extracted and 
the descriptive statistics for the sample, presented in Tables 5.1 through 5.4, were 
calculated using Stata 13.  
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Table 5.1 Classifying characteristics of studies screened  
Screened Studies (2010 – 2017) (n = 3560) # of Studies (%) # of 
Observations 
Articles that addressed a medical practice 2726 (77%) 3560 
Articles with study design of: 
Randomized Controlled Trial 
Observational (prospective or retrospective) 
Prospective (non-randomized) Controlled Trial 
Case-Control 
Other (meta-analysis, case-study, case-series) 
 
1762 (65%) 
725 (27%) 
118 (4%) 
88 (3%) 
33 (1%) 
2726 
RCTs that addressed an existing practice 615 (35%) 1762 
 
 
Based on authors’ conclusions and the information presented within their 
backgrounds and discussion, 331 (54%) were reversals – contradicting the established 
practice being tested – while 280 (46%) confirmed what was believed or upheld the 
standard of care over a lesser or prior standard (reaffirmation). With regard to the trial 
results, 256 (42%) reached positive conclusions while 355 (58%) reached negative 
conclusions or found no statistically significant difference between their comparators. 
Among trials that contradicted the established practice being tested, there were 
several different possible reasons for reversal including: the practice was found to be 
harmful if it was thought beneficial (19%); the practice was found to be ineffective to the 
comparator if it was believed to be effective (46%); the practice was found to be less 
effective or equivalent to a comparator if it was believed to be superior (19%); or the 
practice was found to be beneficial if it was originally believed to be harmful, not-
effective, or inferior to another practice (16%). 
 
Table 5.2 Primary descriptive statistics characterizing evidence reversal 
Characteristics of included Randomized Controlled Trials 
(n = 611) 
# of Trials (%) # of 
Observations 
Authors declarations regarding the tested practice: 
Contradiction (evidence reversal) 
Confirmation (evidence reaffirmation) 
 
331 (54%) 
280 (46%) 
611 
Trial conclusions regarding primary outcome: 
Positive 
Negative or no difference 
 
256 (42%) 
355 (58%) 
611 
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Reason for contradiction of established practice: 
Not effective if thought effective 
Less effective if thought beneficial 
Harmful if thought beneficial 
Beneficial if thought harmful/not-effective/inferior 
 
152 (46%) 
64 (19%) 
63 (19%) 
52 (16%) 
331 
 
 
Additional characteristics describing the methodology, findings are described in 
Table 5.3. Concerning registration, 89% of trials were registered, and of those, 86% were 
accessible and the average duration between trial start and registration was 1.20 years. 
Four hundred forty four (73%) trials had a primary outcome that was oriented around 
harm and 276 (45%) trials had a primary outcome that was significant with a P-value ≤ 
0.05. Among included trials: the mean duration of follow up was 115.34 weeks; the mean 
percentage of subjects lost to follow up was 7%; the mean sample size was 3305; and, if 
provided by the authors, the mean required sample size was 2184.  
 The majority of trials had a primary outcome that was dichotomous (474 [78%]), 
and the results for primary outcomes were presented with a variety of different measures 
of effect including: Hazard Ratio (27%), Relative Risk (19%), Absolute Risk (17%), 
Odds Ratio (8%), Effect Size / Mean Difference (11%), Relative Risk Reduction (1%), 
and 18% where no measure nor magnitude of effect was provided (i.e. Not Applicable). 
The primary outcomes of trials were most often (45%) based on hard, patient-important, 
response variables – such as all-cause or cause-specific mortality, risk of stroke, or 
myocardial infarction – but some studies used composite outcomes (i.e. combinations of 
outcomes) (31%) or surrogate outcomes (e.g. physiological measures or laboratory 
values) (23%) as their primary outcome. The abstract conclusions of most trials (520 
[85%]) were based on the primary outcome, but 232 (38%) abstracts were based on 
secondary outcomes and 52 (9%) were based on subgroup analyses. The reason why the 
Riaz	Qureshi	 	 	
Chapter	V		 The	Characteristics	of	Reversal:	Results	 	
91	
proportions of abstract conclusions do not sum to 100% is because they are not mutually 
exclusive and may have been derived from the primary outcome, and/or the secondary 
outcomes, and/or the subgroup analyses. 
 
Table 5.3 Secondary descriptive statistics characterizing included trials 
Characteristics of included Randomized Controlled Trials 
(n = 611) 
# of Trials (%) or 
Mean (Std. Err.) 
# of 
Observations 
Trials registered 
Protocol / registration accessible 
Mean duration between trial start and registration (years) 
542 (89%) 
464 (86%) 
1.20 (0.13) 
611 
542 
412 
Trials with an unfavourable primary outcome 443 (73%) 611 
Mean duration of follow up (weeks) 115.34 (6.77) 600 
Mean sample size 3305 (467.50) 611 
Mean required sample size (where provided) 2184 (226.14) 477 
Mean loss to follow up as proportion of total sample size 0.07 (0.004) 598 
Trials with significant primary outcomes (P ≤ 0.05) 276 (45%) 611 
Trials with a primary outcome measure of effect: 
HR (Hazard Ratio) 
RR (Relative Risk) 
AR (Absolute Risk) 
ES / MD (Effect Size / Mean Difference) 
OR (Odds Ratio) 
RRR (Relative Risk Reduction) 
NNT / NNH (Number Needed to Treat / Harm) 
N/A (Not Available) 
 
166 (27.2%) 
115 (18.8%) 
103 (16.9%) 
65 (10.6%) 
49 (8%) 
5 (0.8%) 
0 (0%) 
108 (17.7%) 
611 
Trials with a dichotomous primary outcome 474 (78%) 611 
Trials with a primary outcome that is: 
Hard (i.e. clinical / patient-important) 
Composite 
Surrogate 
 
277 (45%) 
192 (31%) 
142 (23%) 
611 
Trials reporting abstract conclusions based on: 
Primary outcome * 
Secondary outcome * 
Subgroup analyses * 
 
520 (85%) 
232 (38%) 
52 (9%) 
611 
* Proportions of sources for abstract conclusions do not sum to 100% because abstract conclusions could be 
derived from none or all three of the sources 
 
 
In comparing descriptive statistics between trials that were classified as reversals 
versus reaffirmations (APPENDIX H: Table 6), the two are largely comparable. The most 
notable difference between the two groups is the proportion of trials having significant 
findings with regard to their primary outcomes, which was 58% among trials that 
confirmed the tested practice, but only 34% among trials that contradicted the practice.  
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The general quality of the trials included in this review was low, as can been seen 
in Table 5.4 as the greatest proportions of studies had PICOTS, ROB, and GRADE 
designations of  ‘Somewhat Insufficient’ (48%), ‘Probably Low Risk of Bias,’ (35%), 
and ‘Very Low Quality’ (31%). 
 
Table 5.4 Descriptive statistics for quality assessments of included trials 
Quality assessments for included Randomized Controlled 
Trials (n = 611) 
# of Trials (%) # of 
Observations 
Trials with overall PICOTS designation: 
Sufficient 
Somewhat insufficient 
Clearly insufficient 
 
243 (40%) 
294 (48%) 
74 (12%) 
611 
Trials with overall ROB designation: 
Definitely low risk of bias 
Probably low risk of bias 
Probably high risk of bias 
Definitely high risk of bias 
 
165 (27%) 
212 (35%) 
167 (27%) 
67 (11%) 
611 
Trials with overall GRADE level of evidence: 
High  
Moderate 
Low 
Very low 
 
124 (20%) 
168 (28%) 
128 (21%) 
191 (31%) 
611 
 
 Figures 5.2, 5.3, and 5.4 depict the distribution of the individual components for 
the PICOTS, ROB, and GRADE assessments for the whole sample. The distributions of 
overall assessments for PICOTS were: 40% ‘Sufficient,’ 48% ‘Somewhat insufficient,’ 
and 12% ‘Clearly insufficient.’ The distributions of overall assessments for ROB were: 
27% ‘Definitely low,’ 35% ‘Probably low,’ 27% ‘Probably high,’ and 11% ‘Definitely 
high.’ The distributions of overall GRADE quality of evidence scores were: 20% ‘High,’ 
27% ‘Moderate,’ 21% ‘Low,’ and 31% ‘Very low.’ 
The PICOTS component that contributed the most to decreasing the sufficiency 
was the ‘Sample size:’ 42% of trials had either a sample smaller than required by their 
reported power calculation or failed to report a required sample size. The ROB 
component that contributed the most to increasing the likelihood of bias in a trial was 
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‘Other:’ 20% of trials had some element of trial design or conduct that implied a high risk 
of bias and was not captured in the other components (e.g. industry 
design/conduct/analysis, stopping early for statistical reasons, extreme baseline 
imbalance, or bias related to the study design/conduct/analysis/reporting). The GRADE 
component that contributed most to downgrading of evidence was ‘Directness and 
applicability:’ 48% of trials were downgraded by -1 for having overall PICOTS of 
‘Somewhat insufficient.’ 
 
Figure 5.2 PICOTS components for all 611 included trials 
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Figure 5.3 ROB components for all 611 included trials 
 
 
Figure 5.4 GRADE components for all 611 included trials 
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5.2  UNIVARIABLE AND OVERALL LOGISTIC REGRESSIONS  
The relationship with reversal for each potential predictor was tested twice: 
individually and controlling for all others. In the univariable analyses – the results of 
which are presented in Table 5.2 – five of the 20 potential predictors were statistically 
significant at an alpha level of 0.05, and 11 had p-values less than 0.5, suggesting a 
relationship that did not reach significance.  Imputing the missing data for four of the 
variables that are to be included in the overall model does not change the magnitude, or 
the significance, of their relationship with reversal. The beta-coefficients for each 
predictor in each of the regression analyses are presented in APPENDIX H. These are 
used to calculate the odds ratios of relevant unit differences for continuous covariates. 
 
Table 5.5 Univariable analyses of potential predictors on “reversal vs. reaffirmation” 
Covariate                                                     (# trials / 611) OR  95% CI P-value 
Percent participants lost to follow up (+10%)                   (598) 0.83 0.69 to 0.99 0.036 
Percent participants lost to follow up (imputed) (+10%)  (611) 0.83 0.69 to 0.99 0.036 
Duration of follow up in weeks (+52)                               (600) 0.99 0.94 to 1.04 0.592 
Duration of follow up in weeks (+52) (imputed)              (611) 0.99 0.94 to 1.04 0.592 
P-value (+0.10)                                                                  (535) 1.18 1.11 to 1.26 < 0.001 
P-value (imputed) (+0.10)                                                 (611) 1.19 1.12 to 1.26 < 0.001 
Sample size (+100)                                                            (611) 1.00 1.00 to 1.00 0.771 
Total number of events (+50)                                            (473) 1.00 1.00 to 1.00 0.252 
Fragility Index (+5)                                                           (367) 1.01 0.93 to 1.09 0.866 
Sufficient Adequacy of Power                                          (611) 1.04 0.74 to 1.46 0.826 
Standardized effect size (+1)                                             (523) 0.89 0.83 to 0.96 0.002 
Standardized effect size (imputed) (+1)                            (611) 0.89 0.83 to 0.96 0.002 
Year of publication (+5)                                                    (611) 1.06 0.89 to 1.25 0.521 
Years between trial start and trial registration (+5)           (412) 0.81 0.55 to 1.19 0.279 
Years between trial completion and publication (+5)       (343) 1.07 0.57 to 2.02 0.835 
Protocol registered                                                            (611) 0.96 0.58 to 1.59 0.874 
Abstract conclusion based on primary outcome               (611) 1.02 0.65 to 1.59 0.946 
Abstract conclusion based on subgroup analyses             (611) 0.50 0.28 to 0.89 0.019 
Abstract conclusion based on secondary outcome           (611) 0.85 0.62 to 1.18 0.342 
Conflicts of interest                                                           (611) 
Non-industry vs. Industry 
None-reported vs. Industry 
 
1.10 
1.26 
 
0.80 to 1.52 
0.39 to 4.06 
0.812 
 
Type of outcome                                                                (611) 
Hard vs. Surrogate 
Composite vs. Surrogate 
 
 
 
1.49 
1.51 
 
0.99 to 2.23 
0.98 to 2.34 
0.111 
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Overall PICOTS                                                                (611) 
Sufficient vs. Clearly insufficient 
Somewhat insufficient vs. Clearly insufficient 
 
1.03 
1.10 
 
0.61 to 1.74 
0.66 to 1.84 
0.900 
 
Overall ROB                                                                     (611) 
Definitely low ROB vs. Definitely high ROB 
Probably low ROB vs. Definitely high ROB 
Probably high ROB vs. Definitely high ROB 
 
2.38 
1.62 
1.44 
 
1.33 to 4.24 
0.93 to 2.82 
0.82 to 2.56 
0.019 
 
Overall GRADE                                                               (611) 
High vs. Very low 
Moderate vs. Very low 
Low vs. Very low 
 
1.27 
1.38 
1.22 
 
0.81 to 2.00 
0.91 to 2.10 
0.78 to 1.91 
0.477 
 
 
 The covariates that we investigated were a mix of continuous, binary, and 
categorical. Unmodified regression results for continuous covariates are the effect of a 1-
unit increase, which is not meaningful for some covariates. The effect of continuous 
predictors is more appropriately presented as that for a relevant unit increase. The 
calculations for these specific unit-difference odds ratios and their respective confidence 
intervals can be found in APPENDIX H. 
There were two continuous covariates for which the effect was so small that a 
relevant unit increase failed to show an effect. For every additional 50 events in a trial, 
the odds of reversal, on average, do not change (OR = 1.00, 95% CI: 1.00 to 1.00 [p = 
0.252]). Nor do the odds of reversal change with an additional 100 subjects (OR = 1.00, 
95% CI: 1.00 to 1.00 [p = 0.771]).  
 Five of the potential predictors were found to be significantly associated with the 
outcome at an alpha of 0.05: overall risk of bias, p-value, proportion lost to follow up, 
standardized effect size, and abstract conclusions based on subgroup hypotheses. As the 
overall Risk of Bias decreases, the odds of reversal increase with each lower designation: 
on average, trials with an overall ROB of ‘definitely low,’ ‘probably low,’ or ‘probably 
high,’ had odds of reversal that were respectively 2.38 [95% CI: 1.33 to 4.24], 1.62 [95% 
CI: 0.93 to 2.82], and 1.44 [95% CI: 0.82 to 2.56] times the odds of trials with an overall 
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ROB that is ‘definitely high’ (p = 0.019). For every increase of 0.1 in the p-value for a 
trial’s primary outcome, the odds of reversal increased by 19% (OR = 1.19, 95% CI: 1.12 
to 1.26 [p < 0.001]).  On average, an increase in the percentage of participants lost to 
follow up of 10% decreases the odds of reversal by 17% (OR = 0.83, 95% CI: 0.69 to 
0.99 [p = 0.036]). The odds of reversal are on average 11% less (OR = 0.89, 95% CI: 
0.83 to 0.96 [p = 0.002]) for every single unit increase in the standardized effect size for a 
trial’s primary outcome. And trials with abstract conclusions based on subgroup analyses, 
had odds of reversal that were on average 50% less (OR = 0.50, 95% CI: 0.28 to 0.89 [p 
= 0.019]) than the odds of reversal compared with trials for which the abstract conclusion 
was not based on subgroup analyses.  
 Four potential predictors had p-values that were less than 0.5 suggesting a 
potential relationship that did not reach significance: ‘years between trial start and 
registration,’ type of primary outcome, overall GRADE, and abstract conclusion based on 
secondary outcomes. We describe the relationships of these covariates with reversal as 
“associations,” based on the direction of their Odds Ratios. A 5-year increase in ‘years 
between trial start and registration’ was associated with an average decrease the odds of 
reversal of 19% (OR = 0.81, 95% CI: 0.55 to 1.19 [p = 0.279]). The type of primary 
outcome used for a comparison (p = 0.181) was associated with reversal. On average, 
when compared with trials using surrogate outcomes for their primary comparison, the 
odds of reversal were 49% (OR = 1.49, 95% CI: 0.95 to 2.34) higher for trials using hard 
outcomes and 47% (OR = 1.47, 95% CI: 0.91 to 2.38) higher for trials using composite 
outcomes. The overall GRADE quality of evidence (p = 0.477) may be associated with 
the outcome, as the odds of reversal, when compared trials of ‘very low quality,’ were 
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27% (OR = 1.27, 95% CI: 0.81 to 2.00) higher for ‘high quality’ trials, 38% (OR = 1.38, 
95% CI: 0.91 to 2.10) higher for ‘moderate quality’ trials, and 22% (OR = 1.22, 95% CI: 
0.78 to 1.91) higher for ‘low quality trials.’ Trials with an abstract conclusion based on 
secondary outcomes was, on average, associated with odds of reversal that were 0.85 
(95% CI: 0.62 to 1.18 [p = 0.342]) times those of trials with abstract conclusions that 
were not based on secondary outcomes.  
 When assessed on their own, six of the potential predictors did not appear to have 
an association with reversal of evidence, having p-values greater than 0.50: ‘years 
between trial end and publication,’ duration of follow up, Fragility Index, Adequacy of 
Power, year of publication, abstract conclusion based on primary outcome, sources of 
potential conflicts of interest, overall PICOTS, and trial registration. We describe the 
relationships of these covariates with reversal as “trends,” based on the direction of their 
Odds Ratios. On average, a 5-year increase in ‘years between trial end and publication’ 
trended towards increasing the odds of reversal by 7% (OR = 1.07, 95% CI: 0.57 to 2.02 
[p = 0.835]). Every additional 52 weeks of follow up, trended to an average decrease in 
the odds of reversal by 1% (OR = 0.99, 95% CI: 0.94 to 1.04 [p = 0.592]). And an 
additional 5-unit difference in Fragility Index trended to increase the odds of reversal by 
1% on average (OR = 1.01, 95% CI: 0.93 to 1.09 [p = 0.866]). On average, the trend of 
trials for which the Adequacy of Power was sufficient had odds of reversal that were 4% 
(OR = 1.04, 95% CI: 0.74 to 1.46 [p = 0.826]) higher than trials for which the Adequacy 
of Power was insufficient. As compared with trials published any year between 2000 and 
2016, trials published an additional 5-years later trended towards reversal, with odds that 
were on average 6% greater (OR = 1.06, 95% CI: 0.89 to 1.25 [p = 0.521]) times greater. 
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For trials that based their abstract conclusion on primary outcomes, the trend was to 
increase the odds of reversal by 2% (OR = 1.02, 95% CI: 0.65 to 1.59 [p = 0.946]) 
compared with trials that did not. The sources of potential conflicts of interest (p = 0.812) 
trended towards influencing reversibility as the odds of reversal for trials with non-
industry funding or no-conflicts reported were respectively 1.10 (95% CI: 0.80 to 1.52) 
and 1.26 (95% CI: 0.39 to 4.06) times that of trials with reported industry conflicts. The 
overall PICOTS (p = 0.900) had a similar trend as the odds of reversal were 1.03 (95% 
CI: 0.61 to 1.74) times higher for trials having ‘sufficient’ PICOTS and 1.10 (95% CI: 
0.66 to 1.84) times higher for trials having ‘somewhat insufficient’ PICOTS, compared to 
trials with PICOTS designated ‘clearly insufficient.’ And lastly, trial registration, on 
average, trended away from reversal, with registered trials having odds of reversal that 
were 4% (OR = 0.96, 95% CI: 0.58 to 1.59 [p = 0.874]) less than trials that were not.  
 Before conducting the overall logistic regression, the correlation of the potential 
predictors with each other was checked (APPENDIX H: Table 7). As there were no 
highly correlated covariates – the greatest magnitude of correlation was -0.27 between 
‘Standardized effect size’ and ‘P-value’ – all pre-specified predictors were included in the 
model. Out of the 15 potential predictors, two were significant at an alpha level of 0.05 
and six had p-values less than 0.50, suggesting a potential relationship with reversal after 
controlling for all other predictors. All regression beta-coefficients for univariable, 
overall, and backwards-stepwise logistic analyses can be found in APPENDIX H: Table 
8. This provides a direct comparison of the changes in covariate relationships with 
reversal across all analyses.  
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Table 5.6 Overall multivariable logistic regression (611 trials) 
Covariate OR 95% CI P-value 
Percent participants lost to follow up (imputed) (+10%) 0.91 0.75 to 1.09 0.296 
Duration of follow up in weeks (imputed) (+52) 0.99 0.93 to 1.04 0.620 
P-value (imputed) (+0.10) 1.16 1.09 to 1.24 < 0.001 
Sample size (+100) 1.00 1.00 to 1.00 0.803 
Standardized effect size (imputed) (+1) 0.93 0.86 to 1.00 0.049 
Year of publication (+5) 1.04 0.85 to 1.28 0.716 
Protocol registered 0.86 0.47 to 1.56 0.616 
Abstract conclusion based on primary outcome  1.14 0.70 to 1.85 0.601 
Abstract conclusion based on subgroup analyses 0.55 0.30 to 1.02 0.058 
Abstract conclusion based on secondary outcome 0.93 0.66 to 1.32 0.696 
Conflicts of interest 
Non-industry vs. Industry 
None-reported vs. Industry 
 
0.87 
0.98 
 
0.59 to 1.27 
0.28 to 3.42 
0.758 
 
 
Type of outcome 
Hard vs. Surrogate 
Composite vs. Surrogate 
 
1.47 
1.45 
 
0.94 to 2.30 
0.90 to 2.35 
0.196 
Overall PICOTS 
Sufficient vs. Clearly insufficient 
Somewhat insufficient vs. Clearly insufficient 
 
0.70 
0.79 
 
0.33 to 1.48 
0.43 to 1.44 
0.640 
Overall ROB 
Definitely low ROB vs. Definitely high ROB 
Probably low ROB vs. Definitely high ROB 
Probably high ROB vs. Definitely high ROB 
 
2.38 
1.62 
1.35 
 
1.00 to 5.64 
0.75 to 3.49 
0.72 to 2.52 
0.206 
Overall GRADE 
High vs. Very low 
Moderate vs. Very low 
Low vs. Very low 
 
0.85 
1.00 
1.03 
 
0.34 to 2.12 
0.49 to 2.04 
0.57 to 1.86 
0.951 
 
 Controlling for all other covariates in the overall model, eight covariates retained 
the same relationship as when they were assessed on their own in that their association 
with prediction or protection of reversal had similar magnitude and significance. As 
compared with trials published any year between 2000 and 2016, trials published five 
years later trended to increasing odds of reversal by 4% on average (OR = 1.04, 95% CI: 
0.85 to 1.28 [p = 0.716]). As the p-value for the trial’s primary outcome increases by 0.1, 
the odds of reversal increase by 16% on average (OR = 1.16, 95% CI: 1.09 to 1.24 [p < 
0.001]). A 1-unit increase in standardized effect size for a trial’s primary comparison 
decreases the odds of reversal by 7% on average (OR = 0.93, 95% CI: 0.86 to 1.00 [p = 
0.049]). Trials for which the abstract conclusion is based on subgroup analyses are 
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associated with an odds of reversal that are, on average, 45% lower than trials that do not 
(OR = 0.55, 95% CI: 0.30 to 1.02 [p = 0.058]). The type of outcome used for a trial’s 
primary comparison (p = 0.196) may be associated with the outcome as the odds of 
reversal for trials with hard and composite outcomes were respectively 47% (OR = 1.47, 
95% CI: 0.94 to 2.30) and 45% (OR = 1.45, 95% CI: 0.90 to 2.35) greater than for trials 
using a surrogate outcome. Controlling for other covariates, an additional 52 weeks of 
follow up trended towards decreasing the odds of reversal by 1% on average (OR = 0.99, 
95% CI: 0.94 to 1.04 [p = 0.620]). The trend among trials that had an abstract conclusion 
based on the primary outcome compared to those that did not, was an average increase in 
odds of reversal of 14% (OR = 1.14, 95% CI: 0.70 to 1.85 [p = 0.601]). Sample size 
retained a lack of association as an additional 100 subjects neither increased nor 
decreased the odds of reversal (OR = 1.00, 95% CI: 1.00 to 1.00 [p = 0.803]).  
 After adjusting for other covariates, five had relationships in the same direction as 
they did on their own, but with different levels of significance. On average, trials with an 
overall ROB of ‘definitely low,’ ‘probably low,’ or ‘probably high,’ had odds of reversal 
that were respectively 2.38 [95% CI: 1.00 to 5.64], 1.62 [95% CI: 0.75 to 3.49], and 1.35 
[95% CI: 0.72 to 2.52] times those of trials with an overall ROB that is ‘definitely high’ 
(p = 0.206). An additional 10% of participants lost to follow up was associated with a 
decrease in odds of reversal by 9% on average (OR = 0.91, 95% CI: 0.75 to 1.09 [p = 
0.296]). Trials with registration or protocols, on average, trended towards odds of 
reversal that were 24% less than those that did not (OR = 0.86, 95% CI: 0.47 to 1.56 [p = 
0.616]). Trials with abstract conclusions based on secondary outcomes, on average, 
trended towards odds of reversal that were 7% less than trials for which the abstract 
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conclusions were not based on secondary outcomes (OR = 0.93, 95% CI: 0.66 to 1.32 [p 
= 0.696]). On average, trials with an overall GRADE quality of evidence rating of ‘high,’ 
‘moderate,’ or ‘low’ quality trended to having odds of reversal that were respectively 
0.85 (95% CI: 0.34 to 2.12), 1.00 (95% CI: 0.49 to 2.04), and 1.03 (95% CI: 0.57 to 1.86) 
times those of trials with overall GRADE ratings of ‘very low’ (p = 0.951). 
 When all potential predictors were included in the overall model, two covariates 
changed their apparent relationship with reversal. As compared with trials reporting 
industry conflicts of interest, trials that reported ‘non-industry’ or ‘no conflicts’ trended 
towards odds of reversal that were on average lower by 13% (OR = 0.87, 95% CI: 0.59 to 
1.27) and 2% (OR = 0.98, 95% CI: 0.28 to 3.42) respectively (p = 0.758). Furthermore, 
after controlling for all other covariates, the overall PICOTS trended towards decreasing 
the odds of reversal: compared with trials that had an overall PICOTS designation of 
‘clearly insufficient,’ trials with designations of ‘sufficient’ and ‘somewhat insufficient’ 
were respectively lower by 30% (OR = 0.70, 95% CI: 0.33 to 1.48) and 21% (OR = 0.79, 
95% CI: 0.43 to 1.44) (p = 0.640). 
Testing the overall model using the Pearson and Hosmer-Lemeshow Goodness-
of-Fit tests produces p-values of 0.210 and 0.824 respectively, suggesting that the model 
adequately describes the database. The overall model has 22 degrees of freedom (15 
covariates and 611 trials) and consequently 15 cases (i.e. reversals) per degree of 
freedom. 
 
5.3  BACKWARDS STEP-WISE MODEL 
The overall logistic model was fit using all potential predictors and demonstrated 
that some covariates may have a significant effect on whether the results of a trial 
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contradict (i.e. reverse) or confirm (i.e. reaffirm) previous beliefs about the tested 
practice, while some may have no effect. Backwards-stepwise regression is generally not 
recommended for model building, but as these are exploratory analyses with no prior 
evidence base from which to construct a model, and with covariates that may have 
varying effects on the outcome, the stepwise approach was deemed suitable. All 
covariates from the overall model were included at the start and a dropping significance 
level of 0.50 was set, based on Harrell’s recommendation.130 
 
Table 5.7 Covariates included in the final model generated by backwards-stepwise 
selection 
Covariate OR 95% CI P-value 
Percent participants lost to follow up (imputed) (+10%) 0.88 0.73 to 1.05 0.152 
P-value (imputed) (+0.10) 1.16 1.09 to 1.24 < 0.001 
Standardized effect size (imputed) (+1) 0.93 0.87 to 1.00 0.054 
Abstract conclusion based on subgroup analyses 0.53 0.29 to 0.98 0.044 
Overall PICOTS 
Sufficient vs. Clearly insufficient 
Somewhat insufficient vs. Clearly insufficient 
 
0.69 
0.81 
 
0.39 to 1.24 
0.47 to 1.41 
0.435 
Overall ROB 
Definitely low ROB vs. Definitely high ROB 
Probably low ROB vs. Definitely high ROB 
Probably high ROB vs. Definitely high ROB 
 
2.10 
1.52 
1.36 
 
1.10 to 3.99 
0.83 to 2.77 
0.74 to 2.48 
0.115 
 
 
 The final model produced by the backwards-stepwise selection included six 
covariates, all of which had similar relationships to reversal as found in the overall 
model. Two of the covariates were associated with increased odds of reversal, while four 
decreased the odds of reversal, thereby increasing the odds of reaffirmation.  
 A 0.10 increase in the p-value of a trial increased the odds of reversal of 16% on 
average (OR = 1.16, 95% CI: 1.09 to 1.24 [p < 0.001]). As compared with trials that had 
‘definitely high’ overall ROB assessments, trials that had ‘definitely low,’ ‘probably 
low,’ or ‘probably high’ overall ROB were associated with increased odds of reversal of 
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respectively 110% (OR = 2.10, 95% CI: 1.10 to 3.99), 52% (OR = 1.52, 95% CI: 0.83 to 
2.77), and 36% (1.36, 95% CI: 0.74 to 2.48) (p = 0.115).  
 On average, increasing the percent of participants lost to follow up by 10% was 
associated with decreased odds of reversal of 12% (OR = 0.88, 95% CI: 0.73 to 1.05 [p = 
0.152]). A 1-unit increase in the standardized effect size for a trial’s primary comparison 
was on average associated with a 7% decrease in the odds of reversal (OR = 0.93, 95% 
CI: 0.87 to 1.00 [p = 0.054]). Trials for which the abstract conclusions were based on 
subgroup analyses had odds of reversal that were 47% less than trials that did not (OR = 
0.53, 95% CI: 0.29 to 0.98 [p = 0.044]). And on average, compared with trials for which 
the overall PICOTS assessment was ‘clearly insufficient,’ trials that were designated 
‘sufficient’ or ‘somewhat insufficient’ were associated with 31% (OR = 0.69, 95% CI: 
0.39 to 1.24) and 19% (OR = 0.81, 95% CI: 0.47 to 1.41) reductions in the odds of 
reversal (p = 0.435).  
 Testing the final model produced by the backwards-stepwise regression with 
Pearson and Hosmer-Lemeshow Goodness-of-Fit tests produce respective p-values of 
0.345 and 0.660, suggesting that the model is adequate to describe the database. The 
model generated by backwards-stepwise regression has 9 degrees of freedom (6 
covariates and 611 trials) and consequently 36 cases (i.e. reversals) per degree of 
freedom. 
 Figure 5.5 presents the odds ratios for all covariates across all regression analyses 
to show their relative magnitude, direction, and significance. The first six characteristics 
(overall ROB, overall PICOTS, abstract conclusion based on subgroup hypotheses, 
standard effect size, p-value, and proportion of participants lost to follow up) are those 
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from the model produced by backwards-stepwise selection and consequently have odds 
ratios from all three logistic regressions. The next nine characteristics (overall GRADE, 
outcome type, conflicts of interest, abstract conclusion based on secondary outcome, 
abstract conclusion based on primary outcome, protocol registered, year of publication, 
sample size, and duration of follow up) were excluded in the backwards-stepwise 
selection, but were included in the overall model and consequently have odds ratios from 
the univariable and multivariable logistic regressions. The last five characteristics (years 
between trial start and registration, years between trial end and publication, total number 
of events, Adequacy of Power, and Fragility Index) were those assessed only in 
univariable analyses and consequently only have a single odds ratio. Statistical 
significance (p ≤ 0.05) of the odds ratios for each characteristic is noted on the graph as 
follows: * = univariable analysis, ** = multivariable analysis, *** = backwards-stepwise 
analysis. 
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Figure 5.5 Odds Ratios of covariates across all logistic regression analyses 
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Chapter Summary: This chapter presents a discussion of the results of our exploratory 
analyses of the characteristics of reversal. A comparison is first made between 
our reproduction of  ‘A decade of reversal,’ followed by a detailed discussion 
of the results from the logistic regressions – both expected and unexpected – 
and how the relationships influence the development of a framework of 
reversibility. The limitations of the study design and methods are presented at 
the end of this chapter.  
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CHAPTER 6 
6.0  COMPARISON TO ‘A DECADE OF REVERSAL’ 
‘A decade of reversal’ by Prasad et al. was the first major step towards 
understanding the phenomenon of evidence reversal. Their analyses provided 
rudimentary explorations of the characteristics of the phenomenon that prepared the field 
for more advanced study.  
The trial conclusions regarding their primary outcome were based on the results, 
discussion, and conclusions, and incorporated statistical significance, direction of effect, 
and the manner in which authors described their findings. Thus, trials with statistically 
significant effects in favour of the intervention or in line with the hypotheses or primary 
question were deemed positive, trials that found statistically significant evidence contrary 
to their hypotheses or against their intervention were deemed negative, and trials that did 
not find a significant effect favouring either comparator were designated as showing no 
difference. We found that 42% of trials had positive conclusions, whereas 58% had 
conclusions that were negative or showed no difference between comparators. Prasad et 
al. found proportions of 38% and 62% respectively for trials that found the practice 
beneficial and trials that were inconclusive or found the intervention to be no better or 
worse than the comparator.4  
 With regard to the determination of trial results that contradict or confirm the use 
of an established standard and the consequent declaration of reversal or reaffirmation, our 
study showed that 54% of RCTs that tested an established medical practice represented 
reversal, and 46% represented reaffirmation. Prasad et al. concluded that 40% of studies 
that tested an existing practice ended in reversal, 38% in reaffirmation, and 22% were 
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inconclusive. This difference between our reproduction and the original likely arose 
because we reached a decision on all trials to force a binary outcome, whereas Prasad et 
al. deemed 22% of trials to be inconclusive.  
 
6.1  INTERPRETATION OF REGRESSION RESULTS 
In this thesis, we have performed a comprehensive analysis that is the first of its 
kind in the field of reversals and deepens the understanding of the phenomenon of 
reversal within high-quality medical literature. This thesis is the first exploration of 
characteristics that may be associated with reversal of established practices and as such, 
we have no literature upon which to base the accuracy, nor credibility of our findings. 
However, we know that reversals require high-quality evidence as the nature of reversal 
is contradicting what was previously believed, based on lower quality evidence.1,2 
Consideration of this is what led to the development of Sutton and Martin’s Framework 
of Reversibility and the rationale for investigating our potential predictors.45  
The Framework of Reversibility included nine characteristics of studies to 
consider in assessing a study’s conclusions with regard to their primary comparison: 
PICOTS, ROB, modified GRADE, modified optimum information size, fragility index, 
years between trial start and registration, years between trial completion and publication, 
whether abstract conclusions were based on secondary outcomes, and whether abstract 
conclusions were based on subgroup analyses.45 In seeking to inform the development of 
this framework, we assessed these characteristics and 12 others, including: proportion of 
participants lost to follow up, duration of follow up, p-value for primary outcome, sample 
size, total number of events, standardized effect size, year of publication, registration of 
the trial or a protocol, whether abstract conclusions were based on the primary outcome, 
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potential sources of conflicts of interest, and the type of outcome used for primary 
comparison of intervention and control groups.  
The overall amount of missing data among the potential predictors was low as can 
be seen in Table 5.3 (Chapter 5) and the mean imputation of missing values did not affect 
the covariate’s relationship to reversal in univariable analyses. As the imputation did not 
statistically change the relationships of variables with missing data, the imputed data 
were used in the overall model to allow the use of all observations in the database. 
In describing the relationships that we found, we are aware that the majority were 
non-significant and the strength and validity of the relationships may be questioned as a 
consequence. In exploring these characteristics and their influence on finding 
contradictory evidence for established practices, we are aware of the low power that we 
have with regards to conclusions and make no claims as to declaring definitive results. 
Our aims were exploratory and we have been consistent in expressing the relationships 
that we have found as presented (i.e. significant associations, non-significant 
associations, or highly non-significant trends), based on the magnitude and directions of 
the odds ratios.  
Among all of the characteristics that we investigated as potential predictors of 
reversal or reaffirmation, most of the relationships were as expected with a few surprising 
results. The expected relationships coincided with our rationale for exploring them and 
how we thought they might influence the likelihood of a trial reversing the established 
practices being tested. Some relationships were unexpected by having no impact on 
reversal, having an influence in the opposite direction as expected, or changing their 
direction of influence after controlling for other covariates. However, in controlling for 
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multiple covariates, we have reduced power and expect unstable estimates around the null 
hypothesis, which is what we see in several categorical covariates. 
6.1.1 Expected relationships 
The relationships that were expected included characteristics from the 
methodology, results, and quality of the trials. In univariable and overall analyses, trials 
that used hard or composite outcomes were more likely to find contradictory results than 
trials using surrogate outcomes. Although non-significant, the trend conforms to the 
expectation that using outcomes that are non-subjective is important when seeking the 
true effect of an intervention, as opposed to outcomes that may confirm a 
pathophysiological pathway, but fail to influence an aspect of health that is tangible to the 
patient.   
We did not expect the year of publication to have an influence on reversal as there 
was no association found in ‘A decade of reversal.’ During a trial’s conduct, greater 
proportions of participants lost to follow up lowered the odds of the trial finding a 
contradictory result (significantly when assessed alone and non-significantly in 
multivariable analyses), which is directly related to the study quality and confidence that 
is held in the findings. When trials have a high degree of loss to follow up, it can be 
difficult to differentiate between a true effect and one that is an artefact of the data that 
remains. Similarly, having a high value for Fragility Index and sufficient Adequacy of 
Power – respectively symbolizing results that are non-fragile and appropriately powered 
to make conclusions – are other markers for confidence in a trial’s results and both 
characteristics trended towards increasing the likelihood of reversal. However, the 
relationships of Fragility Index and Adequacy of Power were only assessed in univariable 
analyses: Fragility Index due to a high degree of missing data and inability to impute the 
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missing data, and the Adequacy of Power because it was an experimental indicator that 
we developed. Further, as they were both highly non-significant with p-values of 0.866 
and 0.826 for FI and sufficient AP respectively, we cannot draw conclusions as to their 
effect on a trial’s reversibility.  
The results of the primary comparison made in a trial also directly influenced the 
odds of reversal. We found the greater the p-value and the smaller the standardized effect 
size for a difference between comparators, the greater the odds that a trial would 
contradict what was previously believed about the established practice being tested. Both 
of these relationships were significant in all analyses and were expected, as a common 
trend of many reversals is high quality trials failing to replicate the results of lower-
quality studies that may have found large and significant effects.  These relationships 
with reversal have also been explored by Ioannidis as The Proteus Phenomenon: 
describing when early extreme results are later contradicted when attempts to replicate 
findings are made.54,56 It is an established publication bias that extreme results are more 
likely to be published than non-significant or modest effects, which may consequently 
lead to early studies of practices presenting findings that are disproportionate or 
exaggerated from the true effect.54  
Interestingly, in our exploration of descriptive statistics we classified the reasons 
for reversal and while the most common reasons fit the trend shown in the data (i.e. 
finding a practice ‘not effective if thought to be’ (46%) or ‘less effective if thought 
beneficial/superior’ (19%)), there were two others: the finding of practices to be ‘harmful 
if thought beneficial’ (19%) or ‘beneficial if thought harmful/not-effective/inferior 
(16%).’ This last reason for reversal is particularly interesting as it demonstrates the 
Riaz	Qureshi	 	 	
Chapter	VI		 Discussion	and	Limitations	 	
113	
complexity of the phenomenon and necessitates a change in the way people think of 
reversal. Evidence reversal does not only occur when new evidence shows a currently 
used practice does not work; rather, it occurs when the current belief about a practice is 
contradicted. Thus, a practice that is not recommended, or is recommended against, may 
be reversed if it is found to have a positive effect when tested, leading to its 
recommendation.  
Many of the characteristics that we assessed were related to the quality of trials 
and most had the expected effect on reversal. A greater number of years between a trial’s 
start and registration was associated with increased odds of reaffirmation. This direction 
of this relationship was expected as an indicator of publication biases since trials that are 
higher quality would be expected to have a shorter duration, with negative values 
indicating pre-registration and positive values indicating retroactive registration. The 
various sources of abstract conclusions were consistent as checks of reporting bias as 
trials that reported their primary outcome in the abstract trended towards being reversals, 
and trials for which the reported conclusions were based on subgroup analyses or 
secondary outcomes were associated with increased odds of reaffirmation. The size of 
these associations became stronger when controlling for all covariates in the overall 
analyses.  
The relationship of the overall Risk of Bias with reversal was expected as each 
increasing quality level (i.e. decreasing risk of bias) had a greater effect on the odds of 
reversal when compared to trials with the greatest risk of bias. This monotonic 
relationship is significant in two regards. First, when assessed on its own, the overall 
categorical predictor was significantly associated with reversal. Although this statistical 
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significance disappeared when controlling for other covariates, the strength of all 
categorical associations was expected to decrease in multivariable analyses because of the 
reduced number of cases in each category upon which to base an estimate of effect. 
Second, the monotonic relationship remained throughout all analyses and, despite a loss 
of statistical significance, retained a similar magnitude of effect. Due to the statistical 
non-significance of this covariate in the overall analyses, we did not conduct a 
multivariable regression on the individual components of the measure. However, the 
apparent relationship indicates that investigating the elements of this measure in future 
study would be warranted and may provide insight into future applications of this 
assessment. 
6.1.2 Unexpected relationships 
While most of the relationships between trial characteristics and reversal were 
expected, there were some characteristics which had unexpected relationships in that they 
were associated with the alternative outcome than we rationalized, or their association 
changed direction after controlling for the effects of other characteristics.  
The association of trial registration and/or use of a protocol with a greater 
likelihood of reaffirmation and a greater number of years between trial completion and 
publication with reversal were both unexpected as we believed registration and fewer 
years between end and publication to be integral to low risk of reporting bias. 
Furthermore, the relationships of other characteristics that were related to reporting and 
publication biases (i.e. duration between start and registration, and the sources of abstract 
conclusions) were as expected. The effect of registration that we found could be due to 
the fact that the majority of trials published before 2006 were not registered because it 
was not yet a standard requirement of clinical trials. Consequently, the proportion of 
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reversals and reaffirmations that would have been registered may be skewed and the true 
effect obfuscated. However, by including the year of publication in the overall analyses, 
the effect of changing requirements over time should have been accounted for, yet in the 
overall analyses the strength of the relationship grows (albeit remaining a non-significant 
trend) instead of diminishing or reversing. Similarly, the duration between trial end and 
publication was only available for some trials that were registered and consequently had a 
high proportion of missing data (44%).  
We believed that a greater duration of follow up would be associated with a 
greater likelihood of reversal as most interventions require a long period of follow up to 
determine their true effect. However, we found that the greater the duration of follow up, 
the odds trended towards reaffirmation – though this effect was small and non-
significant: an increase in follow up of 52 weeks increased the odds of reaffirmation by 
1% in both the univariable and overall analyses.  Also unexpected, for the same reasons, 
were the effects of sample size and total number of events. For each additional 100 
subjects or 50 events in a trial, there were no trends in changing in the odds of reversal 
(OR = 1.00). Both of these characteristics are classically portrayed as being paramount to 
quality trials as they decrease the variability in average outcomes and present more 
accurate portrayals of interventions effects. It is possible that no association was found 
for these characteristics due to the population from which they came. In looking at the 
difference in mean duration of follow up and sample size among reversals and 
reaffirmations (APPENDIX H: Table 6), reaffirmations are 7.28 weeks longer and 
reversals are 273 subjects larger, which may not be a large enough to establish an effect 
on the outcome. It is possible that this similarity could derive from publication in a high-
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quality medical journal, which may accept trials that are of similar size and conduct, 
thereby rendering some characteristics uniform across all trials, regardless of results and 
conclusions.   
Among the unexpected results were three potential predictors that exhibited the 
expected relationships when analyzed on their own (increasing the odds of reversal), but 
changed to increase the odds of reaffirmation when controlling for other covariates in the 
overall analyses. These included: potential conflicts of interest, the overall PICOTS 
assessment, and the overall GRADE quality of evidence.  
While none of the above characteristics were significantly associated with 
reversal or reaffirmation in any of the analyses, they all trended towards increasing the 
odds of reversal on their own, and increasing the odds of reaffirmation when adjusting for 
all covariates. While the change in direction of these relationships in the multivariable 
analyses was interesting, it was unsurprising as they are all categorical covariates and we 
expected low power and unstable estimates around the null for these covariates when 
controlling for other predictors, as the numbers of trials in each category upon which to 
base an estimate are reduced. We expected the declaration of potential conflicts of 
interest as ‘industry’ would lead to greater odds of reaffirmation compared with ‘non-
industry’ or ‘none to declare/reported,’ which is the trend we saw when analyzed as a 
single predictor. We did not expect a monotonic relationship in this covariate as the 
categories were nominal, not ordinal. It is likely that the change in effect was due to the 
instability of estimates around the mean, but it is also possible that there may be other 
characteristics that are influenced by the presence of conflicts of interest (e.g. sources of 
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abstract conclusions, type of outcome used, standardized effect size, or overall PICOTS 
or ROB) that consequently confound the effect in multivariable analyses.  
The overall PICOTS and GRADE assessments are multidimensional summary 
scores for trials that each account for several elements of a trial’s design and conduct. 
Consequently, while higher quality levels of both, on their own, are associated with 
increasing the odds of reversal, it is possible that when controlling for all other covariates 
– some of which may influence the components that make up the summary scores – the 
expected effect is lost. Furthermore, neither summary score had a consistent monotonic 
relationship with reversal as found with the Risk of Bias assessment. In univariable 
analyses, the highest quality PICOTS and GRADE assessment both trended towards 
increasing the odds of reversal to a lesser degree than assessments of moderate quality. 
While the non-significance of these trends is important in knowing the limitations for 
how we draw conclusions regarding the effects of covariates, the fact that we did not find 
a clear effect for GRADE in even the univariable analysis is interesting. Since we 
modified GRADE for application with a single trial – from its validated use in assessing 
aggregate evidence – its relationship to contradictory results may be less appropriate than 
that of a measure designed for a single trial (such as ROB). However, as GRADE is 
considered to be the gold-standard for assessment of evidence, the lack of an apparent 
relationship with reversal demonstrates a need for further exploration on more 
appropriate and larger datasets.  	
6.2  UPDATING THE FRAMEWORK OF REVERSIBILITY 
The framework developed by Sutton and Martin, based on assumptions about the 
nature of trials that lead to reversal, was comprised of eight components: PICOTS, ROB, 
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and modified GRADE assessments, modified optimum information size, fragility index, 
duration from trial start to registration and from completion to publication, and abstract 
conclusions.45  
In extracting these characteristics for testing, the optimum information size was 
amended to Adequacy of Power. The difference being that optimum information size is a 
concept from meta-analyses that was difficult to apply to individual trials – in essence: a 
means of assessing whether or not a meta-analytic database had sufficient power, based 
on the assumption that the overall sample size was equivalent to a trial of the same size – 
but the Adequacy of Power was more applicable to single trials and derived more simply 
from whether the trial met its pre-specified sample size and whether the confidence limits 
of the effect met the trial’s pre-specified delta.  
From our univariable analyses, the fragility index, sufficient Adequacy of Power, 
and duration from trial completion to publication do not appear to influence the 
likelihood of reversal in a meaningful way, so we can remove these from the framework. 
While a measure of the fragility of a trial’s findings is an interesting concept, and 
deserves further study on its own, it may not contribute meaningfully to our framework 
of reversibility given its overlap with other concepts inherent to the framework. 
Additionally, providing context for the FI (e.g. as a percent of loss to follow up or the 
sample size), could increase the meaningfulness of this measure.  
The overall GRADE assessment was highly non-significant and did not 
demonstrate a coherent relationship with reversal across the analyses. For this reason, we 
also remove the modified GRADE assessment from our framework.  
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Both the overall ROB and PICOTS assessments were demonstrably associated 
with reversal and reaffirmation respectively, such that they were included in the final 
model created by the backwards-stepwise regression. It is possible that these two 
characteristics – themselves being two of the components that contributed to the final 
GRADE score – are sufficient measures of study quality and bias and that GRADE is not 
additionally needed in considering the likelihood of reversibility. As such, both of these 
summary scores remain in our framework.  
The years from trial start to registration was only assessed in univariable analyses 
but was found to have a potential association with reaffirmation as the p-value was 0.279 
and the corresponding OR for reversal was 0.81 for an increase of five-years. While non-
significant, the trend is expected and Harrell suggests that a model built on theory is more 
purposeful than one based solely on the data and that the exclusion of all non-significant 
predictors is often inappropriate.130 As such, this covariate remains in our framework.  
Similar justification applies to the retention of the sources of abstract conclusions 
from the original framework to the updated. Although only one source (subgroup 
analyses) had a significant relationship with whether or not the trial found contradictory 
evidence, the other two (primary or secondary outcomes) trended towards the outcome 
that we expected when controlling for other covariates to a greater degree than when they 
were assessed on their own, and together they provide a complete picture of the source of 
a trial’s abstract conclusion.  
After conducting our exploratory analyses of trial characteristics, we found 
several covariates that are strongly associated with reversal or reaffirmation of 
established practices and we are consequently adding them to the framework. The 
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relationships of the p-value and standardized effect size for a trial’s primary comparison 
were both significant in univariable and multivariable analyses. The larger the effect 
found by a trial, and the more significant the result, the more likely that trial was to 
confirm an established practice. The same association with reaffirmation was found for 
increased proportions of subjects lost to follow up. Although it was only significantly 
associated when it was assessed on its own, it was one of the final covariates included in 
the model created by the backwards stepwise regression. The final characteristic that we 
explored and are adding to the updated framework is the type of outcome used for a 
trial’s primary comparison. This covariate was not statistically significant in either the 
univariable or the multivariable regressions, but the association with reversal remained 
almost unchanged both in magnitude and significance between its baseline effect and 
after controlling for other covariates. Furthermore, this is one of the only predictors for 
which an evidence base existed to support its association with evidence reversal as it is 
known that surrogate outcomes do not necessarily correlate with patient important 
outcomes. Because of this, trials that test established practices with hard and definitive 
outcomes may contradict what was believed about practices that were prematurely 
adopted based on results from studies using surrogate outcomes. 
Our updated, proposed framework of reversibility is presented in Table 6.1 and 
includes eight components that are supported by our results as being associated with the 
outcome of contradictory results among randomized controlled trials that test established 
medical practices. These components can separately be placed into five of the domains of 
a randomized controlled trial: design, conduct, results, quality, and reporting. 
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Table 6.1 Updated proposed framework of reversibility 
Component Purpose in the Framework 
Overall PICOTS Multidimensional summary score of the appropriateness of a trial’s question 
and design 
Overall ROB Multidimensional summary score of a trial’s quality 
Years between trial start 
and registration 
Measure of reporting bias as trials should be registered before they begin (i.e. 
have negative values) 
Sources of abstract 
conclusions 
Measure of reporting bias as trials should base abstract conclusions on 
primary outcome, not secondary outcome or subgroup hypotheses 
P-value  Measure of significance of a trial’s findings for primary comparison 
Standardized effect size Measure of the magnitude of effect for primary comparison 
Proportion of subjects 
lost to follow up 
Indicator for the confidence that can be held in a trial’s results 
Type of outcome Indication of the use of an appropriate outcome for finding the clinical effect 
of intervention  		
6.3  STRENGTHS AND LIMITATIONS 
There are many strengths in our study design and conduct, the most prominent 
being that this is the first quantitative assessment of study design elements and their 
relation to evidence reversal in this newly emerging field of meta-research. This study is 
also the largest and most comprehensive examination of the phenomenon to date. The 
similarity of results that we found in the reproduction of ‘A decade of reversal’ is another 
strength that lends validity to our methods. The thoroughness and care that was taken in 
ensuring accurate and consistent data extraction is a major strength of our study. 
Similarly, our high degree of transparency is a major strength as we have provided all 
methods used for data extraction with the intention of increasing the reproducibility of 
our findings for future researchers. However, there are still limitations in the design and 
conduct of our study. The limitations that could be addressed were, to the best of our 
ability, but there were still some that could not be addressed because of time constraints, 
a lack of resources, or necessitated assumptions based on practicality and feasibility. 
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6.3.1 Limitations in the creation of the database of reversals 
• A critical limitation is the use of a single journal (NEJM) as a source of trials and 
potential reversals. An ideal search would have collected RCTs from several 
different journals or databases. However, given the aims of this study and limited 
resources for conducting the study, a single-journal was deemed most feasible and 
appropriate. It does however limit the generalizability of our findings to other 
medical literature where the majority of studies are published, and upon which 
many health-care decisions are made.  
• The lack of time and resources led to several other limitations including the first 
two levels of screening and the data extraction not being done in duplicate. It also 
contributed to a difficulty in reaching decisions with regard to the established use 
of practices, as the reviewers do not have clinical experience and did not have the 
time to conduct literature searches to verify the existence or novelty of every 
practice. While a decision was reached for each trial’s intervention being new or 
existing, and with regards to the outcome being reversal or reaffirmation of 
evidence, the decision was not always clear. Despite the discussion of 
discrepancies and reaching agreement as to what was believed to be the correct 
designation, some readers may disagree with how articles were categorized. We 
tried to be as objective as possible in our determination and to guide the decisions 
by what was provided by the publication authors. Thus, despite this limitation, we 
are confident in our results and feel that a few disagreements from other meta-
researchers would not likely change our conclusions.  
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• Another limitation that is related to our objective judgment of articles is the 
extraction and assessment of PICOTS and ROB. We attempted to prevent 
potential bias and ensure uniformity across extractions in two ways: firstly, by 
extracting a test-set of trials in duplicate and comparing extraction to verify the 
similarity of results; and secondly, by having a protocol with clearly defined 
guidelines for how to extract all elements in the database. However, these 
measures are subjective and even trained assessors may apply different ratings of 
overall sufficiency and likelihood of risk of bias.  
• This same limitation also applies to GRADE because even though the rating 
consistency was mediated slightly by the automatic completion of components 
based on other extracted characteristics, the automatic completion of its individual 
domains were taken from other subjective characteristics (i.e. overall PICOTS, 
overall ROB, ROB for selective outcome reporting, and the adequacy of power.).  
• A further limitation of the GRADE assessment was that it was incomplete. We 
used a modified GRADE that did not include the domain of inconsistency because 
it would not have been feasible to examine the relevant literature for each 
intervention to assess inconsistency of results within that field, nor appropriate to 
compare the inconsistency of results across the many different types of 
interventions that we included in our review. The GRADE component for 
publication bias was also modified to be determined by the likelihood of selective 
outcome reporting because we did not have time to explore the relevant literature 
for each trial’s comparators.   
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• A less consequential limitation of our study conduct was the use of an Excel file 
for our screening and the creation of our database. As a general rule for any study 
involving large amounts of data collection, this practice should be avoided 
because of the potential for transposition errors and incorrectly encoding 
automatic columns. However, the ease of use, availability and access to the 
program, and versatility for analyses across multiple types of quantitative and 
qualitative information made it ideal for this project.  
6.3.2 Limitations of statistical analyses 
• A major limitation of our analysis is the designation of reversal or reaffirmation of 
evidence based on the author’s declaration and description of how their findings 
align with current beliefs about the practice (i.e. whether their findings are 
incongruent or congruent with practitioners’ use). Ideally, cumulative meta-
analyses or a similar measure of sufficiency and stability of the evidence for a 
practice would be used to indicate reversal or reaffirmation. As currently 
designated, these author’s conclusions may yet again be contradicted with time 
and we do not know how the practices and standards have changed since the trials 
that we have used were published. However, populating our database with RCTs 
and not meta-analyses or other standards for decision-making is another 
consequential limitation. Prasad et al. examined all original studies and so we too 
looked at original studies, but chose to examine RCTs because they are the gold 
standard for investigating the effects of interventions and should provide a higher 
level of evidence for decision-making than other original research designs.  
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• Another limitation related to the outcome used in our regression is that all 
reversals, partial and full, were categorized the same. It would have added an 
extra layer of complexity that would have made the project infeasible to try and 
distinguish between complete reversals (e.g. findings that indicate direct harm and 
a recommendation for immediate cessation of use) and partial reversals (e.g. 
findings that a practice does not work as well as was believed, but it still has use 
and a recommendation for further study). Similarly, when a trial tested two 
established practices where there was no consensus about which is better (as was 
often the case), and one was found to be superior, then it was classified as a 
reversal because it contradicted the belief that they were equal, even though in 
doing so they also confirmed the use of the superior practice.  
• This difficulty in classifying reversals and reaffirmations of evidence introduces a 
further limitation by necessitating an assumption for our logistic regressions: 
namely that the outcome follows a binary distribution. We reached a decision on 
all included trials, but Prasad et al. deemed 22% of studies that test established 
practices to be inconclusive – neither reversing, nor reaffirming a practice. While 
the differentiation between reversal and reaffirmation of evidence is not black and 
white, we consider the assumption valid for the purposes of exploring the 
phenomenon of reversals given that most of the decisions for reversals will never 
be without some uncertainty, and most of the decisions could be adequately 
inferred from the original studies’ details.  
• Within the analyses – both descriptive and regression – there are also several 
other assumptions that are limiting but were necessary to allow the analyses to 
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occur. The most prominent of these is that any error in data extraction is random 
and not systematically biased. It was assumed that the judgments made by data 
extractors (RQ and DS) were comparable with respect to PICOTS, ROB, and 
consequently GRADE. As explained in section 6.3.1, we attempted to mitigate 
differences in extraction by comparing responses across a random test-set of 
articles before completing the extraction and by using a pre-specified protocol 
(APPENDIX E) to guide the extraction. 
• Another important limitation in the analysis and extraction arose from the 
inclusion of trials with multiple interventions including multi-arm studies and 
factorial designs. Within our study sample, there were 98 trials with these designs, 
comparing multiple practices against each other and control groups. For these 
trials, we extracted only a single intervention and control group for our summary 
of study results. This simplifying assumption was necessary for project feasibility 
as extraction of every pair of comparisons from the multi-arm and factorial trials 
would have increased the number of “trials” to unmanageable levels. The decision 
to include only a single comparison from each trial publication also acts to 
simplify the analysis as the number of “subjects” that are related is greatly 
diminished and the independence of our observations can be assumed.  
• An assumption made in the overall logistic regression analyses included that all 
measures of effect were directly comparable through the use of a standardized 
effect size. Not all event data is directly comparable when accounting for the 
primary question (e.g. if a trial intended to find an intervention’s effect on time-
to-event, then comparing the overall event rates between groups may not be a 
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valid indicator of the effect in question). Despite this limitation, an assumption 
was made that comparability through the use of a standardized effect size – based 
on the Absolute Risk Difference for dichotomous outcomes, calculated using raw 
data, and based on the mean difference for continuous outcomes – would be 
appropriate to convey the relative magnitude and direction of effect, seen across 
all trials.  
• Calculating the Fragility Index for all trials with dichotomous outcomes that 
compared two interventions in 1:1 allocation involved an assumption that all 
dichotomous event data were comparable, as it is calculated using the numbers of 
events and subjects in each group. This is a limitation as the applicability of the 
Fragility Index to hazard data and trials with long periods of follow-up has been 
questioned due to the tendency of both types of trials to reach similar overall 
event rates in groups with increasing time.  
• Another assumption of the regression analyses was the interpretation of “Not 
Available” as missing data for covariates, and that the overall amount missing 
does not affect the outcome of the analyses. As a result of this interpretation, the 
amount missing for some covariates was exaggerated. ‘N/A’ was used in the 
database for information that could not be found within a trial (e.g. some trials did 
not report a p-value for their primary outcome), and it was also used to denote 
when a response was not possible for a particular covariate (e.g. the Fragility 
Index cannot be calculated for trials that have continuous outcomes, compare 
more than two interventions, or have allocation ratios other than 1:1).  
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• A major limitation with our analyses lies in our choice of backwards-stepwise 
model selection for our exploration of characteristics that may be associated with 
reversal. Stepwise model selection procedures are generally not recommended for 
building predictive models because they are unreliable in the presence of 
collinearity, lead to high-biased R2 values, generate standard errors for the 
parameter estimates that are too small and consequently parameter confidence 
intervals that are too narrow, create parameter estimates that are biased high in 
absolute value, and generate p-values that are biased low.130 Stepwise selection 
procedures can be appropriate for exploratory analyses when there is no prior 
information to guide variable selection. However, while traditional significance 
criteria for exclusion from a model tend to be stringent (e.g. α = 0.05 or 0.10), an 
alpha of 0.5 is more reasonable in allowing for the deletion of some variables that 
may be irrelevant to the outcome, but the retention of most variables that may 
help to predict the outcome, despite insignificance.130 Given that our purposes 
were exploratory and there is no literature to guide variable pre-specification in 
relation to reversal, we believe a backwards-stepwise model selection to be 
appropriate for informing the development of our framework of reversibility.    
• A final limitation in our interpretation of results is the reporting of relationships 
on the basis of the directionality and magnitude of covariate odds ratios. We are 
aware that the majority of potential predictors were not statistically significantly 
associated with our outcome, but as these analyses were exploratory, we felt that 
it was best to describe and interpret the relationships that we found in terms of 
whether they trended towards influencing the outcome in the way that we 
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expected, whether or not they were significant. In doing so, we referred to 
covariates that were highly non-significant (p > 0.5) as trending relationships, 
covariates that were moderately non-significant (0.5 > p > 0.05) as associated, and 
covariates that were significantly associated as such. This is a limitation in that we 
make no claims to these covariates being definitive predictors of contradictory 
findings for established practices, but we present the magnitude and degree of 
associations as we found them and make recommendations for which 
relationships we believe further study or consideration in use is warranted.  
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Chapter Summary: This chapter presents further discussion of the overall results of this 
study, particularly with regards to the impact and applications of this research 
and the future directions that should be explored in the field of reversals. The 
chapter ends by presenting an overall summary of the thesis and its 
conclusions.   
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CHAPTER 7 
7.0  IMPACT AND IMPORTANCE 
Our framework of reversibility consists of eight components of randomized 
controlled trials that have relationships with the likelihood of reversal and cover multiple 
domains from design to reporting. The development of a framework of characteristics 
that should be considered in assessing trials that contradict current standards and 
established practices has important implications for the field of reversals and to our 
knowledge has not previously been attempted. Not only is this the largest review of the 
phenomenon of reversal – updating the previous largest review with an additional seven 
years of studies – but also significantly expands analyses of associations between study 
variables and reversal. This is the most comprehensive, and the first quantitative, 
exploration of trial characteristics that may lead to evidence reversal. This framework can 
serve as a tool to be used by researchers and health policy-makers in guiding the 
decisions around adoption, de-adoption, and dis-investment of practices.   
 
7.1  APPLICATIONS OF THE FRAMEWORK 
The responsibility of identifying evidence reversals lies primarily with the 
researchers and developers of interventions and standards, and also with agencies that 
grant approval for research and implementation.2,26,36 In knowing where the burden of 
proof lies, consideration must be given to the methods and tools that are currently 
employed for identifying and reducing the impact of evidence reversals and medical 
reversals. While standards of practice exist in all scientific disciplines, and new findings 
always require dissemination before they can be implemented, there currently exist 
several methods by which the effect of reversals are mitigated and which may benefit 
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from incorporating our framework of reversibility. These are clinical guidelines, 
knowledge translation, and various other tools for de-implementation of practices.  
7.1.1 Clinical guidelines 
 Evidence Based Medicine is a common goal for decision-makers in literature, yet 
practice does not always follow the best available evidence. Physicians report that the 
proportion of their practices that are evidence based are as low as 50% of their 
practices.141 This proportion is unsurprising given the overwhelming amount of literature 
available to physicians and the difficulty that exists in finding clinically important 
literature that is relevant to practice and has enough evidence to inform a decision.142 A 
major systematic review of the publication of clinically important and relevant articles in 
primary healthcare journals suggests that clinicians would need to read an average of 13-
14 articles to obtain one that is directly clinically relevant.143  
As a consequence of this information overload, many clinicians rely on clinical 
guidelines in medical practice.141 However, the quality of clinical guidelines varies 
significantly based on the methods and processes used to select and apply evidence to 
guide recommendations. As a result, the benefit of clinical guidelines is somewhat 
contested and they are not guaranteed to reduce the impact of medical reversals.144 
Despite their necessity for efficient and consistent practice, there remain several inherent 
difficulties in generation and dissemination of effective and unbiased guidelines.144 These 
challenges may be especially powerful barriers against effectively mitigating the impact 
of evidence reversals. 
The first difficulty in establishing a clinical guideline is creating an impartial team 
where there is no conflict of interest. A survey from 2012 found that 71% of chairs of 
clinical policy committees and 90.5% of co-chairs had financial conflicts of interest and 
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that these conflicts could have a substantial effect on the conclusions and 
recommendations of the guideline.145  
The second major difficulty with guideline creation is missing data as a direct 
result of poor knowledge translation practices (i.e. publication bias) and proprietary rights 
of those who own data.38,146 One of the outcomes of poor knowledge translation that 
contributes to the difficulty in establishing clinical guidelines is a general lack of 
confidence in conclusions of efficacy.147 An evaluation of the quality and sufficiency of 
evidence for clinical practices by The Cochrane Collaboration in 2011 found that as many 
as 45% of Cochrane reviews conclude that there is insufficient evidence to endorse the 
intervention.147 Due to insufficiency of evidence, an analysis of clinical care in Australia 
found that patients only received appropriate care (i.e. based on expert recommendations 
and clinical guidelines) between 54% and 57% of the time.148 Increasing the amount of 
open data and transparency in research findings would be the first step to improving 
clinical guideline development and reducing unnecessary medical reversals.38,149  
Beyond the difficulties associated with conflicts of interest and knowledge 
translation, clinical guidelines are also controversial because they can become out of date 
very quickly, they often require incredible resources to assimilate all the relevant 
information, there are often overlapping guidelines to consider, they are often written for 
a general population but must be applied to patient-specific needs, and they are often not 
sensitive to local needs or circumstances wherein the decision maker might otherwise 
have used the available evidence and their clinical expertise to devise a more appropriate 
therapy.150,151 
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Our application could be used as a tool in the development of clinical guidelines, 
in conjunction with other methods, when considering new evidence that contradicts 
established practices. In order to declare a reversal of evidence and recommend the de-
adoption or adoption of a practice, the totality of evidence in support of it must be 
considered. Our framework suggests a set of characteristics of RCTs that may be 
associated with evidence reversal and should be considered when assessing trials for 
informing changes in recommendations for practice. Furthermore, as the ‘evidence base’ 
for evidence reversals matures to define predictors, future guideline developers should 
consider risk of reversibility of the evidence before they recommend implementation of a 
new intervention. 
7.1.2 Improved knowledge translation 
 Poor knowledge translation (especially premature translation) is directly related to 
evidence reversal.118 According to Prasad, “translation failure occurs when the results of 
preclinical, observational and/or early phase studies fail to predict the results of well done 
(i.e. appropriately controlled, adequately powered, and properly conducted) phase III or 
randomized clinical trials.”118 While knowledge translation and de-implementation go 
hand in hand with medical reversals, there are barriers to knowledge translation and 
reasons why good evidence is not readily adopted into clinical practice.152 Barriers may 
include characteristics of the evidence itself, features of the practice environment (e.g. 
financial disincentives, organizational constraints, perception of liability, patient 
expectations), the prevailing opinions and social contexts for treatment (e.g. standards of 
practice, beliefs held by opinion leaders, out-dated medical training, advocacy groups), or 
knowledge and attitudes about interventions in the professional context (e.g. clinical 
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uncertainty, physician’s sense of competence, compulsion to act, information 
overload).153,154 
If knowledge translation could be improved and clinicians made more aware of 
which treatments had proven efficacy and which did not, it logically follows that there 
should be a decrease in the use of harmful or unnecessary practices. However, there are a 
number of reasons why physicians may continue to use treatments that are harmful or do 
not work, including: clinical experience, over-reliance on a surrogate outcome, natural 
history of the illness, strong belief in the pathophysiological model, ritual or mystique 
(i.e. medical tradition), a need to do something and take action, patients’ expectations, or 
even because the correct questions about the treatment have not yet been asked.52 The 
continued use of practices that should have been phased out is common as evidence 
suggests that up to 25% of patients receive treatments that are harmful and as many as 
40% receive treatments for which the effectiveness is not known or inconclusive.155,156  
The assumption that improved knowledge translation may decrease the premature 
adoption of practices may be questioned with the argument that publication bias leads to 
an incomplete understanding of any given research topic, with preferential publication of 
significant and positive findings.39,157 This argument would infer that improving the 
translation of research findings would not necessarily be commensurate with a decrease 
in the impact of unnecessary reversals if the research that is being translated is being 
published with bias or ‘false’ due to other reasons, such as p-hacking, outcome switching, 
or newness of a field.  
In application to knowledge translation, our framework comprises elements of 
high quality studies at all stages – from conception to publication – that we found to have 
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potential relationships with the conclusions of RCTs that test established practices and 
should be considered by investigators in designing trials of established practices. 
7.1.3 De-implementation tools 
Without knowledge translation, the development of evidence-based clinical 
guidelines would be impossible. These tools for EBM are primarily thought of as 
“positive re-enforcers” (i.e. guidance on what to do in practice), useful for the 
implementation of practices and standards. However, both knowledge translation and 
practice guidelines can also be negative and serve as tools for de-implementation (i.e. 
guidance on what not to do in practice).  
A number of campaigns have been proposed to aid in the de-implementation of 
practices that have been, or are likely to be, reversed. Practices that are the target of de-
implementation are often low value or not supported by the evidence. These tools exist to 
provide summary recommendations for the cessation or continuation of practices based 
on the best available evidence. They include: the United Kingdom’s (UK) National 
Institute for Clinical Excellence (NICE) “do-not-do” lists and Database of Uncertainties 
about the Effects of Treatments (DUETs) 116,158; Canadian, American, and UK “Choosing 
Wisely” Campaigns 70,95,106; the British Medical Journal’s (BMJ) “Too Much Medicine” 
78; and Australia’s “Low-value lists.”66 
 Similarly to the development of guidelines, our framework may have use in 
helping inform the de-implementation of practices that are harmful or of low value. It 
provides a set of characteristics that should be considered when assessing trials that test 
established practices.  
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7.2  A TOOLBOX FOR FUTURE REVERSAL RESEARCH 
 In the pursuit of reducing the burden and harms associated with unnecessary 
medical and evidence reversal, there are two important characteristics to consider. The 
first is the identification of practices or paradigms that are to be tested. There are many 
global initiatives that list contradicted, unproven, or new interventions and claims. These 
categories provide potential targets for reversal and de-implementation and promote 
awareness to practitioners regarding the maturity of interventions that they use in daily 
practice, as many have been adopted prematurely based on inadequate evidence.44 The 
second characteristic is whether or not enough evidence has been accrued to confidently 
make a decision regarding the tested paradigm. One method that has been utilized for 
public health interventions, and which we propose would be appropriate for describing 
the evidence base for reversals, is the calculation of evidence sufficiency and stability.159 
At their core, the characteristics of sufficiency and stability provide a means of 
determining the point at which an intervention has been studied enough that conducting 
another test no longer provides any information of added value for decision-making.159 
When interventions are studied in humans, it is ethically irresponsible to conduct research 
beyond this point as participants will be unnecessarily randomized to receive no benefit 
(or harm if the intervention is determined to be dangerous), the implementation of 
effective risk-reduction interventions will be delayed, and there may be unnecessary 
waste of health care resources.159 
Evidence sufficiency refers to whether or not a meta-analytic database 
demonstrates that an intervention does or does not work to an adequate degree.159 
However, evidence sufficiency is a term that requires further exploration, especially with 
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respect to its relationship to tracking evidence cumulation and ultimately indicating when 
“enough evidence” has accrued, because it has been inadequately discussed in the 
literature and formal definitions still need to be derived. Some have suggested that 
sufficiency refers to whether or not cumulation such as through meta-analysis 
demonstrates that an intervention works, or does not work, with sufficient margin of 
difference and with sufficient precision (narrow CI) to suggest further evidence is 
unlikely to change this conclusion. Sufficiency may be related to the number of 
hypothesis tests (i.e. studies) and the power within those studies.159,160  
Evidence stability refers to the shifts in direction over time for support of the 
intervention being studied.159 Stability derives from the flow of the running estimate 
generated over the sequential meta-analyses: if the evidence all tends to point in one 
direction then the database is stable.159,160  
These definitions represent initial attempts at defining the concept of when there 
is ‘enough evidence’, and should be further defined and tested to determine whether they 
can be better used to inform the concept of evidence reversibility. There are several 
different meta-research methods that have been proposed to describe evidence sufficiency 
or make use of the maturity of evidence in medical decision-making, including Value of 
Information Analysis, Trial Sequential Analysis, and Bayesian analysis. We propose that 
these methods, which we describe in APPENDIX I, be explored as tools for use in future 
research about reversals, particularly with regards to determining the sufficiency and 
stability of the evidence base for practices that should be de-adopted, or those for which 
the evidence is mature enough to warrant a recommendation of adoption into practice. 
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7.3  NEXT STEPS AND FUTURE DIRECTIONS 
With this thesis, we have provided a comprehensive overview and study of a 
phenomenon that is rapidly gaining attention in the medical community and beyond. 
Through literature reviews and detailed exploratory analyses, we have presented the first 
quantitative examination of characteristics that may be associated with reversibility 
within high quality medical literature. However, this thesis is only one step of the many 
required before understanding the phenomenon and being able to reduce the impact of 
reversals on population health.  
Unnecessary reversal implies several harms to the medical industry and the 
patients who are administered treatments including decreased trust in the medical 
community, the possibility of receiving unnecessary or ineffective treatments, and an 
increased risk of unnecessary harm.26 The most efficient way to minimize these harms 
would be to reduce the impact of evidence reversal and medical reversal that occurs as a 
consequence of practices being prematurely adopted: before the evidence has sufficiently 
demonstrated the true effect. If practices were adopted only after the evidence for their 
use had matured, then the rate of unnecessary reversal would be lower.   
This thesis has been a comprehensive analysis of the contradiction of evidence by 
individual trials, and builds upon the foundation of the first area of research in the field 
(identified in our Chapter 2 literature review): research about the phenomenon itself. 
There are already many initiatives worldwide that pursue the second major area of 
research (i.e. the practices that are low value or harmful and should be targeted for de-
adoption and reversal), and our proposed toolbox for reversal includes several methods 
that we believe should be further explored for use in determining the sufficiency and 
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stability of an evidence base to declare a practice as being reversed or a confirmed 
standard of care. One of the next steps for reversal research should be the exploration of 
de-adoption and de-implementation strategies for practices that should not be in use. This 
will be challenging as some practices will have evidence mature enough to support or 
refute their use, but many will have immature evidence to adequately support their use, 
which will require judgement calls about whether likely benefits outweigh the risks and 
costs of continued use. Another major next step for research in reversal will be to explore 
the potential predictors of future reversal – the characteristics of original research that 
lead to practices being prematurely adopted – and to create a predictive model for the 
likelihood that a newly adopted developed practice may be reversed in the future. 
 
7.4  CONCLUSIONS 
Evidence reversal can be defined as “when new evidence that is stronger than 
preceding evidence arises to contradict previously established evidence.” In our analysis 
of 17 years of original studies from the NEJM, a total of 54% of randomized controlled 
trials that tested established practices met the definition of evidence reversals. Within 
these trials, a total of 8 characteristics were associated with reversal including: overall 
PICOTS and ROB assessment, number of years between a trial initiation and registration, 
sources of abstract conclusions, p-value and standardized effect size for the primary 
comparison, proportion of subjects lost to follow up, and use of surrogate versus 
clinically-relevant outcomes. Using these characteristics, we propose an Evidence 
Reversal framework which may be useful for tracking and detecting evidence reversals, 
and for informing design of future robust RCTs that challenge established practices.  
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These results provide a research agenda to better inform related research for the 
rate and predictors of reversal and for identification of low-value practices as targets for 
de-adoption. Perhaps more importantly, this research may help to better inform next steps 
towards preventing premature adoption of new treatments, which represents a significant 
driver of inefficiency and waste in healthcare. 
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APPENDIX A 
SYSTEMATIC REVIEW METHODOLOGY 
 
DATABASE SEARCH STRATEGIES & PRISMA FLOW DIAGRAM 
Table 1: Database Search Strategies and Results  A	
PUBMED Database Search Strategy and Results  (July 6th, 2016) 
Search Search Terms Articles 
1 ("Evidence-based practice"[MeSH Major Topic] OR "Patient care 
management"[MeSH Major Topic]) OR "guidelines as topic"[MeSH Major 
Topic]  
417,307  
 
2 ((((“clinical practice”[All Fields] OR “practice guideline*”[All Fields]) OR 
“physician's practice pattern”[All Fields]) OR “evidence-based”[All Fields]) OR 
“evidence based”[All Fields])  
259,320  
 
3 1 or 2 626,571  
4* ((((((((((((publication) OR publish*) OR evidence) OR practice) OR guideline*) 
OR medical) OR clinical) OR standard) OR standards) OR unexpected) OR 
surprising) N3 ((((((revers*) OR change) OR contradict*) OR divest*) OR de-
implement*))[All Fields] OR disinvest*[All Fields]  
351  
5 3 and 4 55 
6 prasad v[Author] OR ioannidis j[Author] OR ioannidis jp[Author] OR cifu 
a[Author] OR elshaug a[Author]  
1,804 
7 5 or 6 1,844 
FINAL Limit 7 to yr=“2014-Current” 443 
 
MEDLINE (EMBASE) Database Search Strategy and Results  (July 1st, 2016) 
Search Search Terms Articles 
1 exp Evidence-Based Practice/ OR exp Patient Care Management/ OR exp 
Guidelines as Topic/  
777,823 
 
2 (clinical practice OR practice guideline* OR physician's practice pattern OR 
evidence-based OR evidence based)  
331,623 
 
3 1 or 2 937,017 
4* ((publication OR publish* OR evidence OR practice OR guideline* OR medical 
OR clinical OR standard OR standards OR unexpected OR surprising) adj3 
(revers* OR change OR contradict* OR divest* OR de-implement*)).mp. OR 
disinvest*.mp.  
19,891 
5 3 and 4 4,577 
6 (prasad v OR ioannidis j OR ioannidis jp OR cifu a OR elshaug a).au.  1,421 
7 5 or 6 4,577 
FINAL Limit 7 to yr=“2014-Current” 957 
 
MEDLINE (OVID) Database Search Strategy and Results (July 22nd, 2014) 
Search Search Terms Articles 
1 exp Evidence-Based Practice/ OR exp Patient Care Management/ OR exp 
Guidelines as Topic/  
669,457 
 
2 (clinical practice OR practice guideline* OR physician's practice pattern OR 
evidence-based OR evidence based)  
273,895 
 
3 1 or 2 794,592 
4* ((publication OR publish* OR evidence OR practice OR guideline* OR medical 
OR clinical OR standard OR standards OR unexpected OR surprising) adj3 
(revers* OR change OR contradict* OR divest* OR de-implement*)).mp. OR 
disinvest*.mp.  
16,538 
5 3 and 4 3,676 
	 II	
6 (prasad v OR ioannidis j OR ioannidis jp OR cifu a OR elshaug a).au.  1,152 
FINAL 5 or 6 4,811 
* For search #4, the original search strategy was missing a space between “disinvest*” 
and “OR,” thus the final search string lacked results generated from “OR disinvest* OR 
result*”. The updated search strategy includes “disinest*” but excludes “result*” due to 
an extraneous number of results. 
 
TOTAL ARTICLES RETRIEVED FROM MEDLINE 6,201 
 
 
 
EMBASE (EMBASE) Database Search Strategy and Results (July 1st, 2016) 
Search Search Terms Articles 
1 exp Evidence-Based Practice/ OR exp Patient Care Management/ OR exp 
Guidelines as Topic/  
1,704,315 
 
2 (clinical practice OR practice guideline* OR physician's practice pattern OR 
evidence-based OR evidence based)  
680,007 
 
3 1 or 2 1,935,989 
4* ((publication OR publish* OR evidence OR practice OR guideline* OR medical 
OR clinical OR standard OR standards OR unexpected OR surprising) adj3 
(revers* OR change OR contradict* OR divest* OR de-implement*)).mp. OR 
disinvest*.mp.  
27,833 
5 3 and 4 7,960 
6 (prasad v OR ioannidis j OR ioannidis jp OR cifu a OR elshaug a).au.  859 
7 5 or 6 7,960 
FINAL Limit 7 to yr=“2014-Current” 1,902 
 
EMBASE (OVID) Database Search Strategy and Results (July 22nd, 2014) 
Search Search Terms Articles 
1 exp Evidence-Based Practice/ OR exp Patient Care Management/ OR exp 
Guidelines as Topic/  
1,407,119 
 
2 (clinical practice OR practice guideline* OR physician's practice pattern OR 
evidence-based OR evidence based)  
566,343 
 
3 1 or 2 1,598,004 
4* ((publication OR publish* OR evidence OR practice OR guideline* OR medical 
OR clinical OR standard OR standards OR unexpected OR surprising) adj3 
(revers* OR change OR contradict* OR divest* OR de-implement*)).mp. OR 
disinvest*.mp.  
24,119 
5 3 and 4 6,262 
6 (prasad v OR ioannidis j OR ioannidis jp OR cifu a OR elshaug a).au.  637 
FINAL 5 or 6 6,894 
* For search #4, the original search strategy was missing a space between “disinvest*” 
and “OR,” thus the final search string lacked results generated from “OR disinvest* OR 
result*”. The updated search strategy includes “disinest*” but excludes “result*” due to 
an extraneous number of results. 
 
TOTAL ARTICLES RETRIEVED FROM EMBASE 8,796 
 
 
 
 
	 III	
CINAHL Database Search Strategy and Results (July 1st, 2016) 
Search Search Terms Articles 
1 (MH "Professional Practice, Evidence-Based") OR (MH "Evidence- Based 
Dental Practice") OR (MH "Medical Practice, Evidence- Based") OR (MH 
"Nursing Practice, Evidence-Based") OR (MH "Occupational Therapy Practice, 
Evidence-Based") OR (MH "Physical Therapy Practice, Evidence-Based") OR 
(MH "Professional Practice, Research- Based") OR (MH "Physical Therapy 
Practice, Research-Based") OR (MH "Occupational Therapy Practice, Research-
Based") OR (MH "Practice Guidelines") OR (MH "Nursing Practice, Research-
Based") OR (MH "Medical Practice, Research- Based") OR (MH "Practice 
Patterns") OR (MH "Medical Practice") OR (MH "Nursing Care Plans")  
76,539 
 
2 ( clinical practice OR practice guideline* OR physician's practice pattern OR 
evidence- based OR evidence based )  
126,752 
 
3 1 or 2 139,840 
4 ((publication OR publish* OR evidence OR practice OR guideline* OR medical 
OR clinical OR standard OR standards OR surprising OR unexpected) N3 
(revers* OR change OR contradict* OR divest* OR de-implement* OR 
disinvest* OR result*))  
40,459 
5 3 and 4 7,653 
6 AU (prasad v OR ioannidis j OR ioannidis jp OR ioannidis jpa OR cifu a OR 
elshaug a)  
190 
7 5 or 6 7,839 
FINAL Limiters – Published date: 20140101-20161231  1,250 
 
CINAHL Database Search Strategy and Results (July 22nd, 2014) 
Search Search Terms Articles 
1 (MH "Professional Practice, Evidence-Based") OR (MH "Evidence-Based Dental 
Practice") OR (MH "Medical Practice, Evidence-Based") OR (MH "Nursing 
Practice, Evidence-Based") OR (MH "Occupational Therapy Practice, Evidence-
Based") OR (MH "Physical Therapy Practice, Evidence-Based") OR (MH 
"Professional Practice, Research- Based") OR (MH "Physical Therapy Practice, 
Research-Based") OR (MH "Occupational Therapy Practice, Research-Based") 
OR (MH "Practice Guidelines") OR (MH "Nursing Practice, Research-Based") 
OR (MH "Medical Practice, Research-Based") OR (MH "Practice Patterns") OR 
(MH "Medical Practice") OR (MH "Nursing Care Plans")  
106,511 
 
2 ( clinical practice OR practice guideline* OR physician's practice pattern OR 
evidence- based OR evidence based )  
137,475 
 
3 1 or 2 156,054 
4 ((publication OR publish* OR evidence OR practice OR guideline* OR medical 
OR clinical OR standard OR standards OR surprising OR unexpected) N3 
(revers* OR change OR contradict* OR divest* OR de-implement* OR 
disinvest* OR result*))  
36,042 
5 3 and 4 6,313 
6 AU (prasad v OR ioannidis j OR ioannidis jp OR ioannidis jpa OR cifu a OR 
elshaug a)  
268 
FINAL 5 or 6 6,577 
 
TOTAL ARTICLES RETRIEVED FROM CINAHL 7,827 
 
 
 
 
 
	 IV	
Web of Science Database Search Strategy and Results (July 3rd, 2016) 
Search Search Terms Articles 
1 TS=(Evidence-Based Practice OR Patient Care Management OR Guidelines)  447,145 
2 TI=(clinical practice OR practice guideline* OR physician's practice pattern OR 
evidence- based OR evidence based)  
61,470 
 
3 1 or 2 487,183 
4 TI=((publication OR publish* OR evidence OR practice OR guideline* OR 
medical OR clinical OR standard OR standards OR surprising OR unexpected) 
NEAR/3 (revers* OR change OR contradict* OR divest* OR de-implement* OR 
disinvest* OR result*))  
30,851 
5 3 and 4 2,937 
6 AU=(Prasad V OR Ioannidis J OR Ioannidis JP OR Ioannidis JPA OR Cifu A OR 
Elshaug A)  
3,502 
7 5 or 6 6,435 
FINAL #7 From 2014-2016  1,215 
 
Web of Science Database Search Strategy and Results (July 22nd, 2014) 
Search Search Terms Articles 
1 TS=(Evidence-Based Practice OR Patient Care Management OR Guidelines)  354,556 
2 TI=(clinical practice OR practice guideline* OR physician's practice pattern OR 
evidence- based OR evidence based)  
51,412 
 
3 1 or 2 388,323 
4 TI=((publication OR publish* OR evidence OR practice OR guideline* OR 
medical OR clinical OR standard OR standards OR surprising OR unexpected) 
NEAR/3 (revers* OR change OR contradict* OR divest* OR de-implement* OR 
disinvest* OR result*))  
27,607 
5 3 and 4 2,398 
6 AU=(Prasad V OR Ioannidis J OR Ioannidis JP OR Ioannidis JPA OR Cifu A OR 
Elshaug A)  
2,990 
FINAL 5 or 6 5,384 
 
TOTAL ARTICLES RETRIEVED FROM WEB OF SCIENCE 6,599 
 
 
 
Dissertations and Theses Database Search Strategy and Results (July 3rd, 2016) 
Search Search Terms Articles 
1 su(Evidence-Based Practice OR Patient Care Management OR Guidelines)  1,816 
2 all(clinical practice OR practice guideline* OR physician's practice pattern OR 
evidence- based OR evidence based)  
88,179 
 
3 1 or 2 89,262 
4 all((publication OR publish* OR evidence OR practice OR guideline* OR 
medical OR clinical OR standard OR standards OR surprising OR unexpected) 
NEAR/3 (revers* OR change OR contradict* OR divest* OR de-implement* OR 
disinvest* OR result*))  
42,744 
5 3 and 4 6,607 
FINAL Limit to 2014-2016  893 
 
 
  
	 V	
Dissertations and Theses Database Search Strategy and Results (July 22nd, 2014) 
Search Search Terms Articles 
1 su(Evidence-Based Practice OR Patient Care Management OR Guidelines)  1,245 
2 all(clinical practice OR practice guideline* OR physician's practice pattern OR 
evidence- based OR evidence based)  
73,768 
3 1 or 2 74,504 
4 all((publication OR publish* OR evidence OR practice OR guideline* OR 
medical OR clinical OR standard OR standards OR surprising OR unexpected) 
NEAR/3 (revers* OR change OR contradict* OR divest* OR de-implement* OR 
disinvest* OR result*))  
9,517 
FINAL 3 and 4 1,349 
 
TOTAL ARTICLES RETRIEVED FROM DISSERTATIONS AND THESES 2,242 
 
 
 
Canadian Health Research Collection (CHRC) Database Search Strategy and Results  
 (July 5th, 2016) 
Search Search Terms Articles 
1 ((Evidence-Based Practice OR Patient Care Management OR Guidelines) OR 
(clinical practice OR practice guideline* OR physician's practice pattern OR 
evidence-based OR evidence based)) AND ((publication OR publish* OR 
evidence OR practice OR guideline* OR medical OR clinical OR standard OR 
standards) WITHIN-3 (revers* OR change OR contradict* OR divest* OR de- 
implement* OR disinvest* OR surprising result*))  
13,268 
FINAL Limit to 2014-2016  1,900 
 
Canadian Health Research Collection (CHRC) Database Search Strategy and Results  
 (July 22nd, 2014) 
Search Search Terms Articles 
1 All:(Evidence-Based Practice OR Patient Care Management OR Guidelines)  10,902 
2 All:(clinical practice OR practice guideline* OR physician's practice pattern OR 
evidence- based OR evidence based)  
10,734 
3 1 or 2 11,316 
4 All:((publication OR publish* OR evidence OR practice OR guideline* OR 
medical OR clinical OR standard OR standards) WITHIN-3 (revers* OR change 
OR contradict* OR divest* OR de-implement* OR disinvest* OR surprising 
result*))  
11,553 
FINAL 3 and 4 11,225 
 
TOTAL ARTICLES RETRIEVED FROM CHRC 13,125 
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Google Scholar Database Search Strategy and Results (July 22nd, 2014) 
Search Search Terms Articles 
FINAL Author Profile for “Vinay Prasad” [Custom Range: 2014-2016]  86 
FINAL Author Profile for “Adam Cifu” [Custom Range: 2014-2016]  32 
FINAL Author Profile for “John P. A. Ioannidis” [Custom Range: 2014-2016]  203 
FINAL Author Profile for “Dr Adam Elshaug” [Custom Range: 2014-2016]  16 
FINAL (“evidence reversal” OR “clinical reversal” OR “medical reversal” OR 
“divestment” OR “de-implement” OR “disinvestment” OR “surprising result”) 
AND (“evidence based” OR “evidence-based”) [Custom Range: 2014-2016]  
1,000 
 Total 1,337 
 
Google Scholar Database Search Strategy and Results (July 22nd, 2014) 
Search Search Terms Articles 
FINAL Author Profile for “Vinay Prasad” [Custom Range: 2014-2016]  93 
FINAL Author Profile for “Adam Cifu” [Custom Range: 2014-2016]  32 
FINAL Author Profile for “John P. A. Ioannidis” [Custom Range: 2014-2016]  1,132 
FINAL Author Profile for “Dr Adam Elshaug” [Custom Range: 2014-2016]  90 
FINAL (“evidence reversal” OR “clinical reversal” OR “medical reversal” OR 
“divestment” OR “de-implement” OR “disinvestment” OR “surprising result”) 
AND (“evidence based” OR “evidence-based”) [Custom Range: 2014-2016]  
969 
 Total 2,316 
 
TOTAL ARTICLES RETRIEVED FROM GOOGLE SCHOLAR 3,653 
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aFigure 1: PRISMA Flow Diagram 
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APPENDIX B 
DATA EXTRACTION FOR 87 INCLUDED ARTICLES 
 
Table 2: Complete data extraction of 87 included articles 
Author(s)	or	
Organization	
Title	 Year	 Study	Type	 Term(s)	Used	 Relationship	
to	Reversal	
AMSTAR	
Rating	
Score	
AMSTAR	
Quality	
Rating	
Advancing 
Medical 
Professionalism to 
Improve Health 
Care Foundation1 
The American Board of 
Internal Medicine (ABIM) 
Foundation Initiative 
Choosing Wisely 
2012 Systematic 
Review 
Things providers and 
patients should 
question 
Target 1 Very Low 
Quality 
Unnecessary medical 
tests, treatments and 
procedures 
Target 
Wasteful medical tests, 
treatments and 
procedures 
Target 
Australia 
Comprehensive 
Management 
Framework for 
Medicare Benefits 
Schedule2 
Australian Government 
Department of Health and 
Ageing, Medicare 
‘Comprehensive 
Management Framework’ 
environmental scan 
(Australia) 
2011 Collection of 
Studies 
Recommendations for 
practice 
Target 4 Low Quality 
Brien et al3 A scoping review of 
appropriateness of care 
research activity in Canada 
from a health system-level 
perspective 
 
2014 Systematic 
Scoping 
Review 
Inappropriate care Target 5 Low Quality 
British Medical 
Journal4 
BMJ's Too Much 
Medicine 
2013 Systematic 
Review 
Overdiagnosis Phenomenon 1 Very Low 
Quality Too Much Medicine Consequence 
Bryson5 Back to the future: 
Medical reversals and 
perioperative medicine 
2014 Collection of 
Studies 
Medical reversal Phenomenon 1 
 
Very Low 
Quality 
	 IX	
Author(s)	or	
Organization	
Title	 Year	 Study	Type	 Term(s)	Used	 Relationship	
to	Reversal	
AMSTAR	
Rating	
Score	
AMSTAR	
Quality	
Rating	
Choosing Wisely 
Canada6 
The Canadian Medical 
Association (CMA) 
Campaign Choosing 
Wisely 
2014 Systematic 
Review 
Unnecessary tests, 
treatments and 
procedures 
Target 1 Very Low 
Quality 
Cifu and Prasad7 Medical debates and 
medical reversal 
2015 Collection of 
Studies 
Medical reversal Phenomenon 0 Very Low 
Quality 
Davidoff 8 On the undiffusion of 
established medical 
practices 
2015 Collection of 
Studies 
Undiffusion Consequence 1 Very Low 
Quality 
Doust and Del 
Mar9 
Why do doctors use 
treatments that do not 
work? 
2004 Collection of 
Studies 
Ineffective or harmful 
interventions 
Target 1 Very Low 
Quality 
Drazer et al10 Stereostatic body 
radiotherapy for 
oligometastatic breast 
cancer: A new standard of 
care, or a medical reversal 
in waiting? 
2016 Systematic 
Review 
Medical reversal Phenomenon 1 Very Low 
Quality 
Duckett et al11 Identifying and acting on 
potentially inappropriate 
care 
2015 Secondary 
Data Analysis 
and Review 
Inappropriate care Target 2 Very Low 
Quality 
Ebell and Grad12 Top 20 research studies of 
2011 for primary care 
physicians 
2012 Collection of 
Studies 
POEMs likely to 
change practice 
Target 2 Very Low 
Quality 
Ebell and Grad13 Top 20 research studies of 
2012 for primary care 
physicians 
2013 Collection of 
Studies 
POEMs likely to 
change practice 
Target 3 Low Quality 
Ebell and Grad14 Top 20 research studies of 
2013 for primary care 
physicians 
2014 Collection of 
Studies 
POEMs likely to 
change practice 
Target 3 Low Quality 
Ebell and Grad15 Top 20 research studies of 
2014 for primary care 
physicians 
2015 Collection of 
Studies 
POEMs likely to 
change practice 
Target 4 Low Quality 
	 X	
Author(s)	or	
Organization	
Title	 Year	 Study	Type	 Term(s)	Used	 Relationship	
to	Reversal	
AMSTAR	
Rating	
Score	
AMSTAR	
Quality	
Rating	
Ebell and Grad16 Top 20 research studies of 
2015 for primary care 
physicians 
2016 Collection of 
Studies 
POEMs likely to 
change practice 
Target 5 Low Quality 
Elshaug et al17 Building the evidence base 
for disinvestment from 
ineffective health care 
practices: a case study in 
obstructive sleep apnoea 
syndrome 
2007 Collection of 
Studies 
Disinvestment Consequence 2 Very Low 
Quality 
Elshaug et al18 
 
Identifying existing health 
care services that do not 
provide value for money 
2009 Collection of 
Studies 
Assess new  
interventions –  
displace old 
Consequence 1 Very Low 
Quality 
Ineffective, harmful, or 
non-cost-effective 
interventions  
Target 
Legacy items Target 
Technology 
development 
Target 
Elshaug et al19 Over 150 potentially low-
value health care practices: 
an Australian study 
2012 Systematic 
Review 
Low value care Target 5 Low Quality 
Elshaug et al20 The value of low-value 
lists 
2013 Collection of 
Studies 
Low value care Target 1 Very Low 
Quality Waste Target 
Fatovich21 Medical reversal: what are 
you doing wrong for your 
patient today? 
2013 Collection of 
Studies 
Medical reversal Phenomenon 1 Very Low 
Quality 
Finn and 
Greenwald22 
Update in hospital 
medicine: evidence you 
should know 
2015 Collection of 
Studies 
Recommendations for 
practice 
Consequence 4 Low Quality 
	 XI	
Author(s)	or	
Organization	
Title	 Year	 Study	Type	 Term(s)	Used	 Relationship	
to	Reversal	
AMSTAR	
Rating	
Score	
AMSTAR	
Quality	
Rating	
Garner et al23 Reducing ineffective 
practice: challenges in 
identifying low-value 
health care using Cochrane 
Systematic Reviews 
2013 Collection of 
Studies 
Low-value health care Target 2 Very Low 
Quality 
Gnjidic and 
Elshaug24 
 
De-adoption and its 43 
related terms: harmonizing 
low-value care 
terminology 
2015 Collection of 
Studies 
Abandon* Consequence 2 Very Low 
Quality Contradict Phenomenon 
De-adoption Consequence 
Decrease use Consequence 
Decline in use Consequence 
Discontinu* Consequence 
Disinvestment Consequence 
Ineffective Target 
Obsole* Target 
Opportunity cost Phenomenon 
Overdiagnosis Phenomenon 
Overtreatment Consequence 
Re-assessment Consequence 
Resource re-allocation Consequence 
Reversal Phenomenon 
Waste Target 
Haas et al25 Breaking up is hard to do: 
why disinvestment in 
medical technology is 
harder than investment 
2012 Collection of 
Studies 
Disinvestment Consequence 1 Very Low 
Quality Improper use Target 
Negative list Target 
Obsolete / outmoded / 
abandoned 
technologies 
Target 
Services not medically 
necessary 
Target 
Hampton26 Clinical trial results may 
lead to changes in 
cardiovascular care 
2014 Collection of 
Studies 
Change in treatment 
guidelines 
Consequence 1 Very Low 
Quality 
	 XII	
Author(s)	or	
Organization	
Title	 Year	 Study	Type	 Term(s)	Used	 Relationship	
to	Reversal	
AMSTAR	
Rating	
Score	
AMSTAR	
Quality	
Rating	
Hanrahan et al27 Sacred cow gone to 
pasture: a systematic 
evaluation and integration 
of evidence-based practice 
2015 Collection of 
Studies 
Sacred cows Target 2 Very Low 
Quality 
Ioannidis28 Contradicted and initially 
stronger effects in highly 
cited clinical research 
2005 Systematic 
Review 
Contradicted Phenomenon 2 Very Low 
Quality Initially stronger 
effects 
Potential 
Predictor 
Ioannidis29 Evolution and translation 
of research findings: from 
bench to where? 
2006 Collection of 
Studies 
Contradictory results Phenomenon 1 Very Low 
Quality Proteus phenomenon  Phenomenon 
Ioannidis30 Molecular bias 2005 Collection of 
Studies 
Proteus phenomenon Phenomenon 1 Very Low 
Quality 
Ioannidis31 Non-replication and 
inconsistency in the 
genome-wide association 
setting 
2007 Systematic 
Review 
Inconsistent results Potential 
Predictor 
1 Very Low 
Quality 
Non-replication Potential 
Predictor 
Ioannidis and 
Lau32 
Evolution of treatment 
effects over time: 
empirical insight from 
recursive cumulative 
metaanalyses 
2001 Recursive 
Cumulative 
Meta-Analysis 
Uncertainty Potential 
Predictor 
3 Low Quality 
Ioannidis and 
Panagiotou33 
Comparison of effect sizes 
associated with biomarkers 
reported in highly cited 
individual articles and in 
subsequent meta-analyses 
2011 Systematic 
Review 
False positive Potential 
Predictor 
4 Low Quality 
Inflated results Potential 
Predictor 
Ioannidis and 
Trikalinos34 
Early extreme 
contradictory estimates 
may appear in published 
research: the Proteus 
phenomenon in molecular 
genetics research and 
randomized trials 
2005 Systematic 
Review 
Proteus phenomenon Phenomenon 2 Very Low 
Quality 
	 XIII	
Author(s)	or	
Organization	
Title	 Year	 Study	Type	 Term(s)	Used	 Relationship	
to	Reversal	
AMSTAR	
Rating	
Score	
AMSTAR	
Quality	
Rating	
Ioannidis et al35 Genetic associations in 
large versus small studies: 
an empirical assessment 
2003 Systematic 
Review 
Discrepancies of effect 
over time 
Potential 
Predictor 
1 Very Low 
Quality 
Kotzeva et al36 Adding value to health 
care through 
discontinuation of low-
value practices: 
ESSENCIAL Project in 
Catalonia 
2013 Collection of 
Studies 
Low value practices Target 1 Very Low 
Quality 
Laiteerapong and 
Huang37 
The pace of change in 
medical practice and 
health policy: collision or 
coexistence 
2015 Collection of 
Studies 
Medical reversal Phenomenon 1 Very Low 
Quality Change in guideline 
recommendation 
Consequence 
Loder et al38 Choosing wisely in 
headache medicine: the 
American Headache 
Society's list of five things 
physicians and patients 
should question 
2013 Collection of 
Studies 
Overused or misused 
tests and treatments 
Target 2 Very Low 
Quality 
Macleod et al39 Biomedical research: 
increasing value, reducing 
waste 
2014 Collection of 
Studies 
Research Waste Target 2 Very Low 
Quality 
Makic et al40 Evidence-based practice 
habits: putting more sacred 
cows out to pasture 
2011 Collection of 
Studies 
Sacred cows Target 1 Very Low 
Quality 
Makic et al41 Examining the evidence to 
guide practice: challenging 
practice habits 
2014 Collection of 
Studies 
Practices not supported 
by the evidence 
Target 1 Very Low 
Quality 
Sacred cows Target 
Makic et al42 Putting evidence into 
nursing practice: four 
traditional practices not 
supported by the evidence 
2013 Collection of 
Studies 
Sacred cows Target 2 Very Low 
Quality 
	 XIV	
Author(s)	or	
Organization	
Title	 Year	 Study	Type	 Term(s)	Used	 Relationship	
to	Reversal	
AMSTAR	
Rating	
Score	
AMSTAR	
Quality	
Rating	
Malhotra et al43 Choosing wisely in the 
UK: The Academy of 
Medical Royal Colleges' 
initiative to reduce the 
harms of too much 
medicine 
2015 Collection of 
Studies 
Overtreatment Consequence 0 Very Low 
Quality 
Mayer and 
Nachtnebel44 
Disinvesting from 
ineffective technologies: 
lessons learned from 
current programs 
2015 Systematic 
Review 
Disinvestment Consequence 3 Low Quality 
Ineffective technology Target 
Obsolete technology Target 
McCandless et 
al45 
Snake oil version 2 2014 Collection of 
Studies 
Snake oil Target 2 Very Low 
Quality 
McCandless et 
al46 
Snake oil superfoods? 2013 Collection of 
Studies 
Snake oil Target 2 Very Low 
Quality 
McCandless et 
al47 
Snake oil supplements? 2010 Collection of 
Studies 
Snake oil Target 1 Very Low 
Quality 
Mitera et al48 Choosing Wisely Canada 
cancer list: ten low-value 
or harmful practices that 
should be avoided in 
cancer care 
2015 Collection of 
Studies 
Low-value practices Target 2 Very Low 
Quality Harmful practices Target 
Morgan et al49 Update on medical overuse 2015 Systematic 
Review 
Medical overuse Consequence 3 Low Quality 
Overdiagnosis Phenomenon 
Overtreatment Consequence 
National Institute 
for Health and 
Care Excellence 
(NICE)50  
National Institute for 
Health and Care 
Excellence (NICE) “Do 
not do” list 
Current Systematic 
Review 
Do not do 
recommendations 
Target 8 High 
Quality 
National Institute 
for Health and 
Care Excellence 
(NICE)51  
UK Database of 
Uncertainties about the 
Effects of Treatments (UK 
DUETs) 
 
Current Overview 
Systematic 
Review 
Known uncertainty Potential 
Predictor 
2 Very Low 
Quality 
	 XV	
Author(s)	or	
Organization	
Title	 Year	 Study	Type	 Term(s)	Used	 Relationship	
to	Reversal	
AMSTAR	
Rating	
Score	
AMSTAR	
Quality	
Rating	
Niven et al52 Towards understanding the 
de-adoption of low-value 
clinical practices: a 
scoping review 
2015 Systematic 
Review 
Abandon* Consequence 5 Low Quality 
Contradict Phenomenon 
Change in practice Consequence 
Change in use Consequence 
Clinical redesign Consequence 
De-adopt* Consequence 
Decline in use Consequence 
De-commission Consequence 
Decrease use Consequence 
Defunding Consequence 
De-implement* Consequence 
De-list Consequence 
Disadoption Consequence 
Discontinu* Consequence 
Disinvest* Consequence 
Do not do Target 
Drop in use Consequence 
Evidence-based 
reassessment 
Consequence 
Health technology 
reassessment 
Consequence 
Inappropriate use Target 
Ineffective Target 
Low value practice / 
intervention 
Target 
Medical reversal Phenomenon 
Misuse Consequence 
Obsole* Target 
Over use Consequence 
Reallocation Consequence 
Re-appraisal Consequence 
Reassess* Consequence 
	 XVI	
Author(s)	or	
Organization	
Title	 Year	 Study	Type	 Term(s)	Used	 Relationship	
to	Reversal	
AMSTAR	
Rating	
Score	
AMSTAR	
Quality	
Rating	
Redeploy Consequence 
Reduc* Consequence 
Refute Phenomenon 
Re-invest Consequence 
Relinquish* Consequence 
Remov* Consequence 
Replace Consequence 
Re-prioritization Consequence 
Resource release Consequence 
Reversal Phenomenon 
Stop* Consequence 
Substitutional re-
investment 
Consequence 
Withdraw* Consequence 
Withdrawing from a 
service and redeploying 
resources 
Consequence 
Paprica et al53 From talk to action: policy 
stakeholders, 
appropriateness, and 
selective disinvestment 
2015 Collection of 
Studies 
De-implementation Consequence 1 Very Low 
Quality Disinvestment Consequence 
Harmful practices Target 
Inappropriate care Target 
Low-value services Target 
Polisena et al54 Case studies that illustrate 
disinvestment and resource 
allocation decision-making 
processes in health care: a 
Systematic Review 
2013 Systematic 
Review 
Disinvestment Consequence 6 High 
Quality Ineffective 
technologies 
Target 
Obsolete technologies Target 
Prasad55 Translation failure and 
medical reversal: two sides 
of the same coin 
2016 Collection of 
Studies 
Medical reversal Phenomenon 1 Very Low 
Quality Translation failure Phenomenon 
Prasad and Cifu56 A medical burden of 
proof: towards a new ethic 
2012 Collection of 
Studies 
Medical reversal Phenomenon 2 Very Low 
Quality 
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Author(s)	or	
Organization	
Title	 Year	 Study	Type	 Term(s)	Used	 Relationship	
to	Reversal	
AMSTAR	
Rating	
Score	
AMSTAR	
Quality	
Rating	
Prasad and Cifu57 Medical reversal: why we 
must raise the bar before 
adopting new technologies 
2011 Collection of 
Studies 
Medical reversal Phenomenon 1 Very Low 
Quality 
Prasad and Cifu58 The reversal of cardiology 
practices: interventions 
that were tried in vain 
2013 Systematic 
Review 
Medical reversal Phenomenon 2 Very Low 
Quality 
Prasad and 
Ioannidis59 
Evidence-based de-
implementation for 
contradicted, unproven, 
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APPENDIX D 
RATIONALE AND EXAMPLES FOR INCLUSION AND EXCLUSION 
CRITERIA 
 
CLINICAL PRACTICE, RANDOMIZED CONTROLLED TRIAL, EXISTING 
PRACTICE 
 
 In “A decade of reversal: an analysis of 146 contradicted medical practices,” 
Prasad et al. provided little instruction with regards to the methods used to reach their 
decisions on aspects of study classification. While they had less restrictive criteria for 
their review – including all studies that were published as original research articles and 
all studies that tested clinical practices, regardless of study design and whether they were 
new or existing – they still sorted their studies into these different categories to inform 
their descriptive statistics of the ‘study’ population.  
 
Prasad et al.’s methodology for a study’s designation as clinical practice was:  
 
“On the basis of published abstracts, articles were classified as to whether they 
addressed a clinical practice. Articles addressing a medical practice were defined as any 
investigation that assesses a screening, stratifying, or diagnostic test, a medication, a 
procedure or surgery, or any change in health care provision systems. Many research 
articles concern the novel molecular basis of disease or novel insights in 
pathophysiology. These articles were excluded. When practice information could not be 
ascertained by abstract alone, full articles were read.”60  
 
 Prasad et al.’s methodology for classifying study design was: 
 
“Two reviewers (C.T., A.V., M.C., J.R., S.Q., S.J.C., D.B., V.G., or S.S.) and V.P. read 
articles addressing a medical practice in full. ... Methods were classified as one of the 
following: randomized controlled trial, prospective controlled (but nonrandomized) 
intervention study, observational study (prospective or retrospective), case-control study, 
or other methods.”60 
 
 Prasad et al.’s methodology for determining whether a study examined new or 
existing practice was: 
 
“Two reviewers (C.T., A.V., M.C., J.R., S.Q., S.J.C., D.B., V.G., or S.S.) and V.P. read 
articles addressing a medical practice in full. On the ba- sis of the abstract, introduction, 
and discussion, articles were classified as to whether the practice in question was new or 
existing.”60 
 
 The methodology does further explain that designation was performed in 
duplicate and that a third party adjudicated any discrepancies between reviewers. 
However, as is evident from the above excerpts, beyond providing the categories used, 
Prasad et al. provide no direction on how they placed studies into those categories. We 
took the categories that were used by Prasad et al. and created definitions and guidelines 
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to inform each decision. These guidelines were followed as closely as possible, but often 
there was no clear distinction between two options and the decision was made at the 
discretion of the screener.  
 
 The first two levels of screening (‘clinical practice’ and ‘study design’) were not 
conducted in duplicate for two reasons. Firstly, the restriction of time would have made 
screening these stages in duplicate an impossibility, as many articles required careful 
reading of the full text to inform a decision. Secondly, these two levels had the strongest 
rationale and guidelines for following, and the distinction between whether a study 
looked at a clinical practice or not, and between the different study designs, was almost 
always clear. The third level of screening (‘new vs. existing practice’) was conducted in 
duplicate (RQ & DS) to increase the likelihood that we would capture all trials that tested 
established practices (and consequently lead to reversal or confirmation of evidence). All 
discrepancies were resolved through discussion (RQ & DS) or mediator (JM). This level 
was the most difficult to screen as the decision of existing or new practice was made 
based on the evidence provided in each article, not based on the clinical knowledge of the 
screeners.  
 
Other researchers or clinicians who assess the same articles may designate them 
differently across any of the levels, but we are confident in our decisions as they were all 
made from an independent frame of mind and with all of the information presented by the 
authors themselves.  
 
Level 1 – Study subject matter 
 
 This level of screening was two-tiered, however the inclusion of articles was 
based only on the first tier. In assessing the subject matter of a study, we designated the 
direct intervention or thing being studied as well as the primary purpose of that 
investigation. That is to say, we assessed both whether a study investigated a clinical 
practice, as well as whether the goal of the study was to assess efficacy with regards to 
diagnosis, harm, prevention, prognosis, or therapy. While only clinical practices were 
included in our review, to follow the same methods as Prasad et al., the second-tier of 
designation was performed to allow for further description of the included population of 
trials and possible subgroup analyses if it was decided they might be relevant to our 
outcome of interest.  
 
• Clinical Practice: All studies that look at: screening, stratifying, or diagnostic 
tests; any medical intervention such as a medication, procedure, or surgery; or any 
other change in health care provision systems that might be tested such as dietary 
or behavioural interventions and vaccinations.  
• Non-Clinical Practice: All studies that look at a non-clinical element of medicine 
including animal studies, studies to elucidate pathophysiolocal pathways, or 
studies of the molecular basis of disease (e.g. genetic association). 
• Diagnosis: Examines the ability of a test to identify patients with or without a 
selected disease or condition; or identifies the frequency of the selected disease or 
condition. Patients are of two distinct groups, those with the selected disease or 
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condition, and those without the selected disease or condition. 
• Harm: Examines the harmful effects of an intervention on measurable outcomes, 
ideally patient-important outcomes. Patients cannot be randomized to one 
intervention or another. 
• Prevention: Examines the ability of an intervention to prevent a selected disease 
or condition; or the ability of a test to identify apparently healthy patients with a 
selected disease or condition prior to symptom onset. Patients are apparently 
healthy people examined before symptom and disease onset for whether or not 
they develop the selected disease or condition after an intervention; and/or 
identification of protective or risk factors.  
• Prognosis: Examines the clinical course of a selected disease or condition that has 
been treated; or the natural history of a selected disease or condition that has not 
been treated. Patients are unhealthy people examined after symptom and disease 
onset for measurable outcomes – ideally patient-important outcomes (death, 
disease, discomfort, disability, and dissatisfaction) – and/or prognostic factors. 
• Therapy: Examines the effect of an intervention (medication, procedure, or 
surgery) on measurable outcomes, ideally patient-important. Patients are 
unhealthy people with a selected disease or condition after symptom onset 
 
Level 2 – Study design 
 
 In general, the different study designs were clearly discernible from author’s 
writing and descriptions of their methods. If the study design was not immediately 
described in the abstract, then the methods of the full text for the article were examined to 
reach a conclusion. The different study designs had well defined criteria, which allowed 
the decision as to a study’s designation to be reached quickly and accurately. They are: 
 
• Randomized controlled trial: Patients were randomized into two or more 
groups. 
• Prospective controlled (but nonrandomized) intervention study: Patients were 
placed into two or more groups but randomization did not occur. 
• Observational study (prospective or retrospective): Patients were not placed 
into groups and randomization did not occur, or all patients received the same 
intervention. 
• Case-control study: Patients were selected into two groups based on a certain 
diagnosis or key attribute 
• Other: Included other study designs not listed above such as review articles, case 
series, and case studies that did not fit into any of the above categories 
 
Level 3 – New or existing practice 
 
 The designation of whether or not a trial (as all included studies by this tier were 
randomized controlled trials) investigated a new or an existing practice was difficult. As 
with the other classifications, it derived from what was presented by the authors in the 
trial being assessed. However, authors were not always clear in their description of prior 
patterns of use, and they may have over-exaggerated or under-represented a practice’s 
	 XXX	
prior use to suit their background and rationale for conducting the study. As such, this 
designation required careful assessment of the trial in question, utilizing clues from the 
abstract, as well as the full text introduction, discussion, and conclusions. All 
disagreements at this screening level were resolved through discussion.  
 
 To guide inclusion/exclusion at this level, both screeners (RQ & DS) used key 
words and themes that were associated with trials of new or existing practices. These 
were primarily used when the authors did not explicitly say whether or not a practice is 
new or existing. An “existing” practice did not have to be an established standard of care 
to be included: it had to be described as being in use by physicians. Thus, even practices 
where there is considerable debate surrounding their use were included as the practices 
themselves are established enough within the medical community to warrant that debate.  
 
 
Table 4: Key words and themes that were often found in trials of… 
New Clinical Practices Existing Clinical Practices 
• Citation of biological plausibility, animal 
studies, or lab studies in rationale 
• Use of pharmacokinetic endpoints as 
primary outcomes 
• Description of effect of intervention as 
“unknown” 
• Description of intervention use in very 
different populations (e.g. adults vs. 
premature infants) 
• Description of the intervention as untested 
in the population 
• Described as Phase I or II trial 
• Described as Phase III trial, citing only 
previous Phase I or II trials 
• Regulatory approval for tested indication 
after the start of trial recruitment 
• Reference to guidelines or recommendations of 
the practice 
• Mention of “controversy,” “debate” or 
“uncertainty” within the medical literature 
• Reference to prior ‘epidemiological’ or 
‘observational’ studies, which suggests that the 
practice is seeing use outside of experimental 
settings 
• Interventions that are dietary / behavioural / 
supplemental nutrients or vitamins (as these are 
often adopted before they have been rigorously 
tested because they are unlikely to cause harm) 
• Description of intervention use in similar, but 
different, populations (e.g. infants vs. premature 
infants) (required careful consideration of the 
description of use in both populations) 
• Described as Phase IV trial  
• References to older Phase III trials of the same 
intervention 
• Regulatory approval for tested indication before 
the start of trial recruitment 
• Both intervention and control group are existing 
therapies or interventions that approach a 
problem from different positions 
 
 
 While these themes were most often found in trials of the above types of 
interventions, their presence in an article was not definitive in ascribing the status as new 
or existing. Rather, they served as clues to help guide the decision and the search for 
further evidence to inform the decision. Only in cases where the authors failed to provide 
any more rationale or discussion of the interventions in question, were the above key 
words and themes used as the basis for finalizing the decision to include or exclude the 
trial.  
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 The greatest difficulty in this stage of screening arose with interventions that were 
supplementary or commonly used in other settings. The testing of an intervention in a 
new population was classified as a “new intervention,” and as such, it was often difficult 
determine when a population had seen use before. This commonly occurred in cancer 
trials where different combinations of drugs are tested for many different cancers to try 
and find some degree of efficacy or effectiveness. When an intervention was described as 
being tested in a different stage of cancer than it is currently used (e.g. an intervention 
that is currently used for advanced metastatic breast cancer, but being tested for efficacy 
loco-regionally advanced breast cancer), it was counted as a new population excluded. 
However, if the stage of cancer that was being tested was similar to one where it already 
sees use (e.g. an intervention that is currently used for a subcategory of Stage II breast 
cancer, and being tested in the other subcategory of Stage II breast cancer), then the use 
in that population was deemed established and the trial was included. The same 
methodology was used to assess the similarity of other populations and interventions. For 
example, if an intervention was described as currently existing in a certain population and 
being tested in a similar population (e.g. childhood vaccination as common practice in a 
sub-Saharan African country, and being tested in a different sub-Saharan African country 
where it is not common practice), this was counted as an existing intervention and 
included. 
 
This was a difficulty in the screening that may be designated differently by other 
researchers or clinicians assessing the same articles. However, it was unavoidable given 
our time restriction and lack of clinical expertise. Where Prasad et al. had a team of 
physicians to reach conclusions regarding the established use or novelty of practices, we 
did not have the same resources available. This difficulty in assessing new populations 
for existing practices was the most challenging aspect and led to the greatest number of 
initial disagreements between screeners. When a practice could not be classified as new 
or existing, the final decision was to include it (i.e. classify the practice as existing) so as 
to increase the sensitivity of our screening and capture all potential reversals over the 17-
year range.  
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APPENDIX E 
DATA EXTRACTION AND ANALYSIS ELEMENTS 
	
GENERAL STUDY INFORMATION, METHODOLOGY, STUDY RESULTS, STUDY CONCLUSIONS, CONFLICTS OF 
INTEREST, PICOTS ASSESSMENT, RISK OF BIAS RATINGS, GRADE ASSESSMENT 	
Table	5:	Data	extraction	methods	(options	and	rationale)	for	database	characteristics	
General	Study	
Information	
Author(s)	 Authors	of	the	study	or	trial.	Title	 Title	of	the	study	or	trial.	DOI	 Digital	Object	Identifier	for	trial	or	study.	“N/A”	if	none	available.	Date	of	Publication	 Date	the	trial	or	study	was	published.	Year	of	Publication	 Year	the	trial	or	study	was	published.	Protocol	Registered	 Was	the	trial	or	study	protocol	registered,	published,	or	pre-declared?	
- Yes 
- No Registration	Number	 The	registration	number	or	location	of	pre-specified	trial	or	study	protocol.		Year	of	Registration	 Year	the	trial	or	study	was	registered.	Year	Started	 Year	the	trial	or	study	was	reported	as	starting.	Year	of	Completion	 Year	the	trial	or	study	was	reported	as	completed.		Duration	between	Trial	Start	and	Trial	Registration	 Calculated	difference	in	years	between	the	year	the	trial	or	study	started	and	when	it	was	registered.	Duration	between	Trial	Registration	and	Publication	 Calculated	difference	in	years	between	the	year	the	trial	or	study	was	registered	and	when	it	was	published.	Duration	between	Trial	Completion	and	Publication	 Calculated	difference	in	years	between	the	year	the	trial	or	study	was	reported	as	completed	and	when	it	was	published.	Duration	since	Publication	 Calculated	difference	in	years	between	the	year	the	trial	or	study	was	published	and	the	year	of	this	review.			
Methodology	 Population	 Population	in	which	trial	or	study	is	conducted.	If	two	or	more	trials	are	reported	on	in	the	article,	then	use	the	first	reported	trial	or	study.	If	two	or	more	populations	are	reported,	then	use	the	first	reported	population.	
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Protocol	Population	 Did	the	population	(including	inclusion	and	exclusion	criteria)	remain	unchanged	from	protocol	registration	to	publication?	
- Yes 
- No Intervention	Group	 If	two	groups	are	reported	as	intervention	and	control	/	placebo	/	comparison	/	currently-used-practice,	then	use	groups	as	reported.	If	two	groups	are	reported,	but	none	are	labelled	as	control	/	placebo	/	comparison	/	currently-used-practice	/	intervention	then:	
- If	the	two	reported	groups	are	one	low	dose	/	risk	and	one	high	dose	/	risk,	then	use	the	high	dose	/	risk	group	as	the	intervention	group	and	the	low	dose	/	risk	group	as	the	comparison.	
- If	the	two	reported	groups	are	two	interventions	and	neither	is	the	control	/	placebo	/	comparison	/	currently-used-practice,	then	use	the	first	reported	as	the	intervention	group	and	the	second	reported	as	the	comparison	group.	If	more	than	two	groups	are	reported,	and	one	is	control	/	placebo	/	comparison	/	currently-used-practice,	then	use	this	as	the	comparison	group,	and	then:	
- If	the	other	reported	groups	are	low	dose	/	risk	and	high	dose	/	risk,	then	use	the	low	dose	/	risk	as	the	intervention	group.	
- If	the	other	reported	groups	are	interventions	and	neither	are	a	control	/	placebo	/	comparison	/	currently-used-practice,	then	use	the	first	non-control	/	placebo	/	comparison	/	currently-used-practice	reported	as	the	intervention	group.	If	more	than	two	groups	are	reported	and	none	are	control	/	placebo	/	comparison	/	currently-used-practice,	then	use	the	first	mentioned	group	as	the	intervention	and	the	second	mentioned	group	as	the	comparison	group.	If	a	factorial	design	with	control	/	placebo	/	comparison	/	currently-used-practice	and	multiple	interventions,	then	use	the	double	control	/	placebo	/	comparison	/	currently-used-practice	as	the	comparison	group	and	the	first-mentioned	intervention	and	control	/	placebo	/	comparison	/	currently-used-practice	group	as	the	intervention	group.	If	a	factorial	design	with	no	control	/	placebo	/	comparison	/	currently-used-practice,	then	the	first	mentioned	group	is	the	intervention	group	and	the	second	mentioned	group	is	the	comparison	group.	
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Protocol	Intervention	Group	 Did	the	intervention	group	remain	unchanged	from	protocol	registration	to	publication?	
- Yes	
- No Comparison	Group	 See	group	selection	for	intervention	group.	Protocol	Comparison	Group	 Did	the	comparison	group	remain	unchanged	from	protocol	registration	to	publication?	
- Yes	
- No 1o	Outcome	 If	only	one	primary	outcome	is	reported,	then	use	the	sole	reported	primary	outcome.	If	more	than	one	primary	outcome	is	reported,	then	use	the	first	primary	outcome	reported.		If	no	outcomes	are	reported	as	the	primary	outcome,	then	use	the	most	patient-important	outcome	as	the	primary	outcome.	If	primary	outcomes	are	reported	for	both	safety	and	efficacy,	then	use	the	efficacy	primary	outcome.	Protocol	Primary	Outcome	 Did	the	primary	outcome	remain	unchanged	from	protocol	registration	to	publication?	
- Yes	
- No Favourable	or	Unfavourable	Primary	Outcome	 Was	the	primary	outcome	favourable	(e.g.	survival)	or	unfavourable	(e.g.	mortality)?	
- Favourable	
- Unfavorable Unfavourable	Primary	Outcome	 If	the	primary	outcome	was	unfavourable,	then	use	as	reported.	If	the	primary	outcome	was	favourable,	then	use	the	complementary	unfavourable	outcome.	2o	Outcome	(Major)	 If	only	one	secondary	outcome	is	reported,	then	use	the	sole	reported	secondary	outcome.	If	more	than	one	secondary	outcome	is	reported,	then	use	the	most	patient-important	outcome.	i.e.	mortality	Protocol	Secondary	Outcome	 Did	the	secondary	outcome	remain	unchanged	from	protocol	registration	to	publication?	
- Yes	
- No 
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Randomization	 Was	the	trial	randomized?	
- Yes	
- No Duration	of	Follow-Up	 If	the	duration	of	follow-up	for	the	selected	primary	outcome	is	reported,	then	use	this	reported	duration.		If	the	duration	is	not	reported,	but	the	mean	or	median	length	of	follow	up	is,	then	use	the	reported	mean	or	median.	If	the	no	duration	of	follow-up	for	the	selected	primary	outcome	is	reported,	then	use	the	duration	of	follow-up	for	the	entire	trial	or	study.	Protocol	Follow-Up	 Did	the	time	of	follow-up	or	study	or	trial	duration	remain	unchanged	from	protocol	registration	to	publication?	
- Yes	
- No Sample	Size	 Total	number	randomized.	Required	Sample	Size	 Required	sample	size	calculated	prior	to	trial	start.	Protocol	Sample	Size	 Did	the	required	sample	size	remain	unchanged	from	pre-specification	to	publication?	
- Yes	
- No 	
Study	results	 Loss	to	Follow-Up	Total	 Total	loss	to	follow-up	in	entire	trial	or	study.	Also	reported	as	withdrawn,	lack	of	outcome	information,	missing	primary	outcome	data,	or	protocol	violations.	If	the	loss	to	follow-up	is	only	reported	for	each	group,	this	is	calculated	by	summing	the	loss	to	follow-up	in	both	the	selected	intervention	and	comparison	groups.	If	there	are	multiple	groups,	calculate	the	total	loss	to	follow-up	by	summing	the	loss	to	follow-up	from	all	included	groups	If	loss	to	follow-up	is	only	reported	as	a	percentage,	calculated	by	multiplying	the	initial	number	of	included	patients	by	the	percentage	to	receive	a	whole	number.	If	loss	to	follow-up	is	not	reported,	calculated	by	the	difference	between	initial	number	of	included	patients	and	the	number	of	observations	reported	for	the	primary	outcome.			
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Loss	to	Follow-Up	in	Intervention	Group	 Loss	to	follow-up	in	the	selected	intervention	group	for	the	primary	outcome.	Also	reported	as	withdrawn,	lack	of	outcome,	missing	primary	outcome	data,	or	protocol	violations.	If	only	the	total	loss	to	follow-up	is	reported,	then	it	is	assumed	loss	to	follow-up	is	equal	in	all	groups.	This	is	calculated	by	dividing	the	total	loss	to	follow-up	by	the	number	of	groups.	If	loss	to	follow-up	for	the	intervention	group	is	only	reported	as	a	percentage,	calculated	by	multiplying	the	initial	number	of	patients	included	in	the	intervention	group	by	the	percentage	to	receive	a	whole	number.	If	loss	to	follow-up	is	not	reported,	calculated	by	the	difference	between	initial	number	of	patients	included	in	the	intervention	group	and	the	number	of	observations	reported	in	the	intervention	group	for	the	primary	outcome.	Loss	to	Follow-Up	in	Comparison	Group	 Loss	to	follow-up	in	the	selected	comparison	group	for	the	primary	outcome.	Also	reported	as	withdrawn,	lack	of	outcome	information,	missing	primary	outcome	data,	or	protocol	violations.	If	only	the	total	loss	to	follow-up	is	reported,	then	it	is	assumed	loss	to	follow-up	is	equal	in	all	groups.	This	is	calculated	by	dividing	the	total	loss	to	follow-up	by	the	number	of	groups.	If	loss	to	follow-up	for	the	comparison	group	is	only	reported	as	a	percentage,	calculated	by	multiplying	the	initial	number	of	patients	included	in	the	comparison	group	by	the	percentage	to	receive	a	whole	number.	If	loss	to	follow-up	is	not	reported,	calculated	by	the	difference	between	initial	number	of	patients	included	in	the	comparison	group	and	the	number	of	observations	reported	in	the	comparison	group	for	the	primary	outcome.	p-Value	(1o	Outcome)	 Reported	p-value	for	selected	primary	outcome.	If	no	p-value	reported,	then	report	as	“N/A.”		Significant	or	Not	 Is	the	p-value	significant?	
- SS	(p-value	is	significant)	
- NS (p-value is not significant) Reported	Point	Estimate		 Reported	point	estimate	of	effect	for	selected	primary	outcome.	If	both	relative	and	absolute	estimates	are	available,	then	use	absolute	values.	If	crude	/	unadjusted	and	adjusted	estimates	are	available,	then	use	the	crude	/	unadjusted	values.	If	no	point	estimate	is	reported	(common	with	continuous	outcomes),	then	report	as	“Unknown.”		
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Intent-to-treat	analysis	point	estimates	are	used	over	modified-intent-to-treat	analysis	point	estimates	which	are	used	over	per	protocol	analysis	point	estimates	Reported	Confidence	Interval	(1o	Outcome)	 Reported	confidence	interval	or	standard	deviation	of	selected	point	estimate	of	effect	of	selected	primary	outcome.	Type	of	Outcome	 If	both	continuous	and	dichotomous	outcomes	are	reported	for	the	selected	primary	outcome,	then	the	dichotomous	outcome	is	preferred.	
- Continuous	
- Dichotomous Number	of	Events	in	Intervention	Group	 For	dichotomous	outcomes,	number	of	events	of	selected	primary	outcome	in	the	selected	intervention	group.	Number	in	Intervention	Group	 Number	of	population	randomized	to	selected	intervention	group.	Intervention	Group	Rate	 If	dichotomous	outcome,	p̂1	=	intervention	group	rate:	!!̂ = !!!!	
x1	=	number	of	events	in	intervention	group	
n1	=	number	of	patients	in	intervention	group	Number	of	Events	in	Comparison	Group	 For	dichotomous	outcomes,	number	of	events	of	selected	primary	outcome	in	the	selected	comparison	group.	Number	in	Comparison	Group	 Number	of	population	randomized	to	selected	comparison	group.	Comparison	Group	Rate	 If	dichotomous	outcome,	p̂2	=	comparison	group	rate:	!!̂ = !!!!	
x2	=	number	of	events	in	comparison	group	
n2	=	number	of	patients	in	comparison	group	Absolute	Risk	Difference	Lower	95%	Confidence	Interval		Absolute	Risk	Difference	Upper	95%	Confidence	Interval	
If	dichotomous	outcome,	calculated	using	Newcombe-Wilson	hybrid	score	confidence	intervals:		
1/)11(12/)21(22/)2ˆ1ˆ( nLLnUUzppARDLowerLimit −+−−−= α 	
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ARDLowerLimit	=	absolute	risk	difference	lower	CI	interval	
ARDUpperLimit	=	absolute	risk	difference	lower	CI	interval	
p̂2	=	intervention	group	rate	
n2	=	number	of	patients	in	intervention	group	
U2	=	U	calculated	for	intervention	group	
L2	=	L	calculated	for	intervention	group	
p̂1	=	comparison	group	rate	
n1	=	number	of	patients	in	comparison	group	
U1	=	U	calculated	for	comparison	group		
L1	=	L	calculated	for	comparison	group	zɑ/2	=	z	score	for	95%	confidence	interval,	ɑ	of	0.05	=	1.96	Absolute	Risk	Difference	Point	Estimate	 If	dichotomous	outcome,	ARD	=	absolute	risk	difference:	!"# =  !"# − !"#	
IGR	=	intervention	group	rate	
CGR	=	comparison	group	rate	
- Absolute	Risk	Decrease	if	Positive	
- Absolute Risk Increase if Negative Number	Needed	to	Treat	Lower	95%	Confidence	Interval		Number	Needed	to	Treat	Upper	95%	Confidence	Interval	
If	dichotomous	outcome,	calculated	by:	!!!!"#$%!&'&( =  1!"!!""#$%&'&(           !!!!""#$%&'&( =  1!"!!"#$%!&'&(		
NNTLowerLimit	=	number	needed	to	treat	lower	CI	interval	
NNTUpperLimit	=	number	needed	to	treat	upper	CI	interval	
ARDUpperLimit	=	absolute	risk	difference	upper	CI	interval	
ARDLowerLimit	=	absolute	risk	difference	lower	CI	interval	If	the	95%	confidence	intervals	for	absolute	risk	difference	have	opposing	signs	(one	is	negative	and	one	is	positive),	then	report	as	“N/A.”	Number	Needed	to	Treat	Point	Estimate	 If	dichotomous	outcome,	NNT	=	number	needed	to	treat:	!!" =  1!"#	
ARD	=	absolute	risk	difference			
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- Number	Needed	to	Benefit	if	Positive	
- Number Needed to Harm if Negative Total	Number	of	Events	 If	dichotomous	outcome,	X	=	total	number	of	events:	! =  !! +  !!	
x1	=	number	of	events	in	intervention	group	
x2	=	number	of	events	in	comparison	group	Relative	Risk	Difference	 If	dichotomous	outcome,	RRR	=	relative	risk	difference:	!!! =  !"#!!̂ 	
ARD	=	absolute	risk	difference		
p̂2	=	comparison	group	rate	
- Relative	Risk	Decrease	if	Positive	
- Relative Risk Increase if Negative Fragility	Index	(FI)		Reverse	Fragility	Index	(RFI)	 If	dichotomous	outcome	with	a	significant	p-value,	FI	calculated	by	recalculating	the	two-sided	p-value	for	Fischer’s	exact	test	after	adding	an	event	to	the	group	with	the	fewer	reported	events	while	subtracting	a	non-event	from	that	group.	This	process	continues	iteratively	until	the	calculated	p-value	becomes	greater	or	equal	to	0.05.	The	number	reported	in	this	review	is	the	number	of	added	events	required	to	change	the	p-value	from	significant	to	non-significant.	(Calculated	using:	www.fragilityindex.com)	If	dichotomous	outcome	with	a	non-significant	p-value,	RFI	calculated	by	recalculating	the	two-sided	p-value	for	Fischer’s	exact	test	after	subtracting	an	event	from	the	group	with	the	most	reported	events	while	adding	a	non-event	from	that	group.	This	process	continues	iteratively	until	the	calculated	p-value	becomes	less	than	0.05.	The	number	reported	in	this	review	is	the	number	of	subtracted	events	required	to	change	the	p-value	from	non-significant	to	significant.	(Calculated	using	the	reverse	fragility	index	in	the	‘fragility	index’	R	package:	https://cran.r-project.org/web/packages/fragilityindex/README.html)	Reported	Intervention	Group	Mean	or	Median	 If	continuous	outcome,	the	reported	mean	or	median	for	the	selected	primary	outcome	in	the	selected	intervention	group.	Reported	Intervention	Group	Standard	Deviation	or	Interquartile	Range	 If	continuous	outcome,	the	reported	standard	deviation	or	interquartile	range	for	the	selected	primary	outcome	in	the	selected	intervention	group.		If	uneven	CI	around	estimate,	use	the	more	conservative	limit	
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Reported	Control	Group	Mean	or	Median	 If	continuous	outcome,	the	reported	mean	or	median	for	the	selected	primary	outcome	in	the	selected	comparison	group.	Reported	Control	Group	Standard	Deviation	or	Interquartile	Range	 If	continuous	outcome,	the	reported	standard	deviation	or	interquartile	range	for	the	selected	primary	outcome	in	the	selected	comparison	group.	If	uneven	CI	around	estimate,	use	the	more	conservative	limit	Pooled	Standard	Deviation	 If	continuous	outcome,	!! =	pooled	standard	deviation:	!! = !! − 1 !!! + !! − 1 !!!!! + !! − 2 	
n1	=	number	in	intervention	group	
s1	=	standard	deviation	for	intervention	group	
n2	=	number	in	comparison	group	
s2=	standard	deviation	for	comparison	group	Standard	Effect	Size	Lower	95%	Confidence	Interval	(continuous)		Standard	Effect	Size	Upper	95%	Confidence	Interval	(continuous)		Note:	Not	calculated	for	dichotomous	outcomes	
If	continuous	outcome,	calculated	by:		!"#$%!&'&( =  ! −  !ɑ !!! 1!! +  1!!    !""#$%&'&( =  ! +  !ɑ !!! 1!! +  1!!	
	
n1	=	number	in	intervention	group	
n2	=	number	in	comparison	group	
d	=	standard	effect	size	!!	=	pooled	standard	deviation	zɑ/2	=	z	score	for	95%	confidence	interval,	ɑ	of	0.05	=	1.96	Standard	Effect	Size	Point	Estimate	 If	continuous:	dc	=	standard	effect	size;	if	dichotomous:	dd	=	standard	es	!! =  !! −  !!!!       !! =  !"#!"#$%&#!!"#!"#$"%&'      !"#!"#$"%&' =  !! ∗ !!"!!! + !! ∗ !!"!!! 	!!	=	pooled	standard	deviation											Te	/	Ce	=	Treated	/	control	events	!!	=	mean	for	intervention	group					Tne	/	Cne	=	Treated	/	control	non-events	!!=	mean	for	comparison	group								nT	/	nC	=	Treated	/	control	sample	Adequacy	of	Power	(AP)	 If	dichotomous	outcome,	fails	to	meet	AP	if	(in	decreasing	order	of	importance):	
- Risk	Difference	95%	CI	includes	delta	in	either	direction.		
- No	delta	is	reported		
- Doesn’t	meet	sample	size	calculation	provided	in	article.	
		
	 	 	XLI	
If	continuous,	fails	to	meet	AP	if	(in	decreasing	order	of	importance):	
- Standard	effect	size	95%	CI	includes	a	standard	effect	size	greater	or	equal	to	0.5	in	either	direction.	
- Doesn’t	meet	sample	size	calculation	provided	in	article		
Author’s	
conclusions	
End	Point	Conclusions	 - Positive	conclusions		
o If	selected	intervention	group	is	reported	as	beneficial	/	better	than	the	selected	comparison	group,	then	report	as	“Positive.”	
- Negative	conclusions	or	No	difference	
o If selected intervention group is reported as not beneficial / harmful / no 
different than the selected comparison group, then report as “Negative or 
No Difference.” Conclusion	 Abstract	conclusion	/	article	discussion	Does	the	article	contradict	current	medical	practice?	 Based	on	abstract	conclusion	and	article	introduction,	results,	and	discussion.		If	new	practice	versus	current	practice	/	placebo	beneficial,	then	yes.	If	new	practice	versus	current	practice	/	placebo	not	beneficial	/	harmful	/	no	different,	then	no.	If	current	practice	versus	prior	/	inferior	practice	not	beneficial	/	harmful	/	no	different,	then	yes.	If	current	practice	versus	prior	/	inferior	practice	beneficial,	then	no.	
o Yes	
o No How	does	the	article	contradict	current	medical	practice?	 Abstract	background	/	article	introduction	/	article	discussion	Did	the	abstract	conclusion	report	the	primary	outcome?	 Based	on	abstract	conclusion.	o Yes	
o No Was	the	abstract	conclusion	based	on	subgroup	analysis?	 Based	on	abstract	conclusion.	o Yes	
o No Was	the	abstract	conclusion	based	on	a	secondary	outcome?	 Based	on	abstract	conclusion.	o Yes	
o No Was	the	article	withdrawn	or	retracted?	 Was	the	article	withdrawn	or	retracted?	
o Yes	
o No 
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If	article	was	withdrawn	or	retracted,	why?	 Reason	article	was	withdrawn.	Separate	retraction	article	or	from	Retraction	Watch	website	http://retractionwatch.com/	Conclusion	*based	on	trial	authors’	conclusions	not	systematic	review.	 - Reversal: current research shows current practice is ineffective or harmful. - Confirmation: current research shows current practice is superior to previous standard of practice/ is effective/ is beneficial. Reversal	Type	 If	the	conclusion	is	a	reversal,	then	report	if	the	reversal	is	due	to	“Harm	outweighs	benefits,”	“Not	effective,”	“Less	effective,	but	still	beneficial,”	or	“Beneficial	if	thought	harmful/not-effective/inferior.”	Otherwise	report	as	“N/A”	True	Reversal	 o Yes:	GRADE	Rating	is	High	Quality	
o No: GRADE Rating is not High Quality 	
Conflict(s)	of	
Interest	
Conflicts	of	Interest	 If	both	industry	and	non-industry	reported,	then	use	industry.	
o Industry	
o Non-Industry	
o None	Disclosed	Sources	of	Funding	 Listed	sources	of	funding		
PICOTS	
Assessment	
Patient	 Description	 Sufficient:		
o The ‘right’ patient population is identified. 
o The patient population is appropriately generalizable or restricted, included 
or excluded. 
o The ‘right’ setting is identified. 
o The setting is appropriately generalizable or restricted (multi-centre or 
single-centre). 
o Appropriately similar to protocol registration. Insufficient:	
o The ‘right’ patient population is not identified. 
o The patient population is inappropriately generalizable or restricted, 
included or excluded. 
o The ‘right’ setting is not identified. 
o The setting is inappropriately generalizable or restricted (multi-centre or 
single-centre). 
o Inappropriately different from protocol registration. 	
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Reason	 Reasons	behind	the	“Sufficient”	or	“Insufficient”	judgement	call	using	the	above	justification(s).	Sample	Size	 Description	 Sufficient:		
o Actual	sample	size	is	greater	or	equal	to	required	sample	size.	Insufficient:	
o Actual sample size is less than required sample size. Reason	 Reasons	behind	the	“Sufficient”	or	“Insufficient”	judgement	call	using	the	above	justification(s).	Intervention	 Description	 Sufficient:		
o An	appropriate	intervention	is	identified.	
o The	dosage	used	is	specified	and	scientifically	justified.	
o The	frequency	of	treatment	is	specified	and	scientifically	justified.	
o Appropriately	similar	to	protocol	registration.	Insufficient:	
o An	appropriate	intervention	is	not	identified.	
o The	dosage	used	is	not	specified	or	scientifically	justified.	
o The	frequency	of	treatment	is	not	specified	or	scientifically	justified.	
o Inappropriately different from protocol registration. Reason	 Reasons	behind	the	“Sufficient”	or	“Insufficient”	judgement	call	using	the	above	justification(s).	Comparator	 Description	 Sufficient:		
o The	comparator	is	appropriate.	
o Next	best	alternative	to	intervention	
o Competing	alternative	to	intervention	
o Standard	of	care	
o Gold	standard	
o The	placebo	is	appropriate.	
o Appears	similar	to	intervention	
o The	dosage	used	is	specified	and	scientifically	justified.	
o The	frequency	of	treatment	is	specified	and	justified.	
o Appropriately	similar	to	protocol	registration.	Insufficient:	
o The	comparator	is	inappropriate.	
o Inferior	to	other	alternatives	/	standards	of	care	
o Placebo	used	instead	of	an	existing	standard	of	care	
o The	dosage	used	is	not	specified	or	scientifically	justified.	
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o The	frequency	of	treatment	is	not	specified	or	justified.	
o Inappropriately different from protocol registration. Reason	 Reasons	behind	the	“Sufficient”	or	“Insufficient”	judgement	call	using	the	above	justification(s).	Outcomes	 Description	 Sufficient:		
o The	primary	outcome	is	valid.	The	secondary	outcome(s)	are	valid.	
o Patient-important,	clinically	relevant,	hard		
§ Affect	how	a	patient	functions	/	feels	/	survives.	
o Appropriate	surrogate	(validated)	
§ Surrogate	is	correlated	with	the	hard	outcome	of	interest.	
§ Surrogate	fully	captures	the	net	effect	of	treatment	on	the	hard	outcome	of	interest.	
o Appropriate	composite	(validated)	
§ Component	endpoints	of	similar	importance	to	patients.	
§ Component	endpoints	occur	with	similar	frequency.	
§ Component	endpoints	are	likely	to	have	similar	relative	risk	reductions	and	narrow	confidence	intervals.	
o If	disease-specific	mortality	is	measured,	then	so	is	all-cause	mortality.	
o The	timing	/	duration	of	outcome	measurement	are	appropriate.	
o Appropriately	similar	to	protocol	registration.	Insufficient:	
o The	primary	outcome	is	invalid.	The	secondary	outcome(s)	are	invalid.	
o Not	patient-important,	or	a	patient	important	outcome	is	missed.	
o Inappropriate	surrogate	(validated)	
§ Surrogate	is	not	correlated	with	the	hard	outcome	of	interest.	
§ Surrogate	does	not	fully	capture	the	net	effect	of	treatment	on	the	hard	outcome	of	interest.	
o Inappropriate	composite	(validated)	
§ Component	endpoints	are	not	of	similar	importance	to	patients.	
§ Component	endpoints	do	not	occur	with	similar	frequency.	
§ Component	endpoints	are	not	likely	to	have	similar	relative	risks	reductions	and	narrow	confidence	intervals.	
o If	morality	is	measured,	only	cause-specific	or	x-year	survival	is	measured.	
o The	timing	/	duration	of	outcome	measurement	are	inappropriate.	
o Inappropriately different from protocol registration. 
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Reason	 Reasons	behind	the	“Sufficient”	or	“Insufficient”	judgement	call	using	the	above	justification(s).	Type	 o Hard (Patient-Important): Outcomes that affect how a patient functions / 
feels / survives by improving a patient’s quality of life or increasing length 
of life. 
o Surrogate: Outcomes that do not affect how a patient functions / feels / 
survives, but are associated with those outcomes. 
o Composite: A grouping of outcomes with varying importance to the 
patients. Study	Design	 Description	 Sufficient:		
o The	study	design	is	appropriate	and	the	best	possible	scenario	to	answer	the	question.	
o Diagnosis:	Case-Control	Study	(All	patients	receive	both	the	gold	standard	test	and	new	proposed	test	regardless	of	their	actual	diagnosis).	
o Prognosis:	Observational	Study	
o Therapy:	Randomized	Controlled	Trial	
o Prevention:	Randomized	Controlled	Trial	
o Harm:	Case-Control	or	Observational	Study	
o Appropriately	similar	to	protocol	registration	Insufficient:	
o The	study	design	is	inappropriate	or	not	the	best	possible	scenario	to	answer	the	question.	
o Inappropriately different from protocol registration. Reason	 Reasons	behind	the	“Sufficient”	or	“Insufficient”	judgement	call	using	the	above	justification(s).	Study	Purpose	 Description	 Sufficient:		
o Purpose	/	question	is	easily	detectable	and	clearly	phrased.	
o Should	[intervention]	be	used	for	[health	problem]?	
o Should	[intervention]	versus	[comparison]	be	used	for	[health	problem]?	
o Should	[intervention]	be	used	in	[population]?	
o Should	[intervention]	versus	[comparison]	be	used	in	[population]?	
o Appropriately	similar	to	protocol	registration.	Insufficient	
o Purpose	/	question	is	not	detectable	or	clearly	phrased.	
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o Inappropriately different from protocol registration. Reason	 Reasons	behind	the	“Sufficient”	or	“Insufficient”	judgement	call	using	the	above	justification(s).	Overall	 Sufficient:	
o All PICOTS were sufficient. Somewhat	Insufficient:	
o One or two PICOTS were insufficient in way(s) that would not likely affect 
the outcome of the study. Clearly	Insufficient:	
o One or more PICOTS were insufficient in way(s) that could likely affect the 
outcome of the study. 	
Risk	of	Bias	
(ROB)	
Assessment	
Sequence	Generation	 Description	 Method	used	to	generate	the	allocation	sequence	is	described	sufficient	detail	to	allow	an	assessment	of	whether	it	should	produce	comparable	groups.	
- Definitely Low Risk of Bias 
o The	investigators	describe	a	random	component	in	the	sequence	generation	process:	random	number	table,	computer	random	number	generator,	coin	tossing,	shuffling	cards/envelopes,	throwing	dice,	drawing	lots.	
- Probably Low Risk of Bias 
o Sequence	generation	process	is	not	described	but	it	is	clear	that	the	investigators	used	a	random	component	in	their	process.	
- Probably High Risk of Bias 
o Insufficient	information	about	sequence	generation	process	to	permit	judgment.	
o Sequence	generation	process	is	not	described	and	it	is	unclear	whether	the	investigators	used	a	random	component	in	their	process.	
- Definitely High Risk of Bias 
o The	investigators	describe	a	non-random	component	in	the	sequence	generation	process.		
o Usually,	the	description	involves	some	systematic,	non-random	approach:	odd/even	date	of	birth,	day/date	of	admission,	hospital/clinic	record	number.	
o Other: judgment of clinician, preference of participant, results of laboratory 
test/series of tests, availability of intervention. 	
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Reason	 Reasons	behind	the	Risk	Level	of	Bias	judgement	call	using	the	above	justification(s).	Allocation	Concealment	 Description	 Method	used	to	conceal	the	allocation	sequence	is	described	in	sufficient	detail	to	determine	whether	intervention	allocations	could	have	been	foreseen	in	advance	or,	or	during,	enrolment.	
- Definitely Low Risk of Bias 
o Participants	and	investigators	enrolling	participants	could	not	foresee	assignments	because	one	of	the	following,	or	an	equivalent	method,	was	used	to	conceal	allocation:	central	allocation	(telephone/	web-based/	pharmacy-controlled	randomization);	sequentially	numbered	drug	containers	of	identical	appearance;	sequentially	numbers,	opaque,	sealed	envelopes.	
- Probably Low Risk of Bias 
o Allocation	Concealment	is	not	described	in	complete	detail	but	it	is	clear	that	the	investigators	used	a	method	of	concealment.	
- Probably High Risk of Bias 
o Insufficient	information	to	permit	judgment.		
o This	is	usually	the	case	if	method	of	concealment	is	not	described	or	not	described	in	sufficient	detail	to	allow	a	definite	judgment.	
- Definitely High Risk of Bias 
o Participants or investigators enrolling participants could possibly foresee 
assignments and thus introduce selection bias: open random allocation 
schedule, assignment envelopes (missing sequential numbers, opaque or 
sealed), alternation/rotation, date of birth, case record number, any other 
explicitly unconcealed procedure. Reason	 Reasons	behind	the	Risk	Level	of	Bias	judgement	call	using	the	above	justification(s).	Blinding	 Description	 Described	all	measures	used,	if	any,	to	blind	study	participants,	personnel,	and	outcome	assessors	from	knowledge	of	which	intervention	a	participant	received.	Provided	any	information	relating	to	whether	the	intended	blinding	was	effective.	
- Definitely	Low	Risk	of	Bias	
o No	blinding,	but	authors	judge	the	outcome	and	the	outcome	measurement	are	not	likely	to	be	influenced	by	lack	of	blinding.		
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o Blinding	of	participants	and	key	study	personnel;	and	unlikely	that	blinding	could	have	been	broken.	
o Either	participants	or	some	key	study	personnel	were	not	blinded,	but	outcome	assessment	was	blinded	and	the	non-blinding	of	others	is	unlikely	to	introduce	bias.	
- Probably	Low	Risk	of	Bias	
o Blinding	is	not	described	in	detail	but	it	is	clear	that	appropriate	blinding	has	been	used.	
- Probably	High	Risk	of	Bias	
o Insufficient	information	to	permit	judgment.		
o The	study	did	not	address	this	outcome.	
- Definitely	High	Risk	of	Bias	
o No	blinding	or	incomplete	blinding,	and	outcome	or	outcome	measure	is	likely	to	be	influenced	by	lack	of	blinding.	
o Blinding	of	key	study	and	personnel	attempted,	but	likely	that	blinding	could	have	been	broken.	
o Either participants or key study personnel were not blinded, and the non-
blinding of others is likely to introduce bias. Reason	 Reasons	behind	the	Risk	Level	of	Bias	judgement	call	using	the	above	justification(s).	Incomplete	Outcome	Data	 Description	 Described	the	completeness	of	outcome	data	for	each	main	outcome,	including	attrition	and	exclusions	from	the	analysis.		Stated	whether	attrition	and	exclusions	were	reported,	the	numbers	in	each	intervention	group	(compared	with	total	randomized	participants),	reasons	for	attrition/	exclusions	were	reported,	and	any	re-inclusions	in	analyses	performed	by	authors.	
- Definitely	Low	Risk	of	Bias	
o No	missing	outcome	data.	
o Reasons	for	missing	outcome	data	unlikely	to	be	related	to	true	outcome.	
o Missing	outcome	data	balanced	in	numbers	across	intervention	groups,	with	similar	reasons	for	missing	data	across	groups.	
o Missing	data	have	been	imputed	using	appropriate	methods.	
- Probably	Low	Risk	of	Bias			
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o For	dichotomous	outcome	data,	the	proportion	of	missing	outcomes	compared	with	observed	event	rate	not	enough	to	have	a	clinically	relevant	impact	on	the	intervention	effect	estimate.	
o For	continuous	outcome	data,	plausible	effect	size	(difference	in	means	or	standardized	difference	in	means)	among	missing	outcomes	not	enough	to	have	a	clinically	relevant	impact	on	observed	effect	size.	
- Probably	High	Risk	of	Bias	
o Insufficient	reporting	of	attrition/exclusions	to	permit	judgment.	
o The	study	did	not	address	this	outcome.	
- Definitely	High	Risk	of	Bias	
o Reason	for	missing	outcome	data	likely	to	be	related	to	the	true	outcome,	with	either	imbalance	in	numbers	or	reasons	for	missing	data	across	intervention	groups.	
o For	dichotomous	outcome	data,	the	proportion	of	missing	outcomes	compared	with	observed	event	risk	enough	to	induce	clinically	relevant	bias	in	intervention	effect	estimate.	
o For	continuous	outcome	data,	plausible	effect	side	among	missing	outcomes	enough	to	induce	clinically	relevant	bias	in	observed	effect	size.	
o ‘As-treated”	analysis	done	with	substantial	departure	of	the	intervention	received	from	that	assigned	at	randomization.	
o Potentially	inappropriate	application	of	simple	imputation.	
o Loss to follow-up and failure to adhere to the intention to treat principle 
when indicated. Reason	 Reasons	behind	the	Risk	Level	of	Bias	judgement	call	using	the	above	justification(s).	Selective	Outcome	 Description	 Stated	how	the	possibility	of	selective	outcome	reporting	was	examined	by	the	authors,	and	what	was	found.	
- Definitely	Low	Risk	of	Bias	
o The	study	protocol	is	available	and	all	of	the	study’s	pre-specified	(1o	and	2o)	outcomes	that	are	of	interest	in	the	review	have	been	reported	in	the	pre-specified	way.	
- Probably	Low	Risk	of	Bias	
o The	study	protocol	is	not	available,	but	it	is	clear	the	published	reports	include	all	expected	outcomes,	including	those	that	were	pre-specified.		
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- Probably	High	Risk	of	Bias	
o The	study	protocol	is	not	available,	and	it	is	unclear	if	the	published	reports	include	all	expected	outcomes,	including	those	that	were	pre-specified.	
o Insufficient	information	to	permit	judgment.	
- Definitely	High	Risk	of	Bias	
o Not	all	of	the	study’s	pre-specified	primary	outcomes	have	been	reported.	
o One	or	more	primary	outcomes	are	reported	using	measurements,	analysis	methods,	or	subsets	/	subgroups	of	the	data	that	were	not	pre-specified.	Continuous	measurements	that	have	been:	measured	multiple	times;	transformed	from	“final	scores”	to	“changes	from	baseline”;	or	dichotomized	to	a	cut-off	in	ways	that	were	not	pre-specified.	
o One	or	more	reported	primary	outcomes	of	interest	in	the	review	are	reported	incompletely	such	that	they	cannot	be	entered	in	a	meta-analysis.	
o The	study	fails	to	include	results	for	a	key	outcome	that	would	be	expected	to	have	been	reported	in	such	a	study.	
o Reporting some outcomes and not others on the basis of the results. Primary 
outcomes reported as secondary or secondary outcomes reported as primary. Reason	 Reasons	behind	the	Risk	Level	of	Bias	judgement	call	using	the	above	justification(s).	Other	Sources	of	Bias	 Description	 Stated	any	important	concerns	about	bias	not	addressed	in	other	domains	in	the	tool.	
- Definitely	Low	Risk	of	Bias	
o The	study	appears	to	be	free	of	other	sources	of	bias.	
- Probably	Low	Risk	of	Bias	
o It	is	unclear	if	the	study	is	completely	free	of	other	sources	of	bias	but	any	potential	bias	is	not	enough	to	have	a	clinically	relevant	impact.	
- Probably	High	Risk	of	Bias	
o Insufficient	information	to	assess	whether	an	important	risk	of	bias	exists.	
o Insufficient	rationale	or	evidence	that	an	identified	problem	will	induce	bias.	
o Unexplained	industry	involvement		
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- Definitely	High	Risk	of	Bias	
o Potential	source	of	bias	related	to	the	specific	study	design	used.	
o Stopped	early	due	to	some	data-dependent	process	(including	formal-stopping	rule).	
o Extreme	baseline	imbalance.	
o Claimed	to	have	been	fraudulent.	
o Carry-over	effects	in	cross-over	trials.	
o Use	of	un-validated	patient-reported	outcomes.	
o Evidence of potential commercial exploitation (e.g. Industry role in trial 
design/conduct/analysis) Reason	 Reasons	behind	the	Risk	Level	of	Bias	judgement	call	using	the	above	justification(s).	Overall	Risk	of	Bias	 - Definitely Low Risk of Bias 
o All	risk	of	bias	items	are	judged	as	definitely	low	risk	of	bias.	
o Most	risk	of	bias	items	are	judged	as	definitely	low	risk	of	bias	but	one	or	two	are	probably	low	risk	of	bias	in	way(s)	that	would	not	likely	affect	the	outcome	of	the	study.	
- Probably Low Risk of Bias 
o Most	risk	of	bias	items	are	judged	as	definitely	low	risk	of	bias	or	probably	low	risk	of	bias	but	one	or	two	are	probably	high	risk	of	bias	in	way(s)	that	would	not	likely	affect	the	outcome	of	the	study.	
- Probably High Risk of Bias 
o At	least	one	risk	of	bias	item	is	judged	as	probably	high	risk	of	bias	in	way(s)	that	could	likely	affect	the	outcome	of	the	study.	
o One	risk	of	bias	item	is	judged	as	definitely	high	risk	of	bias	in	a	way	that	would	not	likely	affect	the	outcome	of	the	study.	
- Definitely High Risk of Bias 
o At least one risk of bias item is judged as definitely high risk of bias in 
way(s) that could likely affect the outcome of the study. 	
GRADE	
Assessment	
Study	Design	 Type	 Trial:	Study	design	was	determined	to	be	a	“Randomized	Controlled	Trial”	or	“Prospective	Controlled	Intervention	Study”	Initial	Level	of	Confidence	 High:	Study	type	is	a	“Trial”	Risk	of	Bias	 Description	 Overall	ROB	Assessment		
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Downgrade	 Downgrade	of	0	
o Overall	ROB	Assessment	is	judged	to	be	“Definitely	Low	Risk	of	Bias”	or	“Probably	Low	Risk	of	Bias”	Downgrade	of	-1	
o Overall	ROB	Assessment	is	judged	to	be	“Probably	High	Risk	of	Bias”	Downgrade	of	-2	
o Overall ROB Assessment is judged to be “Definitely High Risk of Bias” Directness	and	Applicability	 Description	 Overall	PICOTS	Assessment	Downgrade	 Downgrade	of	0	
o Overall	PICOTS	Assessment	is	judged	as	“Sufficient”	Downgrade	of	-1	
o Overall	PICOTS	Assessment	is	judged	as	“Somewhat	Insufficient”	Downgrade	of	-2	
o Overall PICOTS Assessment is judged as “Clearly Insufficient” Imprecision	 Description	 Adequacy	of	Power	(AP)	Downgrade	 Downgrade	of	0	
o Meets	mOIS	threshold.	Downgrade	of	-1	
o Does not meet mOIS threshold. Publication	Bias	-	Modified	 Description	 Presence	of	Selective	Outcome	Bias		Downgrade	 Downgrade	of	0	
o Selective	Outcome	Bias	is	undetected	and	judged	as	“Definitely	Low	Risk	of	Bias”	or	“Probably	Low	Risk	of	Bias”	Downgrade	of	-1	
o Selective	Outcome	Bias	is	suspected	and	judged	as	“Probably	High	Risk	of	Bias	Downgrade	of	-2	
o Selective Outcome Bias is detected and judged as “Definitely High Risk of 
Bias”  Total	Downgrades	 Calculated	sum	of	all	the	downgrades.	Overall	Quality	of	Evidence	 Trials	begin	initially	at	High	Quality	and	can	only	be	downgraded	from	there.	
o Total downgrade of 0: High Quality 
o Total downgrade of -1: Moderate Quality 
o Total downgrade of -2: Low Quality 
o Total downgrade of ≤-3: Very Low Quality 
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APPENDIX F 
STATA DO-FILE 1 
 
SETTING UP THE DATABASE FOR ANALYSES 
 
/* Before importing the file, the first row which specifies the headings of 
each section of the extraction must be deleted. This will not remove any of 
the names of the variables, but will allow STATA to use the 'firstrow' command. 
Import the excel file, titled "ThesisAnalyses." Use 'firstrow' to specify that  
the first row is the variable names. */ 
 
import excel "/Users/Riaz/Desktop/EvidenceReversalDataExtraction.xlsx", sheet("Data 
Extraction") firstrow 
 
/* There are 161 variables in the excel file, but we have only 20 potential  
predictors that we are interested in and an additional 12 that we are using in  
our descriptive statistics. Instead of using 'drop' and specifying all  
non-included variables, we will use 'keep' to specify the list of variables 
that we want to keep in the dataset. Note that although it will not be used in 
the regression, DOI and ID will be kept as identifiers. */ 
 
keep ID DOI YearofPublication Registered RegistrationnumberorPreSpecif 
Durationbetweenstartandregist Durationbetweentrialcompletion 
DurationofFollowUpinWeeks DurationofFollowUpinWeeksI FavourableorUnfavourable 
SampleSize RequiredSampleSize LosstoFollowUpproportionof 
ImputedLosstoFollowUpProport pValuemainoutcome Alteredpvalue SignificantorNot 
MeasureofEffect TypeofOutcome TotalNumberofEventsAdjustment FragilityIndex 
StandardEffectSizeAll StandardEffectSizeImputed AP EndPointConclusions 
Contradictcurrentmedicalpracti PrimaryOutcomereportedinabstr 
Basedonsubgroupanalysis Basedonsecondaryoutcome ReversalType Funding Type 
Overall OverallBias QualityofEvidence  
 
/* The data has mostly been imported as string variables and must be converted  
appropriately. Numeric variables will be converted using the 'destring'  
command, while categorical variables will be converted to numeric using the  
'encode' command. All original variables will be kept and the newly generated 
"converted" variables will be used for the analyses. */ 
 
encode Registered, generate (Registration) 
encode RegistrationnumberorPreSpecif, generate (RegistrationNumber) 
destring Durationbetweenstartandregist, ignore("N/A") generate (Time_StartandReg) 
destring Durationbetweentrialcompletion, ignore("N/A") generate (Time_EndandPub) 
encode FavourableorUnfavourable, generate (Unfavourable) 
destring DurationofFollowUpinWeeks, ignore("N/A") generate (FollowUpTime)  
destring RequiredSampleSize, ignore("N/A") force generate (NRequired) /* 'force'  
is required as STATA is recognizing a non-numeric character somewhere in the 
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extraction file, other than N/A. However upon close inspection of the data,  
only the trials with N/A are converted to missing, so the use of 'force' does 
not have any impact on the data-conversion with 'destring' */ 
 
destring LosstoFollowUpproportionof, ignore("N/A") generate (LosstoFollowUp) 
destring pValuemainoutcome, ignore("N/A") generate (PValue) 
encode SignificantorNot, generate (Significant) 
encode MeasureofEffect, generate (EffectMeasure) 
encode TypeofOutcome, generate (Dichotomous) 
destring TotalNumberofEventsAdjustment, ignore("N/A") generate (TotalEvents) 
destring FragilityIndex, ignore("N/A") generate (Fragility) 
destring StandardEffectSizeAll, ignore("N/A" "Unknown") generate (StandardES) 
encode AP, generate (AdequacyofPower) 
encode EndPointConclusions, generate (Conclusions) 
encode Contradictcurrentmedicalpracti, generate (Reversal) 
encode PrimaryOutcomereportedinabstr, generate (AbstractOutcomePrimary) 
encode Basedonsubgroupanalysis, generate (AbstractOutcomeSubgroup) 
encode Basedonsecondaryoutcome, generate (AbstractOutcomeSecondary) 
encode ReversalType, generate (ReasonforReversal) 
encode Funding, generate (ConflictsofInterest) 
encode Type, generate (OutcomeType) 
encode Overall, generate (PICOTS) 
encode OverallBias, generate (ROB) 
encode QualityofEvidence, generate (GRADE) 
 
/* Several variables were imported, not as string, but as numeric because they 
contained only numeric data. These will be renamed to more easily identify  
them */ 
 
rename YearofPublication YearPublished 
rename DurationofFollowUpinWeeksI FollowUpTimeImputed 
rename SampleSize NTotal 
rename Alteredpvalue PValueImputed 
rename ImputedLosstoFollowUpProport LosstoFollowUpImputed 
rename StandardEffectSizeImputed StandardESImputed 
 
/* When using the 'encode' command, numeric values are assigned alphabetically. 
This means that the ordinal variables will need to be fixed so that the quality 
ratings appear in the correct order, with the categories that have the highest 
quality having the highest number. PICOT is in the correct order, but for ROB,  
"Definitely Low" has a value of 2, "Probably High" has a value of 3, and  
"Probably Low" has a value of 4, when they should respectively have values of 
4, 2, and 3. This same recoding will be applied to the individual components 
of the ROB. Similarly, for GRADE, "High" has a value of 1, "Moderate" has a 
value of 3, "Low" has a value of 2, and "Very Low" has a value of 4, when  
they should respectively have 4, 3, 2, 1. */  
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recode ROB (2 = 4) (3 = 2) (4 = 3) (1 = 1), generate (ROB_Overall) 
recode GRADE (1 = 4) (3 = 3) (4 = 1) (2 = 2), generate (GRADE_Overall) 
 
/* The recode command is also necessary for most of our binary covariates, for  
which all "No" responses have been given values of 1, and all "Yes" responses  
were given values of 2. Similarly, other binary variables will be recoded so  
that the '0' corresponds to the state of non-interest as follows: Dichotomous 
(1) vs. continuous (0) outcome; Conclusions that are positive (1) vs. negative 
or no difference (0); */ 
 
recode Registration (1 = 0) (2 = 1), generate (_Registration) 
recode RegistrationNumber (97 = 0) (1/600 = 1), generate (RegistrationAvailable) 
recode Unfavourable (1 = 0) (2 = 1), generate (_Unfavourable) 
recode Significant (1 = .) (2 = 0) (3 = 1), generate (_Significant) 
recode Dichotomous (1 = 0) (2 = 1), generate (_Dichotomous) 
recode AdequacyofPower (1 = 0) (2 = 1), generate (SufficientAP) 
recode Conclusions (1 = 0) (2 = 1), generate (_Conclusions) 
recode Reversal (1 = 0) (2 = 1), generate (_Reversal) 
recode AbstractOutcomePrimary (1 = 0) (2 = 1), generate (_AbsOutcomePrimary) 
recode AbstractOutcomeSubgroup (1 = 0) (2 = 1), generate (_AbsOutcomeSubgroup) 
recode AbstractOutcomeSecondary (1 = 0) (2 = 1), generate (_AbsOutcomeSecondary) 
 
/* The database should be set for the analyses at this time. Please see the 
do-file in APPENDIX G for the STATA code to conduct all descriptive and  
logistic regression analyses. */ 
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APPENDIX G 
STATA DO-FILE 2 
 
CONDUCTING DESCRIPTIVE AND LOGISTIC REGRESSION ANALYSES 
 
/* With the database set up after running the do-file from APPENDIX F, this 
do-file conducts all of the analyses presented in the Chapter 5: Results. */ 
 
/* First set of commands collects all of the information necessary to present 
the descriptive statistics found in Tables 5.2, 5.3, and half of Table 5.1.  
The first statistics found in Table 5.1 come from the three tiers of screening 
and correspond with the PRISMA flow diagram found in Figure 5.1. */ 
 
/* Table 5.1:  */ 
 
table Conclusions 
table Reversal  
 
/* Table 5.2: Overall population descriptive statistics */ 
 
table Registration 
table RegistrationAvailable if _Registration == 1 
mean Time_StartandReg 
table Unfavourable 
mean FollowUpTime  
mean NTotal  
mean NRequired  
mean LosstoFollowUp 
table Significant 
table EffectMeasure 
table Dichotomous 
table OutcomeType 
table AbstractOutcomePrimary  
table AbstractOutcomeSubgroup  
table AbstractOutcomeSecondary 
table ReasonforReversal 
table PICOTS 
table ROB 
table GRADE 
 
/* Table 5.3: Descriptive statistics for reversals and reaffirmations */ 
 
sort _Reversal 
by _Reversal: table Registration 
by _Reversal: table RegistrationAvailable if _Registration==1 
by _Reversal: summarize Time_StartandReg 
		
	 LXXI	
by _Reversal: table Unfavourable 
by _Reversal: summarize FollowUpTime NTotal NRequired LosstoFollowUp 
by _Reversal: table Significant 
by _Reversal: table EffectMeasure 
by _Reversal: table Dichotomous 
by _Reversal: table OutcomeType 
by _Reversal: table AbstractOutcomePrimary  
by _Reversal: table AbstractOutcomeSubgroup  
by _Reversal: table AbstractOutcomeSecondary 
by _Reversal: table PICOTS 
by _Reversal: table ROB 
by _Reversal: table GRADE 
 
/* The second set of commands perform all of the regression analyses: first  
the relationship that each potential predictor may have with the outcome is 
looked at individually, then all covariates are included into an overall- 
multivariable logistic regression, and then a backwards-stepwise model is  
created from all of the covariates of interest. */ 
 
/*Table 5.4: Univariable Logistic Regressions for all potential predictors. Also 
included are the 'contrast' commands which test the overall significance of the 
individual factor variables. To generate the table of beta-coefficients, found 
in APPENDIX H, replace each "logistic" command with "logit." */ 
 
logistic _Reversal LosstoFollowUp 
logistic _Reversal FollowUpTime 
logistic _Reversal PValue 
logistic _Reversal NTotal 
logistic _Reversal TotalEvents 
logistic _Reversal Fragility 
logistic _Reversal SufficientmOIS 
logistic _Reversal StandardES 
logistic _Reversal YearPublished 
logistic _Reversal Time_StartandReg 
logistic _Reversal Time_EndandPub 
logistic _Reversal _Registration 
logistic _Reversal _AbsOutcomePrimary 
logistic _Reversal _AbsOutcomeSubgroup 
logistic _Reversal _AbsOutcomeSecondary 
logistic _Reversal i.ConflictsofInterest 
testparm i.ConflictsofInterest 
logistic _Reversal ib3.OutcomeType 
testparm i.OutcomeType 
logistic _Reversal i.PICOTS 
testparm i.PICOTS 
logistic _Reversal i.ROB_Overall 
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testparm i. ROB_Overall 
logistic _Reversal i.GRADE_Overall 
testparm i.GRADE_Overall 
 
/* Conduct univariable logistic regressions for the predictors that have missing 
data imputed to determine if the imputation effects the relationship. If not,  
then the imputed data are used in place of the missing data. */ 
 
logistic _Reversal LosstoFollowUpImputed 
logistic _Reversal FollowUpTimeImputed 
logistic _Reversal PValueImputed 
logistic _Reversal StandardESImputed  
 
/* Check the correlation among all of the non-factor variables to see if any of 
them have a high degree of correlation and warrant the removal of one from the 
overall model. */ 
 
correlate LosstoFollowUpImputed FollowUpTimeImputed PValueImputed NTotal 
StandardESImputed YearPublished _AbsOutcomePrimary _AbsOutcomeSubgroup 
_AbsOutcomeSecondary  
 
/* Full Multivariable Logistic Regression including all covariates; the 'estat gof'  
command tests the goodness-of-fit of the model with Pearson; use of 'group(10)'  
performs the Hosmer-Lemeshow goodness-of-fit test. */ 
 
logistic _Reversal LosstoFollowUpImputed FollowUpTimeImputed PValueImputed 
NTotal StandardESImputed YearPublished _Registration _AbsOutcomePrimary 
_AbsOutcomeSubgroup _AbsOutcomeSecondary i.ConflictsofInterest ib3.OutcomeType 
i.PICOTS i.ROB_Overall i.GRADE_Overall 
estat gof 
estat gof, group(10) 
 
/* Conduct the likelihood ratio tests necessary to determine the overall effect  
of each factor variable in the model. */ 
 
estimates store overall 
logistic _Reversal LosstoFollowUpImputed FollowUpTimeImputed PValueImputed 
NTotal StandardESImputed YearPublished _Registration _AbsOutcomePrimary 
_AbsOutcomeSubgroup _AbsOutcomeSecondary ib3.OutcomeType i.PICOTS 
i.ROB_Overall i.GRADE_Overall 
lrtest overall 
logistic _Reversal LosstoFollowUpImputed FollowUpTimeImputed PValueImputed 
NTotal StandardESImputed YearPublished _Registration _AbsOutcomePrimary 
_AbsOutcomeSubgroup _AbsOutcomeSecondary i.ConflictsofInterest i.PICOTS 
i.ROB_Overall i.GRADE_Overall 
lrtest overall 
		
	 LXXIII	
logistic _Reversal LosstoFollowUpImputed FollowUpTimeImputed PValueImputed 
NTotal StandardESImputed YearPublished _Registration _AbsOutcomePrimary 
_AbsOutcomeSubgroup _AbsOutcomeSecondary i.ConflictsofInterest ib3.OutcomeType 
i.ROB_Overall i.GRADE_Overall 
lrtest overall 
logistic _Reversal LosstoFollowUpImputed FollowUpTimeImputed PValueImputed 
NTotal StandardESImputed YearPublished _Registration _AbsOutcomePrimary 
_AbsOutcomeSubgroup _AbsOutcomeSecondary i.ConflictsofInterest ib3.OutcomeType 
i.PICOTS i.GRADE_Overall 
lrtest overall 
logistic _Reversal LosstoFollowUpImputed FollowUpTimeImputed PValueImputed 
NTotal StandardESImputed YearPublished _Registration _AbsOutcomePrimary 
_AbsOutcomeSubgroup _AbsOutcomeSecondary i.ConflictsofInterest ib3.OutcomeType 
i.PICOTS i.ROB_Overall 
lrtest overall 
 
/* Backwards-Selection Model building with an exit significance level of 0.5.  
The use of 'xi' command is necessary because the stepwise procedure does not  
allow for factor variables. 'Xi' creates dummy variables that can then be used  
in the overall model estimation procedure. */ 
 
xi i.ConflictsofInterest i.OutcomeType i.PICOTS i.ROB_Overall i.GRADE_Overall 
stepwise, pr(0.5): logistic _Reversal LosstoFollowUpImputed FollowUpTimeImputed 
PValueImputed NTotal StandardESImputed YearPublished _Registration 
_AbsOutcomePrimary _AbsOutcomeSubgroup _AbsOutcomeSecondary (_IConflicts_2 
_IConflicts_3) (_IPICOTS_2 _IPICOTS_3) (_IROB_Overa_2 _IROB_Overa_3 
_IROB_Overa_4) (_IGRADE_Ove_2 _IGRADE_Ove_3 _IGRADE_Ove_4) 
estat gof 
estat gof, group(10) 
 
/* Conduct the likelihood ratio tests to find the overall significance of the 
two factor variables that are included in the model. */ 
 
logistic _Reversal LosstoFollowUpImputed PValueImputed StandardESImputed 
_AbsOutcomeSubgroup i.PICOTS i.ROB_Overall 
estimates store backwards 
logistic _Reversal LosstoFollowUpImputed PValueImputed StandardESImputed 
_AbsOutcomeSubgroup i.ROB_Overall 
lrtest backwards 
logistic _Reversal LosstoFollowUpImputed PValueImputed StandardESImputed 
_AbsOutcomeSubgroup i.PICOTS  
lrtest backwards 
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APPENDIX H 
RESULTS 
 
SUPPLEMENTARY TABLES AND FIGURES FOR EXTENDED ANALYSES 
 
Table 6. Comparison of population statistics between reversals and reaffirmations 
Descriptive Population Statistic Reversals  
(n = 331) 
Reaffirmation  
(n = 280) 
Trials registered 
Protocol / registration accessible 
Mean time between trial start and registration (years) 
293 (88%) 
257 (88%) 
1.08 (2.45) 
249 (89%) 
207 (83%) 
1.35 (2.67) 
Trials with a primary outcome oriented around harm 253 (76%) 191 (68%) 
Mean duration of follow up (weeks) 111.99 (162.47) 119.27 (169.90) 
Mean sample size 3430 (11900.5) 3157 (11154.23) 
Mean required sample size (where provided) 2205 (5221.36) 2158 (4586.71) 
Mean loss to follow up (% total sample size) 0.062 (0.086) 0.079 (0.103) 
Trials with significant primary outcomes (P < 0.05) 114 (34%) 162 (58%) 
Trials with a primary outcome measure of effect: 
HR (Hazard Ratio) 
RR (Relative Risk) 
AR (Absolute Risk) 
OR (Odds Ratio) 
ES / MD (Effect Size / Mean Difference) 
RRR (Relative Risk Reduction) 
NNT / NNH (Number Needed to Treat / Harm) 
N/A (Not Available) 
 
99 (30%) 
75 (23%) 
54 (16%) 
23 (7%) 
33 (10%) 
2 (1%) 
0 (0%) 
45 (14%) 
 
67 (24%) 
40 (14%) 
49 (18%) 
26 (9%) 
32 (12%) 
3 (1%) 
0 (0%) 
63 (23%) 
Trials with a dichotomous primary outcome 267 (81%) 207 (74%) 
Trials with a primary outcome that is: 
Hard (patient-important) 
Composite 
Surrogate 
 
156 (47%) 
109 (33%) 
66 (20%) 
 
121 (43%) 
83 (30%) 
76 (27%) 
Trials reporting abstract conclusions based on: 
Primary outcome 
Secondary outcome 
Subgroup analyses 
 
282 (85%) 
120 (36%) 
20 (6%) 
 
238 (85%) 
112 (40%) 
32 (11%) 
Trials with overall PICOTS designation: 
Sufficient 
Somewhat insufficient 
Clearly insufficient 
 
130 (39%) 
162 (49%) 
39 (12%) 
 
113 (40%) 
132 (47%) 
35 (13%) 
Trials with overall ROB designation: 
Definitely low risk of bias 
Probably low risk of bias 
Probably high risk of bias 
Definitely high risk of bias 
 
104 (31%) 
114 (34%) 
85 (26%) 
28 (9%) 
 
61 (22%) 
98 (35%) 
82 (29%) 
39 (14%) 
Trials with overall GRADE level of evidence: 
High  
Moderate 
Low 
Very low 
 
41 (12%) 
100 (30%) 
71 (22%) 
119 (36%) 
 
44 (16%) 
69 (25%) 
75 (27%) 
102 (36%) 
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Table 7. Correlation between potential predictors (not including factor variables) 
 
 
Table 8. Logistic regression beta-coefficient estimates for potential predictors.  
Covariate Logistic Regression Analyses Uni-variable Overall Backwards-stepwise 
Percent participants lost to follow up (imputed) -1.91898 -0.99256 -1.33550 
Duration of follow up (imputed) -0.00026 -0.00027 N/A 
P-value (imputed) 1.74083 1.50488 1.50628 
Sample size 2.08e-06 1.89e-06 N/A 
Standardized effect size (imputed) -0.11555 -0.07462 -0.07196 
Total number of events -0.00011 N/A N/A 
Fragility Index 0.00137 N/A N/A 
Sufficient Adequacy of Power 0.03801 N/A N/A 
Year of publication 0.01094 0.00768 N/A 
Years between trial start and trial registration -0.04203   N/A N/A 
Years between trial completion and publication 0.01348 N/A N/A 
Protocol registered -0.04088 -0.15311 N/A 
Abstract conclusion based on primary outcome  0.01549 0.12919 N/A 
Abstract conclusion based on subgroup 
analyses 
-0.69637 -0.59737 -0.62669 
Abstract conclusion based on secondary 
outcome 
-0.15890 -0.06959 N/A 
Conflicts of interest 
Non-industry vs. Industry 
None-reported vs. Industry 
 
0.09531 
0.22699 
 
-0.14225 
-0.01820 
N/A 
Type of outcome 
Hard vs. Surrogate 
Composite vs. Surrogate 
 
0.39514 
0.41359 
 
0.38554 
0.37397 
N/A 
Overall PICOTS 
Sufficient vs. Clearly insufficient 
Somewhat insufficient vs. Clearly insufficient 
 
0.03193 
0.09658 
 
-0.35935 
-0.24238 
 
-0.36662 
-0.20837 
Overall ROB 
Definitely low ROB vs. Definitely high ROB 
Probably low ROB vs. Definitely high ROB 
Probably high ROB vs. Definitely high ROB 
 
0.86487 
0.48259 
0.36729 
 
0.86599 
0.47941 
0.29949 
 
0.74019 
0.41797 
0.30504 
Overall GRADE 
High vs. Very low 
Moderate vs. Very low 
Low vs. Very low 
 
0.23725 
0.32250 
0.19852 
 
-0.16315 
-0.00172 
0.03025 
N/A 
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Calculating Odds Ratios for relevant unit differences for continuous covariates 
 
OR = e^(β*difference)  
95% CI = e^(β lower limit*difference) to e^(β upper limit*difference) 
 
Univariable analyses: 
 
10% increase in ‘Percent of participants lost to follow up’ = e(-1.92021*0.1) = 0.83 
 95% CI = e(-3.71201*0.1) to e(-0.12841*0.1) = 0.69 to 0.99 
 
Imputed 10% increase in ‘Percent of participants lost to follow up’ = e(-1.91898*0.1) = 0.83 
 95% CI = e(-3.70893*0.1) to e(-0.12903*0.1) = 0.69 to 0.99 
 
52 week increase in “Duration of follow up’ = e(-0.00026*52) = 0.99 
 95% CI = e(-0.00123*52) to e(0.00070*52) = 0.94 to 1.04 
 
Imputed 52 week increase in “Duration of follow up’ = e(-0.00026*52) = 0.99 
 95% CI = e(-0.00123*52) to e(0.00070*52) = 0.94 to 1.04 
 
0.10 increase in ‘P-value’ = e(1.67535*0.1) = 1.18 
 95% CI = e(1.06172*0.1) to e(2.28898*0.1) = 1.11 to 1.26 
 
Imputed 0.10 increase in ‘P-value’ = e(1.74083*0.1) = 1.19 
 95% CI = e(1.14766*0.1) to e(2.33400*0.1) = 1.12 to 1.26 
 
100 subject increase in ‘Sample size’ = e(2.08e-06*100) = 1.00 
 95% CI = e(-0.00001*100) to e(0.00002*100) = 1.00 to 1.00 
 
50 event increase in ‘Total number of events’ = e(-0.00011*50) = 1.00 
 95% CI = e(-0.00029*50) to e(0.00008*50) = 1.00 to 1.00 
 
5 event increase in ‘Fragility index’ = e(0.00137*5) = 1.01 
 95% CI = e(-0.01459*5) to e(0.01734*5) = 0.93 to 1.09 
 
5-year increase in ‘Year of publication’ = e(0.01094*5) = 1.06 
 95% CI = e(-0.02245*5) to e(0.04433*5) = 0.89 to 1.25 
 
5-year increase in ‘Years between start and registration = e(-0.04203*5) = 0.81 
95% CI = e(-0.11807*5) to e(0.03401*5) = 0.55 to 1.19 
 
5-year increase in ‘Years between end and publication’ = e(0.01348*5) = 1.07 
95% CI = e(-0.11346*5) to e(0.14043*5) = 0.57 to 2.02 
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Overall logistic analyses: 
 
10% increase in ‘Percent of participants lost to follow up’ = e(-0.99255*0.1) = 0.91 
 95% CI = e(-2.85571*0.1) to e(0.87060*0.1) = 0.75 to 1.09 
 
52 week increase in “Duration of follow up’ = e(-0.00027*52) = 0.99 
 95% CI = e(-0.00136*52) to e(0.00081*52) = 0.93 to 1.04 
 
0.10 increase in ‘P-value’ = e(1.50488*0.1) = 1.16 
 95% CI = e(0.87718*0.1) to e(2.13258*0.1) = 1.09 to 1.24 
 
100 subject increase in ‘Sample size’ = e(1.89e-06*100) = 1.00 
 95% CI = e(-0.00001*100) to e(0.00002*100) = 1.00 to 1.00 
 
5-year increase in ‘Year of publication’ = e(0.00768*5) = 1.04 
 95% CI = e(-0.03373*5) to e(0.04910*5) = 0.85 to 1.28 
 
 
Backwards-Stepwise analyses: 
 
10% increase in ‘Percent of participants lost to follow up’ = e(-1.33550*0.1) = 0.88 
 95% CI = e(-3.16240*0.1) to e(0.49141*0.1) = 0.73 to 1.05 
 
0.10 increase in ‘P-value’ = e(1.506278*0.1) = 1.16 
 95% CI = e(0.88772*0.1) to e(2.12484*0.1) = 1.09 to 1.24 
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APPENDIX I 
A PROPOSED TOOLBOX FOR REVERSAL 
 
PROPOSED METHODS FOR ASSESSING SUFFICIENCY AND STABILITY IN 
RELATION TO REVERSAL 
 
Sufficiency and Stability for the Identification of Evidence Reversal  
 
Reducing the impact of unnecessary reversals will require the identification of 
practices that have immature evidence among practices that regularly see use, and those 
for which the adoption process is underway. The evidence base for questionable existing 
practices must be assessed to support or contradict continued use, and new practices must 
provide a matured evidence base before recommending their adoption. To this end, we 
propose several different methods or tools for describing the sufficiency and stability of 
evidence among both new and established practices. These include: cumulative meta-
analysis, trial sequential analysis / monitoring, Bayesian analysis, value of information 
analysis, GRADE (Grades of Recommendation Assessment, Development, and 
Education), and the fragility index.  
 
Table 9. Proposed Tools for determining stability and sufficiency of evidence 
Proposed Tool Description 
Cumulative meta-
analysis 
A series of sequential meta-analyses that shows the cumulative evidence for a 
research question with each new piece of evidence. Very clear visual indicator 
of both sufficiency and stability. 
Trial sequential 
analysis / monitoring 
A statistical method for assessing the conclusions made by cumulative meta-
analyses that accounts for multiple testing by creating monitoring boundaries 
calculated from an optimal information size based on the assumption that all 
participants are from a single meta-analysis. Very clear statistical indicator of 
sufficiency.  
Bayesian analysis 
Incorporates measures of sufficiency and stability (i.e. invariance) into the 
calculation of likelihoods based on the prior available information. When 
evidence is sufficient and stable, inferences are good estimators of the truth. 
Complex indicator of sufficiency and stability.  
Value of information 
analysis 
A model for decision-making that utilizes the number of dependent information 
sources, precision of those sources, and consequent value of information gained 
from a source (with greater numbers of sources often being redundant and 
providing lower value). Complex indicator of sufficiency and stability.  
GRADE 
“Grades of Recommendation, Assessment, Development, and Evaluation” is a 
quality assessment tool for rating individual studies or collections of studies 
using biases and study characteristics. Qualitative indicator of sufficiency and 
stability. 
Fragility index 
A measure of the fragility of a study’s significance based on how few events 
(switching from event to non-event) would be required to change a statistically 
significant result a non-significant result. When applied over several studies in 
support of a claim, a clear indicator of sufficiency. 
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Cumulative meta-analysis to identify medical reversal 
 
While improving the development of clinical guidelines and increasing 
knowledge translation are approaches to reducing the prevalence of medical reversals 
before they are identified, there remains the issue of identifying practices that should be 
reversals and are needing de-implementation. There is general agreement in the medical 
literature that the best means of assessing the efficacy and effectiveness of an intervention 
or practice is a meta-analysis of RCTs.81 While there are weaknesses in the process of 
collecting the evidence for a meta-analysis, it is an established statistical method for 
integrating the results of multiple studies to determine the overall effect of an 
intervention.88,89 Applied to the context of medical reversal, where it is necessary to not 
only understand the efficacy of a practice but whether enough evidence has accumulated 
to make a decision, an appropriate technique is cumulative meta-analysis. 
 
Where traditional meta-analysis combines all studies into a single summative 
estimate, cumulative meta-analysis (CM-A) is a process whereby a series of sequential 
meta-analyses are performed – one each time a new study is conducted on the topic – 
thereby generating a running estimate that shows the cumulative strength of the evidence 
for an effect with each additional study.90 Cumulative meta-analysis is ideal for 
determining whether we can trust the evidence for an intervention by allowing for the 
exploration of two values of research that are not addressed by traditional meta-analysis: 
sufficiency and stability.90  
 
A 1992 paper by Lau et al demonstrates the difference in approach between a 
traditional meta-analysis and a cumulative meta-analysis of the same database.91 The 
authors sought to showcase the technique and the value that it provides to practitioners 
and policy makers in providing more definitive evidence for an intervention’s efficacy 
that is current with each new piece of evidence. As an example for the technique, the 
authors examined the use of intravenous streptokinase – compared to placebo or no 
treatment – as a method of reducing total mortality after MI.91 The total database included 
33 trials conducted between 1959 and 1988, with a total of 36974 patients enrolled and 
randomized to intervention or control.91 The authors found that the cumulative evidence 
showed that intravenous streptokinase provided a statistically significant reduction in 
mortality for acute MI after only eight trials – and a total of 2432 patients (odds ratio = 
0.74, 95% CI: 0.59 to 0.92, P = 0.007).91  
 
The difference between these statistical techniques is clear, as are the 
characteristics of sufficiency and stability. While both the conventional and final 
cumulative MA found strong support favouring the use of intravenous streptokinase 
versus placebo or no treatment, in reducing total mortality from acute MI (Z = -8.16, P < 
0001), the results from the individual studies in the conventional meta-analysis appear to 
jump around and there is no definitive pattern on which to base a judgement before the 
final estimate.91 On the other hand, the cumulative meta-analysis depicts a strong trend 
for significance in favour of streptokinase by the 8th study, and all further studies only 
serve to narrow the confidence intervals of the estimate.91 The cumulative MA approach 
suggests that more than 20 trials were conducted unnecessarily, and upwards of 30000 
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patients were randomized to not receive life-saving treatment. If researchers in the late 
1970s had only looked at the cumulative evidence for the intervention, they may have 
seen the efficacy that was evident in the cumulative trends but not apparent with the 
conventional meta-analysis, and streptokinase may have been implemented earlier, with 
fewer resources and patient lives wasted in the pursuit of unnecessary evidence.   
 
Cumulative meta-analysis is a demonstrably powerful technique for identifying 
whether the evidence for the efficacy of an intervention is stable and sufficient enough to 
warrant a reversal. This makes it ideal for the identification of current practices that need 
to be reversed. However, cumulative MA is not the most ideal tool for identifying 
medical reversals before implementation because it requires that enough evidence exists 
to exhibit stability and sufficiency to support a decision. This characteristic of cumulative 
MA could be considered unethical for a practice that is trending towards ineffectiveness 
or harm but has not yet reached a point of maturity. 
 
Trial sequential analysis / monitoring 
 
While cumulative meta-analyses provide a clear visual indication of whether or 
not evidence for a claim is sufficient and stable, the conclusions are at an increased risk 
of being spuriously significant (P < 0.05) as a result of repeated testing for significance as 
data accumulates.80,92 Trial sequential analysis is a statistical technique that is applied to 
cumulative meta-analysis to account for this multiple testing by using monitoring 
boundaries that are based upon an optimal information size.80,92  
 
The “information size” (IS) of a meta-analysis is the anticipated number of 
subjects (i.e. sample size) that is required to detect a pre-specified intervention effect, 
based on desired risks of Type I and II Error and the expected heterogeneity among 
included trials, in an adequately powered trial.80,92 The information size for a meta-
analysis should be the same as expected for a single randomized controlled trial, and any 
meta-analysis conducted before reaching its IS must be evaluated in a way that accounts 
for the increased risk of Type I Error (i.e. by calculating and utilizing monitoring 
boundaries).80,92 
 
Trial Sequential Monitoring Boundaries provide the limits for significance of 
effect in meta-analyses that have sparse data.80,92 Meta-analyses that meet or exceed their 
IS are considered to have sufficient evidence to support their conclusions.80,92  
 
Bayesian analysis 
 
Bayesian analysis is a method of determining the likelihood of future events 
occurring based on the information that is currently available.93 The goals of Bayesian 
analysis are akin to meta-analysis in that it aims to predict or inform decisions based on 
what is known. The biggest difference between the two approaches (respectively: 
Bayesian and Frequentist) is the use of existing evidence and prior beliefs to make 
inferences about probabilities as opposed to basing probabilities off of average values 
that are conditional on the null hypothesis.93  
		
	 LXXXI	
 
Bayesian analysis is commonly used in clinical decision making and could 
possibly be used for the identification of targets for reversal.93 If the available evidence 
for a claim is neither sufficient nor stable enough to make an inference of acceptable 
probability (i.e. the probability of intervention X being an appropriate solution to problem 
Y is less than [threshold percentage]), then it should be tested with an appropriate RCT 
and studied until the evidence is mature enough, such that the inference reaches the pre-
determined threshold.   
 
Value-of-information analysis 
 
Decision-making is often a complex process and it is generally accepted that the 
more evidence is available to inform a decision, the better any inferences based on that 
evidence will be.94 However, when multiple sources of data are dependent on one 
another, the redundancy in data actually decreases the expected value of information 
gained by the multiple sources if they had been independent of one another.94 Value of 
information analysis is a Bayesian model for decision-making where the posterior 
distribution density and likelihood function – and consequently the posterior estimate – 
are calculated based on the number of information sources, the value estimates, and the 
dependence of the errors (i.e. precision) of the estimate.94  
 
Given the usefulness that value of information analysis has for determining the 
expected contribution of new information sources to an evidence base, it been suggested 
as a formal tool for determining the value of proposed randomized trials in moving 
towards the de-implementation of practices that have been established as “unproven” and 
are consequently potential targets for reversal.59 It logically follows that if a proposed 
trial was determined to not provide any new information of value, then the existing 
evidence base would be considered sufficient and stable enough to inform a decision. 
 
GRADE 
 
The Grades of Recommendation, Assessment, Development, and Education tool 
is a measure of study quality.95 It is largely based on the biases that are present in a study 
and the methodology employed to study a clinical question – often expressed as the sum 
of four parts of interest: population, intervention, comparison, and outcome (PICO).95  
 
While GRADE can be used to provide a quality score for a single article, it is also 
frequently used in the generation of clinical guidelines: assimilating multiple studies into 
a cohesive conclusion.96 The GRADE tool has eight criteria for rating the quality of 
evidence – the presence of which can either lower or raise the confidence in study 
conclusions: risk of bias, inconsistency of results, indirectness of evidence, imprecision, 
probability of publication bias, magnitude of effect, dose-response curve, and residual 
confounding supporting conclusions.97 GRADE is well established as being a valid and 
reliable tool for evaluating the level and quality of evidence, and it therefore would be 
appropriate as a measure of both sufficiency and stability to identify an evidence 
reversal.40,95  
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Fragility Index 
 
The Fragility Index is tool that is used to quantify how fragile the results of a 
controlled trial are by identifying the change in the number of events required to turn a 
significant result into a non-significant result.98 There is also an analogue to the fragility 
index that provides the fragility of a trial in the opposite direction. The Reverse Fragility 
Index is the number of subjects in a trial that would be required to experience a non-event 
to take a conclusion from significant to non-significant. This minimum number of 
patients who would need to have a change of status from non-event to event, or visa-
versa, can be compared between trials, with smaller numbers of events indicating a more 
fragile finding.98 In an analysis of 399 RCTs published in high-impact journals, the 
median Fragility Index was 8, 25% of trials had a Fragility Index of 3 or less, and in 53% 
of trials, the Fragility Index was lower than the number lost to follow up.98 If the Fragility 
Index were applied over multiple studies it could provide a potential measure of the 
sufficiency of evidence as very low numbers would indicate that not enough evidence has 
been accumulated to support a claim. 
 
Prioritizing the Identification of Targets for Reversal 
 
 Each of the above tools has applicability in the field of evidence reversals in 
establishing whether or not the evidence has matured enough to declare the practice a 
reversal. These are necessary because concluding the reversal or reaffirmation of a 
practice on the basis of a single study or trial is inappropriate. However, in having these 
tools to find practices that should be de-implemented, there remains the logistic problem 
of identifying the practices upon which to apply these tools. To this end, Prasad and 
Ioannidis have proposed seven factors for consideration in assigning priority to the 
testing of unproven medical practices.59 We support the use of this framework in future 
reversal research, in conjunction with our proposed toolbox of reversal, and our proposed 
framework of reversibility. 
 
1. Priority should be given to test practices for which the current evidence base is 
weakest 
2. Priority should be given to interventions which result in significant net financial 
burden on health payers 
3. Priority should be given to practices that have multiple alternative options, 
especially if the alternatives are of lower cost or less likely to be overturned 
because of a separate mechanism of action or stronger supporting evidence 
4. Priority should be given to test practices with established harms that confer 
substantial morbidity 
5. Priority should be given to test practices for which the cost of testing is far less 
than ongoing expenditures of the practice 
6. Priority should be given to test practices where negative results may have a large 
impact 
7. Priority should be based on the expected value of information to be gained by 
funding a particular study, at the proposed size and cost, that may inform the de-
implementation of a practice 
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